{"title": "PDF", "author": "PDF", "url": "http://acdema.org/downloads/Uso_seguridad_medicamentos_antroposoficos_1.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "Uso\ny\nseguridad\nde\nlos\nmedicamentos\n \n \n \n \n \n \nantropos\u00f3ficos:\n \nUna\nevaluaci\u00f3n\nde\n44.462\npacientes\n \n \n \n \n \nmediante\nla\nred\nde\nfarmacovigilancia\n \n \n \n \n \nEvaMed\n \n \nUse\nand\nSafety\nof\nAnthroposophic\nMedicinal\nProducts:\n \n \n \n \n \n \n \nAn\nAnalysis\nof\n44,662\nPatients\nfrom\nthe\nEvaMed\n \n \n \n \n \n \n \n \nPharmacovigilance Network.\n \nAbstract\n \nBackground\n \nThere\nis\na\nneed\nfor\ndata\non\nthe\nclinical\nsafety\nof\nanthroposophic\nmedicinal\n \n \n \n \n \n \n \n \n \n \n \n \n \nproducts (AMPs).\n \nObjectives\n \nThe\nmain\nobjective\nof\nthis\nanalysis\nwas\nto\ndetermine\nthe\nfrequency\nof\nadverse\n \n \n \n \n \n \n \n \n \n \n \n \n \ndrug reactions (ADRs) to AMPs, relative to the number of AMP prescriptions.\n \nMethods\n \nEvaMed\n(Evaluation\nof\nAnthroposophic\nMedicine)\nwas\na\nprospective\n \n \n \n \n \n \n \n \npharmacovigilance\nstudy\nwith\nthe\npatients\nof\n38\nphysicians\nin\noutpatient\ncare\n \n \n \n \n \n \n \n \n \n \n \nin\nGermany.\nDiagnoses\nand\nprescriptions\nwere\nextracted\nfrom\nthe\nelectronic\n \n \n \n \n \n \n \n \n \n medical\nrecords.\nAll\nphysicians\ndocumented\nADRs\nof\nGrades\nIII\u2013IV\nand\n \n \n \n \n \n \n \n \n \n \nserious\nADRs,\nseven\n\u2018prescriber\nphysicians\u2019\nalso\ndocumented\nnon-serious\n \n \n \n \n \n \n \n \nADRs\nof\nany\nintensity.\nPatients\nwere\neligible\nfor\nthis\nanalysis\nif\nthey\nhad\none\nor\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmore\nAMP\nprescription\nin\nthe\nyears\n2001\u20132010,\nfollowed\nby\none\nor\nmore\n \n \n \n \n \n \n \n \n \n \n \n \nphysician visit.\n \nResults\n \nA\ntotal\nof\n44,662\npatients\nwith\n311,731\nAMP\nprescriptions,\ncomprising\n1722\n \n \n \n \n \n \n \n \n \n \n \ndifferent\nAMPs,\nwere\nincluded.\nOne\nhundred\nADRs\nto\nAMPs\noccurred,\ncaused\n \n \n \n \n \n \n \n \n \n \n \nby\n83\ndifferent\nAMPs.\nADR\nintensity\nwas\nmild,\nmoderate,\nand\nsevere\nin\n50%\n \n \n \n \n \n \n \n \n \n \n \n \n \n(\n\u200b\nn\n=\n50/100),\n43%,\nand\n7%\nof\ncases,\nrespectively;\none\nADR\nwas\nserious.\n \n \n \n \n \n \n \n \n \n \n \n \n \nAmong\npatients\nof\nprescriber\nphysicians,\nADRs\nof\nany\nintensity\noccurred\nin\n \n \n \n \n \n \n \n \n \n \n \n0.071%\n(\n\u200b\nn\n=\n67/94,734)\nof\nAMP\nprescriptions\nand\nin\n0.502%\n(\n\u200b\nn\n=\n65/12,956)\n \n \n \n \n \n \n \n \n \n \n \n \n \nof\npatients\nprescribed\nAMPs.\nIn\nsubgroup\nanalyses\naccording\nto\nage,\nspecific\n \n \n \n \n \n \n \n \n \n \n \nAMPs\nor\nAMP\ngroups,\ndosage\nforms,\nand\nconcentrations\n(altogether\n11\n \n \n \n \n \n \n \n \n \n \ngroups),\nthe\nhighest\nADR\nfrequency\nwas\n0.290%\nof\nprescriptions\n(for\none\n \n \n \n \n \n \n \n \n \n \n \nspecific\nAMP).\nAmong\nall\npatients,\nserious\nADRs\noccurred\nin\n0.0003%\n(\n\u200b\nn\n=\n \n \n \n \n \n \n \n \n \n \n \n \n1/311,731) of prescriptions and 0.0022% (\n\u200b\nn\n\u200b\n = 1/44,662) of patients.\n \nConclusion\n \nIn\nthis\nanalysis\nfrom\na\nlarge\nsample,\nADRs\nto\nAMP\ntherapy\nin\noutpatient\ncare\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nwere rare; ADRs of high intensity as well as serious ADRs were very rare.\n \n \nResumen\n \n \n \nAntecedentes\n \nExiste\nla\nnecesidad\nde\nobtener\ndatos\nacerca\nde\nla\nseguridad\ncl\u00ednica\nde\n \n \n \n \n \n \n \n \n \n \n \n \nlos medicamentos antropos\u00f3ficos.\n \n \nObjetivos\n \nEl\nobjetivo\nprincipal\nde\neste\nan\u00e1lisis\nfue\ndeterminar\nla\nfrecuencia\nde\n \n \n \n \n \n \n \n \n \n \n reacciones\nadversas\na\nmedicamentos\nantropos\u00f3ficos,\nen\nrelaci\u00f3n\ncon\nel\n \n \n \n \n \n \n \n \n \nn\u00famero de prescripciones de estos medicamentos antropos\u00f3ficos.\n \n \nM\u00e9todos\n \nEvaMed\n(Evaluaci\u00f3n\nde\nla\nMedicina\nAntropos\u00f3fica)\nfue\nun\nestudio\n \n \n \n \n \n \n \n \n \nprospectivo\nde\nfarmacovigilancia\ncon\npacientes\nprocedentes\nde\n38\n \n \n \n \n \n \n \n \nm\u00e9dicos\nambulatorios\nde\nAlemania.\nLos\ndiagn\u00f3sticos\ny\nlas\nprescripciones\n \n \n \n \n \n \n \n \n \nse\nobtuvieron\nde\nlos\nregistros\nm\u00e9dicos\nelectr\u00f3nicos.\nTodos\nlos\nm\u00e9dicos\n \n \n \n \n \n \n \n \n \n \ndocumentaron\nlas\nreacciones\nadversas\nde\ngrados\nIII-IV\ny\nlas\nreacciones\n \n \n \n \n \n \n \n \n \n \nadversas\ngraves.\nSiete\n\"m\u00e9dicos\nprescriptores\"\ntambi\u00e9n\nrecogieron\n \n \n \n \n \n \n \ndocumentalmente\nreacciones\nadversas\nno\ngraves\nde\ncualquier\ngrado\nde\n \n \n \n \n \n \n \n \n \nintensidad.\nA\nlos\npacientes\nque\nse\neligieron\npara\neste\nan\u00e1lisis\nse\nles\nhab\u00eda\n \n \n \n \n \n \n \n \n \n \n \n \n \nprescrito\nal\nmenos\nen\nuna\nocasi\u00f3n\nun\nmedicamento\nantropos\u00f3fico\nentre\n \n \n \n \n \n \n \n \n \n \nlos\na\u00f1os\n2001-2010,\ny\ntras\nesa\nprescripci\u00f3n\nhab\u00edan\nacudido\nuna\no\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \nveces a ese mismo m\u00e9dico.\n \n \nResultados\n \nSe\nincluyeron\nun\ntotal\nde\n44.662\npacientes\ncon\nuna\nsuma\nde\n311.731\n \n \n \n \n \n \n \n \n \n \n \n \nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos,\nque\nincluyeron\n1.722\n \n \n \n \n \n \n \ntipos\nde\nmedicamentos\nantropos\u00f3ficos\ndiferentes.\nSe\nprodujeron\ncien\n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nmedicamentos\ncausados\n\u200b\u200b\npor\n83\nmedicamentos\n \n \n \n \n \n \n \n \nantropos\u00f3ficos\ndiferentes\n\u200b\ncuya\nintensidad\nfue\nleve\no\nmoderada\ny\ngrave\nen\n \n \n \n \n \n \n \n \n \n \n \n50%\n(n\n=\n50/100),\n43%\ny\n7%\nde\nlos\ncasos,\nrespectivamente;\ny\nsolo\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde las reacciones fue considerada grave.\n \n \n \nEntre\nlos\npacientes\na\nlos\nque\nlos\nm\u00e9dicos\nles\nhab\u00edan\nprescrito\n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos,\nlas\nreacciones\nadversas\nde\ncualquier\n \n \n \n \n \n \n intensidad\nocurrieron\nen\nun\n0,071%\n(n\n=\n67\n/\n94.734)\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \nprescripciones\nmedicamentos\nantropos\u00f3ficos,\nsiendo\nesto\nun\n \n \n \n \n \n \n0,502%\n(n\n=\n65\n/\n12.956)\nde\nlos\npacientes\nque\nrecibieron\n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos.\nEn\nlos\nan\u00e1lisis\nde\nsubgrupos\nseg\u00fan\n \n \n \n \n \n \n \n \nla\nedad,\nlos\ngrupos\nde\nmedicamentos\nantropos\u00f3ficos\no\n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nespec\u00edficos,\nlas\nformas\nde\n \n \n \n \n \n \ndosificaci\u00f3n\ny\nlas\nconcentraciones\n(en\ntotal\n11\ngrupos),\nla\nfrecuencia\n \n \n \n \n \n \n \n \n \n \nm\u00e1s\nalta\nde\nreacciones\nadversas\na\nmedicamentos\nfue\ndel\n0,290%\nde\n \n \n \n \n \n \n \n \n \n \n \nlas\nprescripciones\n(para\nun\nmedicamento\nantropos\u00f3fico\nespec\u00edfico).\n \n \n \n \n \n \n \nEntre\ntodos\nlos\npacientes,\nse\nprodujeron\nreacciones\nadversas\na\n \n \n \n \n \n \n \n \n \nmedicamentos\ngraves\nen\nel\n0,0003%\n(n\n=\n1\n/\n311,731)\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \nprescripciones, esto es el 0,0022% (n = 1 / 44,662) de los pacientes.\n \n \nConclusi\u00f3n\n \nEn\neste\nan\u00e1lisis,\nque\ncuenta\ncon\nun\nmuestreo\ngrande,\nlas\nreacciones\n \n \n \n \n \n \n \n \n \n \n \nadversas\nal\ntratamiento\ncon\nmedicamentos\nantropos\u00f3ficos\nen\natenci\u00f3n\n \n \n \n \n \n \n \n \nambulatoria\nfueron\npoco\nfrecuentes.\nLas\nreacciones\nadversas\ngraves\nde\n \n \n \n \n \n \n \n \n \nalta\nintensidad\ny\nlas\nreacciones\nadversas\ngraves\nresultaron\nmuy\n \n \n \n \n \n \n \n \n \ninfrecuentes.\n \n \nClaves\n \n\u25cf\nEste\nan\u00e1lisis\npara\nevaluar\nla\nseguridad\nse\nllev\u00f3\na\ncabo\ncon\n44.662\n \n \n \n \n \n \n \n \n \n \n \n \npacientes\nambulatorios\ny\nun\ntotal\nde\n311.731\nde\nprescripciones\nde\n \n \n \n \n \n \n \n \n \n \nmedicamentos antropos\u00f3ficos.\n \n\u25cf\nLas\nreacciones\nadversas\na\nestos\nmedicamentos\nfueron\nraras\n \n \n \n \n \n \n \n \n(0,071%\nde\nlas\nprescripciones)\ny\nlas\nreacciones\nadversas\ngraves\n \n \n \n \n \n \n \n \n \nfueron muy raras (0,0003%).\n \u25cf\nPor\ntanto,\nse\npuede\nconcluir\nque\nla\nterapia\ncon\nmedicaci\u00f3n\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3fica resulta un tratamiento seguro.\n \n \n \n1.\nAntecedentes\n \n \n1.1\n\u200b\nFarmacovigilancia\nde\nmedicamentos\nutilizados\nen\nel\nsistema\n \n \n \n \n \n \n \nm\u00e9dico generalista\n \n \nLa\nseguridad\ncl\u00ednica\nde\nlos\nmedicamentos\nque\nse\nhallan\nen\nel\n \n \n \n \n \n \n \n \n \n \n \nmercado\nes\nun\nproblema\nactual\nde\nsalud\np\u00fablica\ny\nresulta\nde\nprimordial\n \n \n \n \n \n \n \n \n \n \n \n \nimportancia de cara a su regulaci\u00f3n.\n \n \n \n \nLa\nciencia\nrelacionada\ncon\nla\ndetecci\u00f3n,\nla\nevaluaci\u00f3n,\nla\n \n \n \n \n \n \n \n \n \ncomprensi\u00f3n\ny\nla\nprevenci\u00f3n\nde\nlos\nefectos\nadversos\no\ncualquier\notro\n \n \n \n \n \n \n \n \n \n \n \nproblema\nrelacionado\ncon\nlos\nmedicamentos\nse\nconoce\ncomo\n \n \n \n \n \n \n \n \nfarmacovigilancia.\nLos\nm\u00e9todos\nutilizados\nen\nesta\nfarmacovigilancia\n \n \n \n \n \n \n \nincluyen\npruebas\nprecl\u00ednicas,\nnotificaci\u00f3n\nespont\u00e1nea\nde\nsospecha\nde\n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nmedicamentos,\nestudios\nde\ncasos\ny\ncontroles,\n \n \n \n \n \n \n \n \n \nestudios\nde\ncohortes,\nan\u00e1lisis\nde\nbases\nde\ndatos\ny\nensayos\ncl\u00ednicos\n[9].\n \n \n \n \n \n \n \n \n \n \n \n \nLos\ncentros\nnacionales\ne\ninternacionales\nde\nfarmacovigilancia\n(por\n \n \n \n \n \n \n \n \nejemplo,\nel\nCentro\nde\nMonitoreo\nde\nUppsala\nde\nla\nOMS\n[8],\nla\nAgencia\n \n \n \n \n \n \n \n \n \n \n \n \n \nEuropea\nde\nMedicamentos\n[3])\nson\nactores\nprincipales\npara\niniciar\ny\n \n \n \n \n \n \n \n \n \n \ncoordinar\nactividades\nde\nfarmacovigilancia,\naunque\nlas\niniciativas\n \n \n \n \n \n \n \ntambi\u00e9n pueden provenir de otros interesados.\n \n \n \nActualmente\nla\nfarmacovigilancia\nse\nha\ndiversificado\npara\ndar\n \n \n \n \n \n \n \n \ncabida\na\ndiferentes\ngrupos\nde\nproductos\nterap\u00e9uticos,\ncomo\npueden\nser\n \n \n \n \n \n \n \n \n \n \nlos\nprocedentes\nde\nplantas\n[11]\ny\notros\nmedicamentos\nutilizados\nen\n \n \n \n \n \n \n \n \n \n \nsistemas\nm\u00e9dicos\nintegrales\n[7,\n13,\n43].\nDe\nestos\nmedicamentos\nde\nuso\n \n \n \n \n \n \n \n \n \n \n \ngeneral,\nalgunos,\npor\nejemplo,\nlos\nutilizados\ntradicionalmente\nen\nChina\n \n \n \n \n \n \n \n \n \n[43]\ny\nlos\nde\nmedicina\ntradicional\nindia\n[13])\nse\nprodujeron\n \n \n \n \n \n \n \n \n \n \nhist\u00f3ricamente\n\u00fanicamente\npara\nsu\nuso\nlocal.\nActualmente,\nla\n \n \n \n \n \n \n \n producci\u00f3n\na\nescala\nindustrial\nse\nha\ndesarrollado\nsin\nel\nriguroso\ncontrol\n \n \n \n \n \n \n \n \n \n \n \nde\ncalidad\nde\nla\nfabricaci\u00f3n\nmoderna\nde\nmedicamentos,\ny\nen\nmuchos\n \n \n \n \n \n \n \n \n \n \n \npa\u00edses,\nestos\nmedicamentos,\nde\nuso\ngeneral,\nse\nencuentran\nregulados\n \n \n \n \n \n \n \n \n \ncomo\nalimentos\no\ncomplementos\nalimenticios\no\nson\nimportados\npara\nsu\n \n \n \n \n \n \n \n \n \n \nuso\nsin\nninguna\nregulaci\u00f3n.\nAlgunos\nde\nestos\nmedicamentos\nde\nuso\n \n \n \n \n \n \n \n \n \n \ngeneral\nse\nhan\nllegado\na\nasociar\ncon\nreacciones\nadversas\nfrecuentes\ny\n \n \n \n \n \n \n \n \n \n \n \ngraves,\nincluyendo\ntoxicidad.\nLas\nactuales\niniciativas\nde\n \n \n \n \n \n \n \nfarmacovigilancia\nhacia\nestos\nmedicamentos\nde\nuso\ngeneral\nhan\nde\n \n \n \n \n \n \n \n \n \nenfrentar\ndesaf\u00edos\nespec\u00edficos,\ncomo\nson,\npor\nejemplo,\nproblemas\nde\n \n \n \n \n \n \n \n \n \nclasificaci\u00f3n,\nfalta\nde\nestandarizaci\u00f3n,\ncontaminaci\u00f3n\npor\nmetales\n \n \n \n \n \n \n \npesados \n\u200b\u200b\no pesticidas [12]).\n \n \nPara\nlos\nmedicamentos\nde\nuso\ngeneral\nempleados\nen\nhomeopat\u00eda\n \n \n \n \n \n \n \n \n \ny\nmedicina\nantropos\u00f3fica,\nla\nsituaci\u00f3n\nhist\u00f3rica\ny\nnormativa\nes\ndiferente,\n \n \n \n \n \n \n \n \n \n \nya\nque\ndesde\nel\n\u00faltimo\ncuarto\ndel\nsiglo\nXX,\nestos\nse\nhan\ncomercializado\n \n \n \n \n \n \n \n \n \n \n \n \n \nen\npa\u00edses\neuropeos\ncomo\nAustria,\nFrancia,\nAlemania\ny\nSuiza\ncomo\n \n \n \n \n \n \n \n \n \n \nf\u00e1rmacos\ny\nhan\nsido\nfabricado\nseg\u00fan\nlos\nest\u00e1ndares\nde\n\u200b\nBuenas\n \n \n \n \n \n \n \n \n \n \nPr\u00e1cticas\nde\nFabricaci\u00f3n\nsujetas\na\nla\nmoderna\nregulaci\u00f3n\nde\n \n \n \n \n \n \n \n \n \nmedicamentos.\nLas\ntinturas\nmadre\nque\npudieran\nposeer\nuna\ntoxicidad\n \n \n \n \n \n \n \n \n \nrelevante,\ncomo,\npor\nejemplo\nel\nAc\u00f3nito\no\nel\nCinabrio\nhan\nde\nhallarse\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \ndiluciones\nelevadas\nde\nacuerdo\ncon\nlos\nrequisitos\nde\nseguridad\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \nreglamentaciones\neuropeas\n[7,\n15,\n32].\nLas\nreacciones\nadversas\na\nestos\n \n \n \n \n \n \n \n \n \n \nmedicamentos\nson\ninfrecuentes\ny\ngeneralmente\nde\nuna\ngravedad\nque\n \n \n \n \n \n \n \n \n \nva\nde\nleve\na\nmoderada;\nsiendo\nlas\nreacciones\nanafil\u00e1cticas\nposibles,\n \n \n \n \n \n \n \n \n \n \npero\nmuy\ninfrecuentes\n[14,\n27,\n30].\nSin\nembargo,\nla\ngran\nmayor\u00eda\nde\n \n \n \n \n \n \n \n \n \n \n \n \nestos\nmedicamentos\nde\nuso\ngeneral\nse\nintrodujeron\nen\nel\nmercado\n \n \n \n \n \n \n \n \n \n \neuropeo\nantes\nde\nla\nuniversalizaci\u00f3n\nde\nlos\nensayos\ncl\u00ednicos,\npor\ntanto,\n \n \n \n \n \n \n \n \n \n \n \npara\nmuchos\nde\nellos,\nlos\ndatos\nde\nseguridad\nde\nlos\nestudios\ncl\u00ednicos\n \n \n \n \n \n \n \n \n \n \n \n \na\u00fan\nresultan\nescasos.\nAdem\u00e1s,\nexiste\nuna\nnecesidad\nde\nrecabar\nestos\n \n \n \n \n \n \n \n \n \n \nmencionados datos cl\u00ednicos de seguridad para ser empleados en ni\u00f1os.\n \n \nUna\ncaracter\u00edstica\nde\ntodos\nlos\nmedicamentos\nque\nse\nemplean\na\n \n \n \n \n \n \n \n \n \n \nnivel\nglobal\nes\nla\ngran\ncantidad\nde\nproductos\nm\u00e9dicos\ndiferentes\nque\nse\n \n \n \n \n \n \n \n \n \n \n \n \nemplean\ndentro\nde\ncada\nsistema\nm\u00e9dico\ny,\na\nmenudo,\nunidos\na\nterapias\n \n \n \n \n \n \n \n \n \n \n \n \nsin medicamentos.\n \n  \nPara\nacomodarse\na\nesta\ny\notras\ncaracter\u00edsticas\ndescritas\n \n \n \n \n \n \n \n \nanteriormente,\nse\nha\npropuesto\nuna\nestrategia\nde\ninvestigaci\u00f3n\nde\ncinco\n \n \n \n \n \n \n \n \n \n \npasos\npara\nsistemas\nm\u00e9dicos\ngeneralistas\ny\nsus\ncorrespondientes\n \n \n \n \n \n \n \n \nmedicamentos de uso general:\n \n \n1.\nContexto, paradigmas, comprensi\u00f3n filos\u00f3fica y utilizaci\u00f3n\n \n2.\nEstado de seguridad;\n \n \n3.\nEfectividad comparativa;\n \n \n4.\nEficacia de los componentes;\n \n \n5.\nMecanismos de acci\u00f3n biol\u00f3gicos [20].\n \n \n \nEn\neste\nmodelo,\nla\nevaluaci\u00f3n\ndel\nefecto\ndel\nmedicamento\ntiene\n \n \n \n \n \n \n \n \n \n \nlugar\nprimero\na\nnivel\nde\ntodo\nel\nsistema\n(Paso\n3:\neficacia\ncomparativa)\ny,\n \n \n \n \n \n \n \n \n \n \n \n \n \nposteriormente,\na\nnivel\nde\nlos\ncomponentes\ndel\nsistema\n(por\nejemplo,\n \n \n \n \n \n \n \n \n \n \ndel\nsistema\nsanitario\nmedido\nindividualmente).\nDel\nmismo\nmodo,\nla\n \n \n \n \n \n \n \n \n \nevaluaci\u00f3n\nde\nseguridad\n(Paso\n2)\nincluye\nan\u00e1lisis\na\nnivel\nde\ntodo\nel\n \n \n \n \n \n \n \n \n \n \n \n \nsistema\nm\u00e9dico,\nas\u00ed\ncomo\npara\ntodos\nlos\nindividuos\nque\ncomponen\nel\n \n \n \n \n \n \n \n \n \n \n \nmencionado\nsistema\n[29].\nEl\npresente\nan\u00e1lisis\nse\nrefiere,\nen\neste\n \n \n \n \n \n \n \n \n \n \ncontexto,\na\nlos\nmedicamentos\nutilizados\nen\nel\nsistema\nm\u00e9dico\ngeneral\n \n \n \n \n \n \n \n \n \n \ny\nsu\nalcance\nprincipal\nes\nel\nuso\n(Paso\n1)\ny\nen\nla\nseguridad\n(Paso\n2)\na\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nnivel de todo el sistema.\n \n \n1.2 Medicamentos antropos\u00f3ficos y estudio Eva Med\n \nLa\nMedicina\nantropos\u00f3fica\nfue\ndesarrollada\nen\ntorno\nal\na\u00f1o\n1920\nen\n \n \n \n \n \n \n \n \n \n \n \n \nAlemania\ny\nSuiza\nsiendo\nactualmente\npracticada\npor,\naproximadamente\n \n \n \n \n \n \n \n \nunos\n19.000\nm\u00e9dicos\nde\ntodo\nel\nmundo\n[4].\nLa\nterapia\nantropos\u00f3fica\nse\n \n \n \n \n \n \n \n \n \n \n \n \nemplea\nen\nhospitales\ny\nen\ncentros\nambulatorios\ncubriendo\nla\nmayor\u00eda\n \n \n \n \n \n \n \n \n \n \nde\nlos\nmedicamentos\nantropos\u00f3ficos\nm\u00e9dicos,\nempleando\nuna\ngran\n \n \n \n \n \n \n \n \ncantidad\nde\ndiferentes\nmedicamentos\nque\nsuperan\nlas\n1300\nreferencias\n \n \n \n \n \n \n \n \n \ncomercializadas.\nDatos\nobtenidos\nen\nAlemania\nentre\nlos\na\u00f1os\n \n \n \n \n \n \n \n \n2012-2014.\n \n \nLos\nmedicamentos\nantropos\u00f3ficos\ntienen\nsu\norigen\nen\nel\nmundo\nvegetal,\n \n \n \n \n \n \n \n \n \n \nanimal\no\nmineral,\nsiendo\nsiempre\nsustancias\nqu\u00edmicamente\ndefinibles\n \n \n \n \n \n \n \n \n[26];\nlos\nest\u00e1ndares\nde\ncalidad\npara\nlos\nmateriales\nde\npartida\ny\nlos\n \n \n \n \n \n \n \n \n \n \n \n \nprocedimientos\nde\nfabricaci\u00f3n\nest\u00e1n\ndescritos\nen\nla\nFarmacopea\n \n \n \n \n \n \n \n Europea\n(Ph.Eur.),\nen\nla\nalemana\n[Deutsches\nArzneibuch\n(DAB),\n \n \n \n \n \n \n \n \nDeutsches\nHom\u00f6opathisches\nArzneibuch\n(HAB)],\nen\nla\nfrancesa\n(Ph.fr.)\n \n \n \n \n \n \n \n \ny\nen\nla\nsuiza\n(Ph.\nHelv.),\nas\u00ed\ncomo\nen\nlas\nFarmacopeas\nantropos\u00f3ficas\n \n \n \n \n \n \n \n \n \n \n \n \ndenominadas\nAnthroposophic\nPharmaceutical\nCodex\n(APC)\n[26].\nLos\n \n \n \n \n \n \n \nprocedimientos\nde\nfabricaci\u00f3n\npara\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \nincluyen\nprocedimientos\nest\u00e1ndar\nutilizados\npara\nla\nfabricaci\u00f3n\nde\n \n \n \n \n \n \n \n \nmedicamentos homeop\u00e1ticos o de fitoterapia\n \n \n \n \nLa\nfarmacolog\u00eda\nantropos\u00f3fica\ntambi\u00e9n\ncuenta\ncon\nprocedimientos\n \n \n \n \n \n \n \nespec\u00edficos, como son:\n \n \n\u25cf\nLa\nproducci\u00f3n\nde\nespejos\nmet\u00e1licos\n(que\nconsiste\nen\nla\n \n \n \n \n \n \n \n \n \n \ncondensaci\u00f3n\nde\nvapores\nmet\u00e1licos\nsobre\nuna\nsuperficie\npara\n \n \n \n \n \n \n \n \nformar un espejo [26])\n \n \n \n\u25cf\nEl procesamiento de plantas medicinales mediante\n \n\u25cb\nfermentaci\u00f3n,\n \n \n\u25cb\ntostado\n \n\u25cb\ncarbonizaci\u00f3n\n \n\u25cb\nincineraci\u00f3n\n \n \n\u25cb\ndigesti\u00f3n (tratamiento t\u00e9rmico a 37 \u00b0 C)\n \n \n\u25cf\nEl\ncultivo\nde\nplantas\nen\nsuelos\nque\nse\nhan\ntratado\npreviamente\n \n \n \n \n \n \n \n \n \n \n \ncon\nsales\nmet\u00e1licas\ndiluidas\n,\nen\nlo\nque\nse\nha\ndenominado\n \n \n \n \n \n \n \n \n \n \n \nespec\u00edficamente vegetabilizaci\u00f3n de metales).\n \n \n \nLos\nmedicamentos\nantropos\u00f3ficos\nse\nfabrican\nen\nforma\nde\ntinturas\n \n \n \n \n \n \n \n \n \nmadre\ny\nen\npotencias\ndecimales\nhomeop\u00e1ticas\n(que\nimplican\ndiluciones\n \n \n \n \n \n \n \n \n \nsucesivas\nde\n1:10).\nSe\nadministran\npor\nv\u00eda\noral,\nrectal,\nvaginal,\npor\nv\u00eda\n \n \n \n \n \n \n \n \n \n \n \n \nocular\nen\nforma\nde\ncolirios,\nnasal\no\nmediante\ninyecciones\nsubcut\u00e1neas,\n \n \n \n \n \n \n \n \n \n \nintramusculares\no\nintravenosas\n[26].\nEn\nresumen,\na\npesar\nde\ncierta\n \n \n \n \n \n \n \n \n \n \nsimilitud\ncon\nlos\nmedicamentos\nhomeop\u00e1ticos\ny\nde\norigen\nvegetal,\nlos\n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\ncomo\ngrupo\ntienen\npropiedades\npropias\ne\n \n \n \n \n \n \n \n \ninherentes  que pueden influir en su seguridad cl\u00ednica.\n  \nTanto\nla\nseguridad\ncomo\nlos\nefectos\ndel\ntratamiento\ncon\nmedicamentos\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\nse\nhan\nevaluado\na\nnivel\nde\ntodo\nel\nsistema\nsanitario\n \n \n \n \n \n \n \n \n \n \n \ncomo a nivel individual de cada medicamento.\n \n \nUna\nrevisi\u00f3n\nsistem\u00e1tica\nde\nlos\nestudios\ncl\u00ednicos\nde\nla\nmedicina\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3fica\ndesde\n2011\ncomprende\n255\nestudios\nque\nincluyeron\nel\n \n \n \n \n \n \n \n \n \ntratamiento\ncon\nmedicamentos\nde\norigen\nantropos\u00f3fico,\ncon\n38\nestudios\n \n \n \n \n \n \n \n \n \nque\neval\u00faan\ntodo\nel\nsistema\ny\n217\nestudios\nreferidos\na\nmedicamentos\n \n \n \n \n \n \n \n \n \n \n \nindividuales\no\na\npeque\u00f1os\ngrupos\nde\nf\u00e1rmacos.\nEstos\nestudios\nfueron\n \n \n \n \n \n \n \n \n \n \nvalidados\npor\nrevisiones\nexternas\nalcanzando\nuna\nalta\nevaluaci\u00f3n,\n \n \n \n \n \n \n \n \naunque\nmuchos\nde\nellos\ncontaron\ncon\ndeficiencias\nmetodol\u00f3gicas.\nLas\n \n \n \n \n \n \n \n \n \nconclusiones\nde\nlas\nrevisiones\nde\nlos\ndiferentes\nensayos\ncon\ndise\u00f1o\ny\n \n \n \n \n \n \n \n \n \n \n \ncalidad\ndispar\nestudiando\nuna\nvariedad\nde\nenfermedades\nmostraron,\nen\n \n \n \n \n \n \n \n \n \nsu\nmayor\u00eda,\nresultados\ncl\u00ednicos\nsatisfactorios\ny\nefectos\nsecundarios\n \n \n \n \n \n \n \n \nmarginales,\ncon\nuna\nalta\nsatisfacci\u00f3n\ndel\npaciente\ny\nunos\ncostes\n \n \n \n \n \n \n \n \n \n \npresumiblemente menores a los de otras terapias [30].\n \n \nUna\noportunidad\npara\nevaluar\nla\nseguridad\ncl\u00ednica\nde\nlos\n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nfue\nla\nllamada\nEvaluaci\u00f3n\nde\nla\n \n \n \n \n \n \n \n \nFarmacovigilancia\nde\nla\nMedicina\nAntropos\u00f3fica\n(\n\u200b\nEvaMed\n\u200b\n),\nun\nestudio\n \n \n \n \n \n \n \n \nprospectivo\nalem\u00e1n,\nmultic\u00e9ntrico\nque\nobserv\u00f3\ny\nanaliz\u00f3\nla\nprescripci\u00f3n\n \n \n \n \n \n \n \n \n \ny\nla\nseguridad\nde\nlos\nmedicamentos\nque\nse\nemplean\nen\nla\nMedicina\n \n \n \n \n \n \n \n \n \n \n \n \nantropos\u00f3fica.\nEl\nestudio\nEvaMed\nemple\u00f3\nun\nnuevo\nm\u00e9todo\npara\nla\n \n \n \n \n \n \n \n \n \n \nextracci\u00f3n\nautom\u00e1tica\nde\ndatos\nb\u00e1sicos\nan\u00f3nimos\nde\nlos\nregistros\n \n \n \n \n \n \n \n \n \nm\u00e9dicos\nelectr\u00f3nicos\nde\nlos\nm\u00e9dicos,\ncombinado\ncon\nun\nenfoque\n \n \n \n \n \n \n \n \n \nestructurado\npara\nla\ndetecci\u00f3n\ny\nel\ninforme\nde\nsospechas\nde\nReacciones\n \n \n \n \n \n \n \n \n \n \n \nadversas\na\nmedicamentos\ndurante\nla\natenci\u00f3n\nambulatoria\nde\nrutina.\n \n \n \n \n \n \n \n \n \nLos\nan\u00e1lisis\nprevios\nde\nEvaMed\nincluyeron\nlas\nprescripciones\ncon\n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\na\nni\u00f1os\ndurante\nun\na\u00f1o\n(2005\n[25]),\nlas\n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nmedicamentos\nde\nun\npeque\u00f1o\nsubgrupo\n \n \n \n \n \n \n \n \nmedicamentos\n(extractos\nde\norigen\nvegetal\nde\nplantas\nde\nla\nfamilia\nde\n \n \n \n \n \n \n \n \n \n \n \nlas\ncompuestas,Asteraceae\n[23])\ny\nla\nseguridad\nde\ntodos\nlos\n \n \n \n \n \n \n \n \n \nmedicamentos\ndurante\nun\nper\u00edodo\nde\ncinco\na\u00f1os\ny\nmedio,\ncomprendido\n \n \n \n \n \n \n \n \n \n \nentre\nenero\nde\n2004\na\nJunio\n\u200b\u200b\ndel\n2009\naunque\ncarece\nde\ndatos\nsobre\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsubgrupo\nde\nmedicamentos\nantropos\u00f3ficos\n[40].\nEn\nel\npresente\n \n \n \n \n \n \n \n documentos\nse\npresenta\nun\nan\u00e1lisis\nde\nprescripci\u00f3n\ny\nseguridad\nde\n \n \n \n \n \n \n \n \n \n \ntodos\nlos\nlos\nmedicamentos\nantropos\u00f3ficos\nen\nEvaMed.\nEn\ncomparaci\u00f3n\n \n \n \n \n \n \n \n \n \ncon\nlos\nan\u00e1lisis\nprevios,\neste\ninforme\ncubre\nun\nper\u00edodo\nde\n \n \n \n \n \n \n \n \n \n \ndocumentaci\u00f3n\nm\u00e1s\nextenso\n(10\na\u00f1os,\n2001-2010)\ny\nproporciona\ndatos\n \n \n \n \n \n \n \n \n \nespec\u00edficos\nsobre\nReacciones\nadversas\na\nmedicamentos\n \n \n \n \n \n \nantropos\u00f3ficos,\ntestando\ntambi\u00e9n\nindicados\nlos\ndiferentes\nsubgrupos\na\n \n \n \n \n \n \n \n \nlos que pertenecen.\n \n \n2.\nM\u00e9todos\n \n \n2.1 Objetivos\n \nEl\nobjetivo\nprincipal\nde\neste\nan\u00e1lisis\nEvaMed\nfue\n\u200b\ndeterminar\nla\n \n \n \n \n \n \n \n \n \n \nfrecuencia\nde\nreacciones\nadversas\na\nmedicamentos\n \n \n \n \n \n \nantropos\u00f3ficos\n\u200b\n,\nen\nrelaci\u00f3n\ncon\nla\ncantidad\nde\nprescripciones,\npara\n \n \n \n \n \n \n \n \n \ntodos\nlos\nmedicamentos\nantropos\u00f3ficos\ny\npara\ncada\nuno\nde\nellos,\n \n \n \n \n \n \n \n \n \n \nespec\u00edficamente,\nen\nsubgrupos\nseg\u00fan\nla\nedad,\nlos\ngrupos\nterap\u00e9uticos\no\n \n \n \n \n \n \n \n \n \n \nlas formas de dosificaci\u00f3n y las concentraciones.\n \n \nOtros objetivos fueron\n \n\u25cf\ndescribir\nlas\ncaracter\u00edsticas\nde\nla\nprescripci\u00f3n\nde\nmedicamentos\n \n \n \n \n \n \n \n \nantropos\u00f3ficos y otros medicamentos\n \n\u25cf\npara\ncomparar\nla\nfrecuencia\nde\nreacciones\nadversas\na\n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nen\nrelaci\u00f3n\na\notros\nmedicamentos\n \n \n \n \n \n \n \nque no tienen ese origen.\n \n \n \n2.2 La red de farmacovigilancia EvaMed\n \nEvaMed\nse\nrealiz\u00f3\ncomo\nun\nestudio\nprospectivo,\nmultic\u00e9ntrico\ny\n \n \n \n \n \n \n \n \n \nemp\u00edrico\nllev\u00e1ndose\na\ncabo\nen\nconsultas\nm\u00e9dicas\nambulatorias\na\nlo\n \n \n \n \n \n \n \n \n \n \nlargo\nde\ntoda\nAlemania.\nLas\ndescripciones\ndetalladas\ntanto\nde\nla\n \n \n \n \n \n \n \n \n \n \nconfiguraci\u00f3n,\ncomo\nde\nlos\nparticipantes\ny\nla\nrecopilaci\u00f3n\nde\ndatos\nse\n \n \n \n \n \n \n \n \n \n \n \nhan publicado en otra parte [24, 40].\n \n \nEn\nresumen,\nparticiparon\n38\nm\u00e9dicos\n(21\nm\u00e9dicos\nde\nfamilia,\n9\n \n \n \n \n \n \n \n \n \n \npediatras, 4 internistas y 4 de otras especialidades). Proced\u00edan de\n \n de\n12\nde\nlos\n16\nestados\nfederales\nalemanes;\ncontaban\ncon\nal\nmenos\n5\n \n \n \n \n \n \n \n \n \n \n \n \n \na\u00f1os\nde\nexperiencia\npr\u00e1ctica\nen\nla\nmedicina\nantropos\u00f3fica,\ny\nutilizaron\n \n \n \n \n \n \n \n \n \n \nun\nsistema\nde\nregistro\nm\u00e9dico\nelectr\u00f3nico\nque\ncumpl\u00eda\ncon\nlos\nrequisitos\n \n \n \n \n \n \n \n \n \n \n \nt\u00e9cnicos para la recopilaci\u00f3n pr\u00e1ctica de datos.\n \n \nPara\ncada\nconsulta\ncon\nel\npaciente,\nlos\ndatos\nb\u00e1sicos\nan\u00f3nimos\n \n \n \n \n \n \n \n \n \n \nse\nextrajeron\nautom\u00e1ticamente\nde\nlos\nregistros\nm\u00e9dicos\nelectr\u00f3nicos:\n \n \n \n \n \n \n \n \nfecha\nde\nconsulta;\nedad\ndel\npaciente,\nsexo,\ndiagn\u00f3stico\no\ndiagn\u00f3sticos;\n \n \n \n \n \n \n \n \n \n \nprescripciones\nfarmacol\u00f3gicas\ncompletas\ny\ntratamiento\nno\n \n \n \n \n \n \nfarmacol\u00f3gico.\nTodos\nlos\nm\u00e9dicos\nse\nvieron\nobligados\na\nvincular\ntodas\n \n \n \n \n \n \n \n \n \n \nlas\nprescripciones\nmedicamentos\na\nlas\nrespectivas\nindicaciones\ncon\nlos\n \n \n \n \n \n \n \n \n \nrespectivos\ndiagn\u00f3sticos)\ny\ndocumentar\ntodas\nlas\nreacciones\nadversas\n \n \n \n \n \n \n \n \ngraves,\nas\u00ed\ncomo\ntodas\nlas\nreacciones\nadversas\nde\nintensidad\nIII-IV\na\n \n \n \n \n \n \n \n \n \n \n \ncualquier\nmedicamento.\nAdem\u00e1s,\nun\nsubgrupo\nde\nsiete\n\"m\u00e9dicos\n \n \n \n \n \n \n \n \nprescriptores\"\nacord\u00f3\ntambi\u00e9n\ndocumentar\ntodas\nlas\nreacciones\n \n \n \n \n \n \n \nadversas\nno\ngraves\nde\ncualquier\nintensidad.\nPor\nlo\ndem\u00e1s,\nel\nestudio\nse\n \n \n \n \n \n \n \n \n \n \n \n \nrealiz\u00f3\nen\ncondiciones\nhabituales\nen\nuna\nconsulta\ncon\nreacciones\n \n \n \n \n \n \n \n \n \nadversas\na\nmedicamentos\nidentificadas\nen\nlas\nconsultas\nde\nseguimiento\n \n \n \n \n \n \n \n \n \nordinarias,\nsin\nninguna\nvisita\nde\nseguimiento\nprogramada\nadicional.\nLos\n \n \n \n \n \n \n \n \n \nm\u00e9dicos\nfueron\nremunerados\ncon\n15\neuros\npor\ncada\ninforme\nde\n \n \n \n \n \n \n \n \n \n \nreacciones\nadversa\ndocumentada\npero\nno\npor\nsu\nparticipaci\u00f3n;\nlos\n \n \n \n \n \n \n \n \n \npacientes no recibieron ning\u00fan tipo de remuneraci\u00f3n.\n \n \n2.3 Criterios para ser elegidos en este an\u00e1lisis\n \nEva\nMed\neligi\u00f3\npara\neste\nan\u00e1lisis\na\nm\u00e9dicos\no\npacientes\ncon\nlos\n \n \n \n \n \n \n \n \n \n \n \n \nsiguientes criterios:\n \n\u25cf\nAl\nmenos\ndeber\u00edan\ntener\nuna\nprescripci\u00f3n\ndocumentada\ncon\nun\n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3fico\nentre\nel\n1\nde\nenero\nde\n2001\ny\nel\n31\n \n \n \n \n \n \n \n \n \n \n \n \nde diciembre de 2010\n \n\u25cf\nPosteriormente\na\nesta\nprescripci\u00f3n\ndeb\u00eda\nexistir,\nal\nmenos\nuna\n \n \n \n \n \n \n \n \n \nvisita\na\nun\nm\u00e9dico\nque\nse\nencontrase\ndentro\ndel\nprograma\nEva\n \n \n \n \n \n \n \n \n \n \n \nMed\nen\nel\nperiodo\nentre\nel\n2\nde\nenero\nde\n2001\ny\nel\n31\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \ndiciembre de 2011\n \n \n Estos\ncriterios\nse\nseleccionaron\npara\nidentificar\na\nlos\npacientes\na\n \n \n \n \n \n \n \n \n \n \nlos\nque\nse\npod\u00edan\ndetectar\nuna\nreacci\u00f3n\nadversa\na\nalg\u00fan\ntipo\nde\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamento\nantropos\u00f3fico\n(la\ndocumentaci\u00f3n\nEvaMed\ncomenz\u00f3\nen\n \n \n \n \n \n \n \n1997,\npero\ndurante\nlos\na\u00f1os\n1997-2000\nsolo\nse\ndocumentaron\n70\n \n \n \n \n \n \n \n \n \n \nmedicamentos\ny\nno\nse\npresentaron\nreacciones\nadversas\na\nlos\n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos;\npor\nlo\nque\nestos\na\u00f1os\nquedaron\n \n \n \n \n \n \n \n \nexcluidos del an\u00e1lisis).\n \n \n2.4 Obtenci\u00f3n de los resultados\n \n \nEl\nprimer\ndato\na\ntener\nen\ncuenta\nen\neste\nan\u00e1lisis\nfue\nla\nfrecuencia\n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nreacciones\nadversas\na\nlos\nmedicamentos\nantropos\u00f3ficos\n[fuese\nde\nla\n \n \n \n \n \n \n \n \n \n \nintensidad\nque\nfuese\n,\ndesde\nel\ngrado\nIII-IV\nhasta\nlas\ngraves\n(SADR)],\n \n \n \n \n \n \n \n \n \n \n \n \nrelacion\u00e1ndolas\ncon\nel\nn\u00famero\nde\nprescripciones\nmedicamentos\n \n \n \n \n \n \n \nantropos\u00f3ficos.\n \nLos siguientes datos que se tuvieron en cuenta fueron:\n \n \n\u25cf\nPropiedades\nde\nlos\nmedicamentos\nantropos\u00f3ficos\nprescritos:\n \n \n \n \n \n \ningredientes,\nprocedimientos\nde\nfabricaci\u00f3n,\nconcentraci\u00f3n\nde\n \n \n \n \n \n \nprincipios activos, formas de administraci\u00f3n.\n \n\u25cf\nIndicaciones\npara\nla\nprescripci\u00f3n\nde\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \ny de medicamentos no antropos\u00f3ficos;\n \n\u25cf\nFrecuencia\nde\nreacciones\nadversas\nde\nlos\nmedicamentos\n \n \n \n \n \n \n \nantropos\u00f3ficos\ny\nde\nlos\nno\nantropos\u00f3ficos,\nen\nrelaci\u00f3n\ncon\nla\n \n \n \n \n \n \n \n \n \n \ncantidad de prescripciones\n \n\u25cf\nCaracter\u00edsticas\npropias\nde\nlas\nreacciones\nadversas\na\n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\ny\na\nlos\nque\nno\nson\nmedicamentos\n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos,\ncuantificando\nen\ncada\nuno\nde\nlos\ngrupos\nla\n \n \n \n \n \n \n \n \n \nintensidad\ny\ntipo\nde\ns\u00edntomas;\nla\nfrecuencia,\nprevalencia,\n \n \n \n \n \n \n \n \nduraci\u00f3n,\nmanejo,\nresultado\ny\ngravedad\nde\ndichas\nreacciones\n \n \n \n \n \n \n \n \nadversas.\n \n \n2.5\nDocumentaci\u00f3n,\npreparaci\u00f3n\ny\nclasificaci\u00f3n\nde\nlos\ndatos\n \n \n \n \n \n \n \n \nobtenidos\n \n El\nt\u00e9rmino\n\"prescripci\u00f3n\"\nse\nrefiere\na\ncada\nuna\nde\nlas\n \n \n \n \n \n \n \n \n \n \nprescripciones\nde\nun\nm\u00e9dico\nde\nfamilia\nde\nun\nmedicamento\ncont\u00e1ndose\n \n \n \n \n \n \n \n \n \n \npor separado cada una de estas prescripciones\n \n \nEl\nconjunto\nde\ndatos\npara\nel\npresente\nan\u00e1lisis\nfue\nrecopilado\npor\nel\n \n \n \n \n \n \n \n \n \n \n \n \nautor\nKirsten\nHeckenbach\nverificando\nlos\ndatos\nde\nprescripci\u00f3n\ndel\n \n \n \n \n \n \n \n \n \nconjunto\nde\ndatos\nsin\nprocesar,\nexcluyendo\nprescripciones\nque\nno\n \n \n \n \n \n \n \n \n \nhacen\nreferencia\na\nmedicamentos,\ncomo,\npor\nejemplo,\nsuplementos\n \n \n \n \n \n \n \n \nalimenticios,\nproductos\nde\ncuidado\ncorporal;\nprescripciones\nde\n \n \n \n \n \n \n \nmedicamentos\ninclasificables\ny\nconsultas\nsin\nprescripci\u00f3n.\n \n \n \n \n \n \nPosteriormente\nla\nautora\nAnja\nGlockman,\nverific\u00f3\ny\nclasific\u00f3\ntodas\nlas\n \n \n \n \n \n \n \n \n \n \nprescripciones de medicamentos antropos\u00f3ficos.\n \n \n2.5.1 Medicamentos antropos\u00f3ficos\n \n \nLos\nmedicamentos\nantropos\u00f3ficos\nse\ndefinieron\nde\nacuerdo\ncon\nla\n \n \n \n \n \n \n \n \n \nLey\nalemana\nde\nmedicamentos\n[2].\nA\nefectos\npr\u00e1cticos,\ntodos\nlos\n \n \n \n \n \n \n \n \n \n \nmedicamentos\ncomercializados\nen\nAlemania\npor\nlos\nfabricantes\nAbnoba\n \n \n \n \n \n \n \n \n(Pforzheim,\nAlemania),\nBirken\n(Niefern-\u00d6schelbronn,\nAlemania),\nHelixor\n \n \n \n \n \n \n(Rosenfeld,\nAlemania),\nWala\n(Bad\nBoll,\nAlemania)\ny\nWeleda\n(Arlesheim,\n \n \n \n \n \n \n \n \n \nSuiza)\nfueron\nclasificados\ncomo\nmedicamentos\nantropos\u00f3ficos.\nPara\nlos\n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nse\nestableci\u00f3\ncomo\nunidad\nde\nan\u00e1lisis\n \n \n \n \n \n \n \n \ncada\nproducto\nque\ncontase\ncon\nun\nregistro\nseparado\no\nautorizaci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \ncomercializaci\u00f3n\ny\ncon\nuna\ninscripci\u00f3n\npor\nseparado\nen\nel\nlistado\nde\nuno\n \n \n \n \n \n \n \n \n \n \n \n \nde sus respectivos fabricantes\n \nPor\nconsiguiente,\nlos\nmedicamentos\nantropos\u00f3ficos\ninscritos\ncon\n \n \n \n \n \n \n \nel\nmismo\nregistro,\naunque\ntuviesen\nun\ntama\u00f1o\no\nconcentraci\u00f3n\ndiferente\n \n \n \n \n \n \n \n \n \n \nse agruparon juntos.\n \nEn\nEvaMed,\nlos\nmedicamentos\nprescritos\nse\nidentificaron\nde\n \n \n \n \n \n \n \n \nacuerdo\ncon\nel\nC\u00f3digo\nNacional\nAlem\u00e1n\nde\nMedicamento\n \n \n \n \n \n \n \n \n(Pharmazentralnummer,\nPZN).\nSin\nembargo,\nlos\nc\u00f3digos\nPZN\nno\nse\n \n \n \n \n \n \n \n \n \nhallan\nen\ntodos\nlos\nmedicamentos\nantropos\u00f3ficos,\ny\nalgunos\nde\nestos\n \n \n \n \n \n \n \n \n \n \nse\ntuvieron\nque\ndocumentar\nmediante\ntexto\nlibre\no\nnombres\npropios\n \n \n \n \n \n \n \n \n \n \nsuyos\no\nabreviaturas.\nAdem\u00e1s,\nalgunos\nc\u00f3digos\nPZN\nrelacionados\ncon\n \n \n \n \n \n \n \n \n medicamentos\nantropos\u00f3ficos\nfueron\nmodificados\ndurante\nel\nper\u00edodo\nde\n \n \n \n \n \n \n \n \nestudio.\n \n \nEstos\nfactores\nsupusieron\nun\nriesgo\nde\nclasificaciones\nerr\u00f3neas,\n \n \n \n \n \n \n \n \nen\nparticular\nentre\nmedicamentos\nantropos\u00f3ficos,\nhomeop\u00e1ticos\no\n \n \n \n \n \n \n \nfitoterap\u00e9uticos.\nPara\nminimizar\nestos\nposibles\nerrores\nde\nclasificaci\u00f3n,\n \n \n \n \n \n \n \n \ntodas\nlas\nprescripciones\nmedicamentos\nantropos\u00f3ficos\n(>\n300,000)\nse\n \n \n \n \n \n \n \n \nvolvieron\na\nevaluar\nmediante\ninspecci\u00f3n\nvisual\nde\ncada\nregistro\nen\nel\n \n \n \n \n \n \n \n \n \n \n \nconjunto\nde\ndatos,\ny\nla\nclasificaci\u00f3n\ncomo\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \n \n \nse\ncotej\u00f3\nmediante\nuna\nverificaci\u00f3n\ncruzada\ncon\nla\nbase\nde\ndatos\nde\n \n \n \n \n \n \n \n \n \n \n \n \ntodos\nlos\nmedicamentos\nantropos\u00f3ficos\ndisponibles\nen\nel\nmercado\n \n \n \n \n \n \n \n \nalem\u00e1n\ndurante\nel\nper\u00edodo\nde\ndocumentaci\u00f3n\n.\nLa\nbase\nde\ndatos\nde\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nque\nse\nemple\u00f3\nfue\nla\nde\nla\nESCAMP\n \n \n \n \n \n \n \n \n \n \n(European\nScientific\nCooperative\non\nAnthroposophic\nMedicinal\n \n \n \n \n \n \nProducts)\ny\nse\nclasificaron\ncon\nrespecto\na\nlas\nmaterias\nprimas,\n \n \n \n \n \n \n \n \n \n \nprocesos\nde\nfabricaci\u00f3n,\ny\nformas\nde\ndosificaci\u00f3n,\nde\nacuerdo\ncon\nAPC\n \n \n \n \n \n \n \n \n \n \n \n(Anthroposophical pharmaceutical codex,  en su  cuarta edici\u00f3n [26].\n \n \nPara\nlos\nmedicamentos\nantropos\u00f3ficos\nunicistas\nmencionados\nen\n \n \n \n \n \n \n \neste\ndocumento,\nlos\nnombres\nregistrados\nse\nrecodificaron\ncomo\n \n \n \n \n \n \n \n \nnombres\ngen\u00e9ricos:\npara\nlos\nmedicamentos\nantropos\u00f3ficos\nfabricados\n \n \n \n \n \n \n \nde\nentre\nuno\ny\ntres\nmateriales\nde\npartida,\nlos\nmateriales\nde\npartida\nse\n \n \n \n \n \n \n \n \n \n \n \n \n \nenumeraron\nen\nel\norden\nutilizado\nen\nlas\nlistas\nde\nmedicamentos;\npara\n \n \n \n \n \n \n \n \n \n \n \nlos\nmedicamentos\nantropos\u00f3ficos\nfabricados\na\npartir\nde\ncuatro\no\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \nmateriales\nde\npartida,\nse\nenumeraron\nlos\ndos\nprimeros\nmateriales\nde\n \n \n \n \n \n \n \n \n \n \npartida, seguidos de la palabra 'comp.'.\n \n \n2.5.2 Otros Medicamentos\n \n \n \nMedicamentos\nno\nantropos\u00f3ficos\nfueron\nclasificados\nen\nel\nInstituto\n \n \n \n \n \n \n \n \nde\nInvestigaci\u00f3n\nHavelh\u00f6he\n(en\nalem\u00e1n:\nForschungsinstitut\nHavelh\u00f6he,\n \n \n \n \n \n \n \nFIH)\nde\nacuerdo\ncon\nel\nSistema\nde\nClasificaci\u00f3n\nAnat\u00f3mica,\nTerap\u00e9utica\n \n \n \n \n \n \n \n \n \n \nQu\u00edmica (ATC).\n \n \n2.5.3 Indicaciones\n  \nLas\nindicaciones\npara\nlas\nprescripciones\nfueron\nclasificadas\npor\n \n \n \n \n \n \n \n \nlos\nm\u00e9dicos\nparticipantes\nde\nacuerdo\ncon\nla\nClasificaci\u00f3n\nInternacional\n \n \n \n \n \n \n \n \n \nde\nEnfermedades\nen\nsu\nd\u00e9cima\nrevisi\u00f3n\n(CIE-10);\nesto\nresult\u00f3\nparte\n \n \n \n \n \n \n \n \n \n \nrutinaria\nen\nel\ntrabajo\nde\nlos\nm\u00e9dicos,\nya\nque\nya\nque\nen\nel\nSistema\n \n \n \n \n \n \n \n \n \n \n \n \n \n \np\u00fablico\nde\nSalud\nde\nAlemania,\nla\nremuneraci\u00f3n\nde\nlos\nm\u00e9dicos\npara\n \n \n \n \n \n \n \n \n \n \n \nconsultas\nde\npacientes\nrequiere\nal\nmenos\nun\ndiagn\u00f3stico\nde\nCIE-10\npor\n \n \n \n \n \n \n \n \n \n \n \nconsulta.\nPara\neste\nan\u00e1lisis,\nlos\ndiagn\u00f3sticos\nse\nagruparon\nseg\u00fan\nlos\n \n \n \n \n \n \n \n \n \n \ncap\u00edtulos de diagn\u00f3stico ICD-10 y los bloques de diagn\u00f3stico ICD-10.\n \n \n2.5.4 Reacciones adversas\n \n \nPor cada reacci\u00f3n adversa los m\u00e9dicos documentaron:\n \n\u25cf\nFecha de inicio y fecha de curaci\u00f3n y remisi\u00f3n completa.\n \n\u25cf\nFrecuencia de la reacci\u00f3n (una vez, varias veces, continua).\n \n\u25cf\nGravedad\nde\nla\nreacci\u00f3n\n(clasificada\nde\nacuerdo\ncon\nlas\n \n \n \n \n \n \n \n \n \nrecomendaciones\ndel\nCentro\nde\nMonitoreo\nUppsala\nde\nla\nOMS\n[8]:\n \n \n \n \n \n \n \n \n \n \nGrados\nI\n=\nleve,\nII\n=\nmoderado,\nIII\n=\nsevero,\nIV\n=\ncon\nriesgo\npara\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nvida).\n \n\u25cf\nS\u00edntomas.\n \n\u25cf\nGravedad\nde\ncada\nuno\nde\nestos\ns\u00edntomas\n(leve,\nmoderado,\n \n \n \n \n \n \n \n \n \nsevero).\n \n\u25cf\nTratamiento\nde\nla\nreacci\u00f3n\nadversa\n(retirada\nde\nlos\nmedicamentos,\n \n \n \n \n \n \n \n \n \nreducci\u00f3n\nde\nla\ndosis,\ncambio\nde\nterapia,\nning\u00fan\ncambio\nen\nel\n \n \n \n \n \n \n \n \n \n \n \nmedicamento y ning\u00fan tratamiento adicional, etc).\n \n \n\u25cf\nResultado tras la retirada del f\u00e1rmaco.\n \n\u25cf\nReevaluaci\u00f3n.\n \n\u25cf\nResultado\n(recuperado,\na\u00fan\nno\nrecuperado,\nda\u00f1o\npermanente,\n \n \n \n \n \n \n \ndesconocido, muerte).\n \n\u25cf\nDiagn\u00f3sticos al inicio de la reacci\u00f3n adversa al medicamento.\n \n\u25cf\nTodos\nlos\nmedicamentos\nutilizados\nal\ninicio\nde\nla\nreacci\u00f3n\nadversa\n \n \n \n \n \n \n \n \n \n \nal medicamento.\n \n\u25cf\nFecha de inicio de la toma del medicamento.\n \nPara\ncada\nmedicamento\nempleado:\nevaluaci\u00f3n\nde\nlos\nm\u00e9dicos\nde\n \n \n \n \n \n \n \n \n \nla\nrelaci\u00f3n\ncausal\ncon\nla\nreacci\u00f3n\nadversa\na\nese\nmedicamento\nen\n \n \n \n \n \n \n \n \n \n \n cuesti\u00f3n.\n \n \nLos\ninformes\nde\nreacci\u00f3n\nadversa\nal\nmedicamento\nde\nlos\nm\u00e9dicos\n \n \n \n \n \n \n \n \n \n \nse\nevaluaron\nen\nFIH\n(Instituto\nde\ninvestigaci\u00f3n\nde\nHavelh\u00f6he)\ncon\nla\n \n \n \n \n \n \n \n \n \n \n \nclasificaci\u00f3n de\n \n \n\u25cf\nGravedad\nde\nla\nreacci\u00f3n\nadversa\nal\nmedicamento.\nUna\nreacci\u00f3n\n \n \n \n \n \n \n \n \n \nadversa\ngrave\nal\nmedicamento\ndefinida\nseg\u00fan\nla\nConferencia\n \n \n \n \n \n \n \n \nInternacional\nsobre\nArmonizaci\u00f3n\n[6]\ncomo\nuna\nreacci\u00f3n\nadversa\n \n \n \n \n \n \n \n \nal\nmedicamento\nque\ncurse\ncon\nla\nmuerte,\nque\nrequiera\n \n \n \n \n \n \n \n \n \nhospitalizaci\u00f3n\no\nprolongaci\u00f3n\nde\nla\nhospitalizaci\u00f3n\nexistente,\nque\n \n \n \n \n \n \n \n \ngenere\nuna\ndiscapacidad\npersistente\no\nsignificativa,\no\nque\npueda\n \n \n \n \n \n \n \n \n \nresultar potencialmente mortal\n \n \n \n\u25cf\nSe\nestableci\u00f3\nla\nrelaci\u00f3n\ncausal\nentre\nla\nreacci\u00f3n\nadversa\nal\n \n \n \n \n \n \n \n \n \n \nmedicamento\ndocumentada\ny\nlos\nmedicamentos\nutilizados\n \n \n \n \n \n \n(clasificados\nseg\u00fan\nel\nCentro\nde\nMonitoreo\nde\nUppsala\nde\nla\nOMS\n \n \n \n \n \n \n \n \n \n \n \n[8]\nclasific\u00e1ndolas\ncomo\ncierto,\nprobable,\nposible,\nimprobable,\n \n \n \n \n \n \n \ncondicional, no clasificado, no evaluable\n \n \n \n \nLa\nevaluaci\u00f3n\nde\ncausalidad\nfue\nrealizada\nen\nel\nFIH\n(Instituto\nde\n \n \n \n \n \n \n \n \n \n \n \ninvestigaci\u00f3n\nde\nHavelh\u00f6he)\nde\nforma\nindependiente\npor\ndos\nm\u00e9dicos\n \n \n \n \n \n \n \n \n \nde\ninvestigaci\u00f3n\ncapacitados\npara\npoder\nvalorar\nsi\nla\nreacci\u00f3n\nadversa\n \n \n \n \n \n \n \n \n \n \nes\nimputable\nal\nmedicamento,\nutilizando\nun\nformulario\nde\nverificaci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \ninforme\nde\ncaso\npredefinido.\nEn\nlos\ncasos\nde\ndesacuerdo\nentre\nlos\ndos\n \n \n \n \n \n \n \n \n \n \n \n \nm\u00e9dicos\ninvestigadores,\nse\nconsult\u00f3\na\nun\nequipo\nde\nexpertos\nformado\n \n \n \n \n \n \n \n \n \n \npor tres m\u00e9dicos y dos farmac\u00e9uticos [40].\n \n \nLos\ns\u00edntomas\nde\nlas\nreacciones\nadversas\na\nmedicamentos\nse\n \n \n \n \n \n \n \n \n \nclasificaron\npor\nAnja\nGlockmann,\nde\nacuerdo\ncon\nel\nDiccionario\nM\u00e9dico\n \n \n \n \n \n \n \n \n \n \npara\nActividades\nRegulatorias\n(MedDRA,\nVersi\u00f3n\n19.0,\nMedDRA\nMSSO,\n \n \n \n \n \n \n \n \nMcLean,\nVA,\nEE.\nUU.).\nCon\nfines\ndescriptivos,\nla\nfrecuencia\nde\n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\nse\nclasific\u00f3\nde\nacuerdo\ncon\nlas\nrecomendaciones\n \n \n \n \n \n \n \n \n \ndel\nConsejo\nde\nOrganizaciones\nInternacionales\nde\nCiencias\nM\u00e9dicas\n \n \n \n \n \n \n \n (CIOMS)\n[5]\ncomo\n'muy\ncom\u00fan'\n(\u2265\n10%),\n'com\u00fan'\n(1\n<x\n<10%\n),\n\"poco\n \n \n \n \n \n \n \n \n \n \n \n \n \ncom\u00fan\" (0.1 <x <1%), \"raro\" (0.01 <x <0.1%) y \"muy raro\" (<0.01%).\n \nCada\nm\u00e9dico\nparticipante\nrecibi\u00f3\nfue\nformado\nde\nmanera\npresencial\n \n \n \n \n \n \n \n \n \npara\nayudar\na\nla\ndetecci\u00f3n,\nclasificaci\u00f3n\ne\ninforme\nde\nreacciones\n \n \n \n \n \n \n \n \n \n \nadversas [39].\n \n \n2.6 An\u00e1lisis de los datos\n \n \nTodos\nlos\npacientes\nque\ncumpl\u00edan\ntodos\nlos\nrequisitos\ny\ncriterios\n \n \n \n \n \n \n \n \n \n \npara\npoder\nser\nelegidos\nse\nincluyeron\nen\nel\nan\u00e1lisis.\nEl\nan\u00e1lisis\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \ndatos\nse\nrealiz\u00f3\nempleando\nlos\nprogramas\nIBM\nSPSS\nStatistics\n19\u00ae\n \n \n \n \n \n \n \n \n \n \n(International\nBusiness\nMachines\nCorp.,\nArmonk,\nNY,\nEE.\nUU.)\nY\n \n \n \n \n \n \n \n \n \nStatXact\u00ae 9.0.0 (Cytel Software Corporation, Cambridge, MA, EE. UU.).\n \n \n \nLos\ndatos\nque\nfaltaron\nen\nlas\nvariables\nindividuales\nno\nfueron\n \n \n \n \n \n \n \n \n \n \nreemplazados.\n \nEl\nan\u00e1lisis\nfue\ndescriptivo.\nAdem\u00e1s,\nse\nrealizaron\nan\u00e1lisis\nde\ndos\n \n \n \n \n \n \n \n \n \n \nvariables\nde\nmuestras\nindependientes\nutilizando\nm\u00e9todos\nno\n \n \n \n \n \n \n \nparam\u00e9tricos:\npara\nlos\ndatos\ndicot\u00f3micos,\nse\nutiliz\u00f3\nla\nprueba\nexacta\nde\n \n \n \n \n \n \n \n \n \n \n \nFisher;\npara\ndatos\nmultinomiales,\nla\nprueba\nde\nFisher-Freeman-Halton;\n \n \n \n \n \n \n \n \npara\ndatos\nordenados\npor\nrango\no\ncontinuos\nse\nemple\u00f3\nla\nprueba\nU\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nMann-Whitney\ncon\nestimaci\u00f3n\ndel\ncambio\nmediano\ne\nintervalo\nde\n \n \n \n \n \n \n \n \n \nconfianza\ndel\n95%\n(IC\n95%)\nseg\u00fan\nHodges-Lehmann.\nTodos\nlos\nan\u00e1lisis\n \n \n \n \n \n \n \n \n \n \nfueron\nbilaterales.\nLos\ncriterios\nde\nsignificaci\u00f3n\nfueron\np\n<0,05\ny\nun\n \n \n \n \n \n \n \n \n \n \n \nintervalo\nde\nconfianza\nIC\ndel\n95%,\nsin\nincluir\nal\n0.\nDado\nque\neste\nfue\nun\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nestudio\ndescriptivo,\nno\nse\nrequiri\u00f3\nning\u00fan\najuste\npara\ncomparaciones\n \n \n \n \n \n \n \n \n \nm\u00faltiples [19].\n \n \n3.\nResultados\n \n \n3.1 Pacientes, m\u00e9dicos y medicaciones incluidas en el an\u00e1lisis\n \n \nEl\nconjunto\nde\ndatos\nobtenidos\nen\nel\nan\u00e1lisis\nconten\u00eda\n88.682\n \n \n \n \n \n \n \n \n \n \npacientes\ncon\nun\ntotal\nde\n863.340\nprescripciones\nmedicamentosas.\nDe\n \n \n \n \n \n \n \n \n \nestos,\n44.662\npacientes\ncon\nun\ntotal\nde\n717.545\nprescripciones\n \n \n \n \n \n \n \n \n cumplieron\ntodos\nlos\ncriterios\nde\nelegibilidad\ny\nse\nincluyeron\nen\nel\n \n \n \n \n \n \n \n \n \n \n \nan\u00e1lisis (Tabla 1).\n \n \nTabla 1 Inclusi\u00f3n de los pacientes en el an\u00e1lisis\n \n \nNum\n \nCriterio de inclusi\u00f3n\n \nPacient\nes\n \nMedicam\n \ntotales\n \nMedicam\n.\n \n \nAntropos\n \nMedicam.\n \nNo antropos\n \nInclusi\u00f3n\nen\nel\n \n \n \nan\u00e1lisis por\n \n1\n \nAl\nmenos\nuna\n \n \n \nprescripci\u00f3n\nde\n \n \n1997-2010\n \n88.682\n \n863.340\n \n336.365\n \n527.075\n \n \n2\n \nAl\nmenos\nuna\n \n \n \nprescripci\u00f3n\nde\n \n \n2001-2010\n \n88.672\n \n863.270\n \n336.238\n \n527.032\n \n \n3\n \nNum\n2\nal\nmenos\n \n \n \n \nuna\nprescripci\u00f3n\nde\n \n \n \nun\nmedicam.\n \n \nantropos\u00f3fico\n \n62.956\n \n756.757\n \n336.238\n \n420.519\n \n \n4\n \nNum\n3\nal\nmenos\n \n \n \n \nuna\nvisita\nal\nm\u00e9dico\n \n \n \n \ntras\nprescripci\u00f3n\nde\n \n \n \nun\nmedicam.\n \n \nantropos\u00f3fico\n \n \n44.462\n \n715.545\n \n311.731\n \n405.814\n \nPrescripciones\n \nde\n \nmedicamentos\n \ncon\nreacciones\n \n \ngrados III-IV\n \n5\n \nNum\n4\n\u200b\nPacientes\nde\n \n \n \n \nun\nm\u00e9dico\n \n \nprescriptor\n \n12.956\n \n243.147\n \n94.734\n \n148.413\n \nPrescripciones\n \nde\n \nmedicamentos\n \ncon\nreacciones\n \n \ngrados I-IV\n \n \n \n \nLos\ngrupos\nde\nedad\nfueron\n0-2\na\u00f1os\n(27,1%\nde\nlos\npacientes\n \n \n \n \n \n \n \n \n \n \n \nevaluables,\nn\n=\n12.065\n/\n44.573),\n3-6\na\u00f1os\n(17,9%),\n7-10\na\u00f1os\n(11,1%),\n \n \n \n \n \n \n \n \n \n \n \n \n11-17\na\u00f1os\n(7,5%),\n18-\n44\na\u00f1os\n(17,7%),\n45-64\na\u00f1os\n(12,6%)\ny\n\u2265\n65\n \n \n \n \n \n \n \n \n \n \n \n \n \na\u00f1os\n(6,2%)\ncon\nuna\nedad\npromedio\nde\n8,0\na\u00f1os\n[rango\n0-101\na\u00f1os,\n \n \n \n \n \n \n \n \n \n \n \n \nrango\nintercuart\u00edlico\n(IQR)\n2,0-38,0\na\u00f1os,\nmedia\n20,1\na\u00f1os,\ndesviaci\u00f3n\n \n \n \n \n \n \n \n \n \nest\u00e1ndar\n(DE)\n22.9].\nUn\ntotal\nde\n57,2%\n(n\n=\n25.533\n/\n44.658)\nde\ntodos\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\npacientes\ny\n70,8%\n(n\n=\n11.490\n/\n16.230)\nde\nadultos\n(\u2265\n18\na\u00f1os)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nfueron\nmujeres.\nUn\ntotal\nde\n54,6%\n(n\n=\n24.392\n/\n44.662)\nde\npacientes\n \n \n \n \n \n \n \n \n \n \n \n \n \nfueron\ntratados\npor\nm\u00e9dicos\nde\nfamilia,\nun\n35,4%\npor\npediatras,\nun\n \n \n \n \n \n \n \n \n \n \n 5,6%\npor\nm\u00e9dicos\ninternistas,\nun\n2,6%\npor\ndermat\u00f3logos\ny\nun\n1,8%\npor\n \n \n \n \n \n \n \n \n \n \n \n \nginec\u00f3logos.\n \n \nComparando\nlos\npacientes\nde\nlos\nm\u00e9dicos\nprescriptores\n(n\n=\n \n \n \n \n \n \n \n \n \n12.956\npacientes)\na\nlos\nde\notros\nm\u00e9dicos\n(n\n=\n31.617),\nlos\npacientes\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\nm\u00e9dicos\nprescriptores\nfueron\nde\nmedia\n2.0\na\u00f1os\nm\u00e1s\nj\u00f3venes\n(IC\n \n \n \n \n \n \n \n \n \n \n \n95%\n2.0-2.0\na\u00f1os,\np\n<0.001),\ncon\nun\nleve\nmenor\nproporci\u00f3n\nde\nmujeres\n \n \n \n \n \n \n \n \n \n \n \n \nentre\ntodos\nlos\npacientes\n(55,9\nvs\n57,7%,\np\n=\n0,0003),\nmientras\nque\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \ndistribuci\u00f3n\npor\nsexo\nen\nadultos\nno\ndifiri\u00f3\nsignificativamente\n(72,0\nvs\n \n \n \n \n \n \n \n \n \n \n70,4%, p = 0.0691).\n \n \n3.2 Documentaci\u00f3n, periodo, visitas al m\u00e9dico y prescripciones\n \n \nEl\nper\u00edodo\nde\ndocumentaci\u00f3n\ndesde\nla\nprimera\nhasta\nla\n\u00faltima\n \n \n \n \n \n \n \n \n \n \nvisita\nal\nm\u00e9dico\ndurante\nel\nper\u00edodo\nde\nestudio\nde\ncada\npaciente\nfue\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n0-11\nmeses\nen\nel\n34,9%\n(n\n=\n15.598\n/\n44.662)\nde\nlos\npacientes,\n12-23\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmeses\nen\nel\n18,8%\nde\nlos\npacientes,\n24-35\nmeses\nen\n14,7%,\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \npacientes\n36-47\nmeses\nen\n12,0%,\ny\n\u2265\n48\nmeses\nen\n19,5%,\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \npacientes\ncon\nun\nper\u00edodo\nmedio\nde\ndocumentaci\u00f3n\nde\n21,7\nmeses\n(RIQ\n \n \n \n \n \n \n \n \n \n \n \n7.7-42.9\nmeses,\npromedio\n27,1\nmeses,\nSD,\ndesviaci\u00f3n\nest\u00e1ndar\ndel\n \n \n \n \n \n \n \n \n \n22,4).\nEl\nn\u00famero\nde\nvisitas\nal\nm\u00e9dico\npor\npaciente\ndurante\ntodo\nel\n \n \n \n \n \n \n \n \n \n \n \n \nper\u00edodo\nde\ndocumentaci\u00f3n\nfue\nde\n1\nhasta\n9\nvisitas\nen\nel\n67,2%\n(n\n=\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n30.032\n/\n44.662)\nde\nlos\npacientes,\n10-19\nvisitas\nen\n20,6%\nde\nlos\ncasos,\n \n \n \n \n \n \n \n \n \n \n \n \n \n20-29\nvisitas\nen\n6.9%\nde\nlos\npacientes\ny\nentre\n30-192\nvisitas\nen\n5,3%,\n \n \n \n \n \n \n \n \n \n \n \n \n \ncon\nuna\nmedia\nde\n6,0\nvisitas\n(IQR\n3.0-12.0\nvisitas,\npromedio\nde\n9,8\n \n \n \n \n \n \n \n \n \n \n \n \nvisitas, SD, desviaci\u00f3n est\u00e1ndar 11,1) por paciente.\n \n \nEn\ncomparaci\u00f3n\ncon\nlos\notros\npacientes,\nlos\npacientes\nde\nlos\n \n \n \n \n \n \n \n \n \n \nm\u00e9dicos\nprescriptores\ntuvieron\nun\nper\u00edodo\nde\ndocumentaci\u00f3n\nm\u00e1s\nlargo\n \n \n \n \n \n \n \n \n \n(media\nde\ndiferencia\n50,0\nd\u00edas,\nIC\n95%\n39,0-62,0\nd\u00edas,\np\n<0.001)\ny\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \n \nconsultas\nm\u00e9dicas\n(diferencia\nmedia\nde\n1,0\nvisita,\nIC\n95%\n1,0-1,0\n,\np\n \n \n \n \n \n \n \n \n \n \n \n \n<0,001).\n \n \nDurante\nel\nper\u00edodo\nde\ndocumentaci\u00f3n,\nlos\n44.662\npacientes\n \n \n \n \n \n \n \n \nrecibieron\nun\ntotal\nde\n717.545\nMP\nprescripciones,\nde\nlos\ncuales\n43.4%\n \n \n \n \n \n \n \n \n \n \n (n\n=\n311,731)\nfueron\nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \n \n(Tabla\n1);\nlas\nprescripciones\nrestantes\nfueron\nde\nmedicamentos\n \n \n \n \n \n \n \n \nqu\u00edmicos\nconvencionales\n(41,2%),\nhomeop\u00e1ticos\n(10,0%)\no\nde\n \n \n \n \n \n \n \nfitoterapia\n(5,4%)\n(de\nahora\nen\nadelante\nresumidos\ncomo\n \n \n \n \n \n \n \n \n\"medicamentos no antropos\u00f3ficos\").\n \n \n \n3.3 Medicamentos antropos\u00f3ficos\n \n \n3.3.1Indicaciones\n \n \nDe\nlas\n311.731\nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos,\n \n \n \n \n \n \n \nse\npudieron\ncodificar\ncon\nun\ndiagn\u00f3stico\nde\nCIE-10\nn\n=\n303.725\n(97,4%)\n \n \n \n \n \n \n \n \n \n \n \n \nprescripciones.\n \n \nEntre\nlos\nadultos\nde\nedad\nsuperior\no\nigual\na\n18\na\u00f1os,\nlos\ngrupos\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \npatolog\u00edas\nque\nentraban\ncon\nun\ncriterio\ndiagn\u00f3stico\nICD-10\nm\u00e1s\n \n \n \n \n \n \n \n \n \nfrecuentes\nfueron\nM00-M99\nEnfermedades\nmusculoesquel\u00e9ticas\n \n \n \n \n \n(11,6%,\nn\n=\n13.404\n/\n115.057\nde\nprescripciones),\nJ00-J99\n \n \n \n \n \n \n \n \n \nEnfermedades\nrespiratorias\n(11,6%),\nC00-D48\nNeoplasias\n(11,0\n%)\ne\n \n \n \n \n \n \n \n \nI00-I99\nEnfermedades\ncardiovasculares\n(10,3%)\n(Tabla\n2).\nLos\nbloques\n \n \n \n \n \n \n \n \nde\ndiagn\u00f3stico\nICD-10\nm\u00e1s\nfrecuentes\nfueron\nC00-C75\nNeoplasias\n \n \n \n \n \n \n \n \nmalignas,\nprimarias,\nespec\u00edficas\n(7,1%\nn\n=\n8143\n/\n115.046\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \nprescripciones\nevaluables),\nJ00-J06\nInfecciones\nrespiratorias\nsuperiores\n \n \n \n \n \n \nagudas\n(4,9%),\nM40-M54\nDorsopat\u00edas\n(4,6\n%)\ne\nI10-I15\nEnfermedades\n \n \n \n \n \n \n \n \n \nhipertensivas (4,0%).\n \n \nEntre\nlos\nni\u00f1os\nde\n0-17\na\u00f1os,\nlos\ncap\u00edtulos\nde\ndiagn\u00f3stico\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \nfrecuentes\nde\nla\nCIE-10\nfueron\nlas\nenfermedades\nrespiratorias\nJ00-J99\n \n \n \n \n \n \n \n \n \n(32,4%\nde\nlas\nprescripciones\nevaluables,\nn\n=\n61.127\n/\n188.668),\n \n \n \n \n \n \n \n \n \n \nA00-B99\nciertas\nenfermedades\ninfecciosas\ny\nparasitarias\n(9,9%)\ny\n \n \n \n \n \n \n \n \nR00-R99\nS\u00edntomas,\nsignos\ny\nhallazgos\ncl\u00ednicos\ny\nde\nlaboratorio\n \n \n \n \n \n \n \n \n \nanormales,\nno\nclasificados\nen\notra\nparte\n(9,8%)\n(Tabla\n2).\nLos\nbloqueos\n \n \n \n \n \n \n \n \n \n \n \ndiagn\u00f3sticos\nICD-10\nm\u00e1s\nfrecuentes\nfueron\nJ00-J06\nInfecciones\n \n \n \n \n \n \n \nrespiratorias\nagudas\nsuperiores\n(16,5%,\nn\n=\n31.080\n/\n188.598\n \n \n \n \n \n \n \n \n prescripciones\nevaluables),\nL20-L30\nDermatitis\ny\neczema\n(5.8%),\n \n \n \n \n \n \n \nH65-H75\nEnfermedades\ndel\no\u00eddo\nmedio\ny\notros\nprocesos\nmastoideos\n(\n \n \n \n \n \n \n \n \n \n \n5,3%),\nJ30-J39\nOtras\nenfermedades\ndel\ntracto\nrespiratorio\nsuperior\n \n \n \n \n \n \n \n \n(4,3%)\ny\nJ40-J47\nEnfermedades\ncr\u00f3nicas\nde\nlas\nv\u00edas\nrespiratorias\n \n \n \n \n \n \n \n \n \ninferiores (4,1%).\n \n \nTabla 2\n \n \nIndicaciones\npara\nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos,\n \n \n \n \n \n \ncap\u00edtulos\nde\ndiagn\u00f3stico\nm\u00e1s\nfrecuentes\nde\nla\nClasificaci\u00f3n\nInternacional\n \n \n \n \n \n \n \n \n \nde Enfermedades, D\u00e9cima Revisi\u00f3n\n \n \n \nCap\u00edtulo\n \nC\u00f3digo\n \nDescripci\u00f3n\n \nPacient\nes\n \n \nNum\n \n(%)\n \nAdultos\n \n18-101\n \na\u00f1os\n \n \nNum\n \n(%)\n \nNi\u00f1os\n \n0-17\n \na\u00f1os\n \n \nNum\n \n(%)\n \nX\n \nJ00-\n \nJ99\n \nEnfermedades\ndel\nsistema\n \n \n \nrespiratorio\n \n74.441\n \n24,5\n \n13.314\n \n11,5\n \n51.127\n \n32,4\n \nXVIII\n \nR00-\n \nR99\n \nS\u00edntomas,\nsignos\ny\nhallazgos\n \n \n \n \ncl\u00ednicos\ny\nde\nlaboratorio\nanormales,\n \n \n \n \n \nno clasificados en otra parte\n \n24.899\n \n8,2\n \n6414\n \n5,6\n \n8485\n \n9,8\n \n \nI\n \n \nEnfermedades\ninfecciosas\ny\n \n \n \nparasitarias\n \n22.529\n \n7,4\n \n3840\n \n3,3\n \n8689\n \n9,9\n \nXII\n \n \nEnfermedades\ndermatol\u00f3gicas\ny\n \n \n \nsubcut\u00e1neas\n \n19.642\n \n6,5\n \n6021\n \n5,2\n \n13.622\n \n7,2\n \nV\n \n \nTrastornos\nmentales\ny\nde\n \n \n \n \ncomportamiento\n \n18.321\n \n6,0\n \n9749\n \n8,5\n \n8572\n \n4,5\n \nXI\n \n \nEnfermedades\ndel\nsistema\n \n \n \ndigestivo\n \n \n17.497\n \n5,9\n \n7867\n \n6,8\n \n10.080\n \n5,3\n \nXX\n \n \nCausas\nexternas\nde\nmortalidad\ny\n \n \n \n \n \nmorbilidad\n \n17.405\n \n5,7\n \n2610\n \n2,3\n \n14.795\n \n7,8\n \nXIII\n \n \nEnfermedades\n \nmusculoesquel\u00e9ticas\ny\ndel\nsistema\n \n \n \n \nconectivo\n \n15.569\n \n5,1\n \n13.404\n \n11,6\n \n \n2165\n \n1,1\n \nIV\n \n \nEnfermedades\nmetab\u00f3licas,\ndel\n \n \n \nsistema\nendocrino\ny\ntrastornos\n \n \n \n \nalimentarios\n \n13.718\n \n4,5\n \n8943\n \n7,8\n \n4775\n \n2,5\n \nII\n \n \nNeoplasias\n \n13.393\n \n12.703\n \n690\n 4,4\n \n11,0\n \n0,4\n \nIX\n \n \nEnfermedades cardiovasculares\n \n13.006\n \n4,3\n \n11.904\n \n10,3\n \n1102\n \n0,6\n \nVIII\n \n \nEnfermedades\ndel\no\u00eddo\ny\n \n \n \n \nmastoides\n \n12.864\n \n4,2\n \n1263\n \n1,1\n \n11.601\n \n6,1\n \nXIV\n \n \nEnfermedades\ndel\nsistema\n \n \n \ngenitourinario\n \n8687\n \n2,9\n \n5077\n \n4,4\n \n3610\n \n1,9\n \nXIX\n \n \nlesiones,\nintoxicaciones\ny\notras\n \n \n \n \nenfermedades\natribuibles\na\ncausas\n \n \n \n \nexternas\n \n8582\n \n2,8\n \n3.396\n \n3,0\n \n5186\n \n2,7\n \nVII\n \n \nEnfermedades oculares y anexas\n \n7780\n \n2,6\n \n1735\n \n1,5\n \n6045\n \n3,2\n \nVI\n \n \nEnfermedades del sistema nervioso\n \n6236\n \n2,1\n \n4.167\n \n3,6\n \n2069\n \n1,1\n \n \n \nOtras\nenfermedades\ncon\nun\n \n \n \n \nporcentaje menor al 2%\n \n8708\n \n2,9\n \n2.650\n \n2,3\n \n6055\n \n3,2\n \n \n \nTotal de diagn\u00f3sticos evaluados\n \n303.725\n \n100,0\n \n115.057\n \n 100,0\n \n188.668\n \n100,0\n \n \n \n3.3.2 Prescripciones y productos\n \n \nDe\nlas\n311.731\nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \nrecetadas\nen\nel\nper\u00edodo\n2001-2010,\nun\ntotal\nde\n311.381\nprescripciones\n \n \n \n \n \n \n \n \n \n \n(99,89%)\nse\nencontraban\nregistradas\nen\nla\nBase\nde\nDatos\nde\nla\n \n \n \n \n \n \n \n \n \n \n \nESCHAMP,\nque\ncorresponde\na\n1.722\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \ndiferentes,\nlo\nque\nrepresenta\nel\n74.2%\nde\nun\ntotal\nde\n2.321\n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\ndiferentes\ncomercializados\nen\nAlemania\n \n \n \n \n \n \nen este per\u00edodo.\n \n \nDe\nlos\nmedicamentos\nantropos\u00f3ficos\nprescritos,\nel\n8,8%\n(n\n=\n \n \n \n \n \n \n \n \n \n152/1722)\nse\nprescribieron\nsolamente\nen\nuna\nocasi\u00f3n\ndurante\nel\nper\u00edodo\n \n \n \n \n \n \n \n \n \n \nde\ndocumentaci\u00f3n,\nel\n22,9%\nde\nlos\nmedicamentos\nantropos\u00f3ficos\nse\n \n \n \n \n \n \n \n \n \nhab\u00edan\nprescrito\nentre\n2\ny\n9\nocasiones\ncada\nuno,\nel\n32,2%\ncontaban\ncon\n \n \n \n \n \n \n \n \n \n \n \n \n \nentre\n10\ny\n29\nprescripciones,\nel\n27,9%\nten\u00edan\nde\n50\na\n499\nrecetas,\ny\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n8,2%\nten\u00eda,\nal\nmenos,\n500\nprescripciones,\ncon\nuna\nmedia\nde\n25,\n0\n \n \n \n \n \n \n \n \n \n \n \n prescripciones\npor\nmedicamento\nantropos\u00f3fico\n(IQR\n6.0-99.3\n \n \n \n \n \n \nprescripciones, media 180,8, SD 620.0).\n \n \nEl\nn\u00famero\nde\nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos\npor\n \n \n \n \n \n \n \n \npaciente\n(las\nprescripciones\nrepetidas\ndel\nmismo\nmedicamento\n \n \n \n \n \n \n \nantropos\u00f3fico\nse\ncuentan\npor\nseparado)\nfueron\n1-4\nprescripciones\nde\n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nen\n54,2%\n(n\n=\n24.211\n/\n44.662)\nde\n \n \n \n \n \n \n \n \n \n \npacientes,\n5-9\nprescripciones\nen\n25,3%,\n10-19\nprescripciones\nen\n14,1%,\n \n \n \n \n \n \n \n \n \ny\nal\nmenos\n20\nprescripciones\nen\n6,4%,\ncon\nuna\nmedia\nde\n4.0\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\npor\npaciente\n(IQR\n2.0-8.0\nprescripciones,\n \n \n \n \n \n \n \nmedia 7.0, SD 9.7).\n \n \nTabla 3 Medicamentos antropos\u00f3ficos prescritos con mayor frecuencia:\n \n \n \nOrden\n \nNombre\ndel\n \n \nmedicamento\n \nantropos\u00f3fico\n \nForma\n \nfarmac\n \nNum.\nde\n \n \nprescr\n \n% de prescr\n \n1\n \nAlthaeae/Solanum\n \n \ncomp\n \nJarabe\n \n10.859\n \n3,5\n \n2\n \nBelladonna/Cham\nomilla comp\n \nSupositorios\n \n9717\n \n3,1\n \n3\n \nApis/Belladonna/\n \nMercurius\n \nGl\u00f3bulos\n \n7917\n \n2,5\n \n4\n \nCal\u00e9ndula/Eucalip\ntus\n \nGotas\n \nnasales\n \n6492\n \n2,1\n \n5\n \nApisinium/Bellado\nnna/Cinnabaris\n \nTrituraci\u00f3n\n \n5412\n \n1,7\n \n6\n \nAconitum/Bryonia\n \nP\u00edldoras\n \n5244\n \n1,7\n \n7\n \nBerberis/Prunus\n \n \nSil\u00edcea\n \nUng\u00fcento\n \nnasal\n \n4822\n \n1,5\n \n8\n \nOnopordon/\n \nHyosciamus/\n \nDiluci\u00f3n\n \n4704\n \n1,5\n Pr\u00edmula\n \n9\n \nLevisticum\n \nDiluci\u00f3n\n \n4502\n \n1,4\n \n10\n \nBryonia/Spongia\n \ncomp\n \nDiluci\u00f3n\n \n3736\n \n1,2\n \n11\n \nPetasites/Picea/\n \nPlantago\n \nJarabe\n \n3685\n \n1,2\n \n12\n \nPyrites\n \nTrituraci\u00f3n\n \n3496\n \n1.1\n \n13\n \nPyrites/Cinnabaris\n \nComprimido\ns\n \n3346\n \n1.1\n \n14\n \nFragaria/Vitis\n \nComprimido\ns\n \n3322\n \n1,1\n \n15-\n \n1722\n \nResto\nde\n \n \nproductos\n \nmenores al 1%\n \n \n234.127\n \n75,2\n \n \nTOTAL\n \n \n311.381\n \n100\n \n \nCon\nrespecto\nal\nn\u00famero\nde\nprescripciones\nde\nmedicamentos\n \n \n \n \n \n \n \n \nantropos\u00f3ficos\npor\npaciente,\nlos\npacientes\nde\nlos\nm\u00e9dicos\nque\n \n \n \n \n \n \n \n \n \nprescriben\nno\ndifirieron\nsignificativamente\nfrente\na\nlos\nm\u00e9dicos\n \n \n \n \n \n \n \n \nconvencionales\n(media\nde\nla\ndiferencia\nde\n0,0\nprescripciones,\nIC\ndel\n \n \n \n \n \n \n \n \n \n \n95%:\n0,0-0,0).\nUn\ntotal\nde\n57,6%\n(n\n=\n179.703\n/\n311731)\nde\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos\nfueron\nemitidas\npor\n \n \n \n \n \n \n \nm\u00e9dicos\nde\nfamilia,\n34,4%\npor\npediatras,\n5,1%\npor\ninternistas,\n1,8%\npor\n \n \n \n \n \n \n \n \n \n \n \ndermat\u00f3logos y 1,1% por ginec\u00f3logos.\n \n \nLos\n14\nmedicamentos\nantropos\u00f3ficos\nm\u00e1s\nfrecuentemente\n \n \n \n \n \n \nprescritos\nse\nenumeran\nen\nla\nTabla\n3.\nDe\nestos,\nonce\nmedicamentos\n \n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\n(todos\nexcepto\nlos\nn\u00fameros\n2,\n8\ny\n14)\ngeneralmente\nse\n \n \n \n \n \n \n \n \n \n \n \nrecetan para tratar enfermedades infecciosas.\n \n \nLos\nmedicamentos\nantropos\u00f3ficos\nque\nse\nfabricaron\na\npartir\nde\nun\n \n \n \n \n \n \n \n \n \n \n\u00fanico\ncomponente\nrepresentan\nel\n56,2%,\nn\n=\n968/1\n\u200b\n722\n,\nde\nm\u00e1s\nde\nun\n \n \n \n \n \n \n \n \n \n \n \n \n principio\nactivo\n(36,5%)\no\nde\nuna\no\nvarias\ncomposiciones\nseg\u00fan\nel\nAPC\n \n \n \n \n \n \n \n \n \n \n \n \n(Anthroposophical\npharmaceutical\ncodex)\n[26]\n(7,2%).\nEntre\nlos\n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nfabricados\na\npartir\nde\nun\n\u00fanico\nmaterial\n \n \n \n \n \n \n \n \n \n \nde\npartida\n(n\n=\n968),\neste\nprocede\ndel\nreino\nmineral\nen\nun\n13,8%\n(n\n=\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n134/968),\nde\norigen\nvegetal\nen\nun\n46,8%,\nde\norigen\nanimal\nen\nun\n21,7%.\n \n \n \n \n \n \n \n \n \n \n \n \n \nSe\npuede\nconsiderar\nuna\nsustancia\nqu\u00edmicamente\ndefinible\nen\n13,0%,\ny\n \n \n \n \n \n \n \n \n \n \nuna\nsustancia\n(sal\nmet\u00e1lica\no\nmineral)\nque\nhab\u00eda\nsido\nsometida\na\n \n \n \n \n \n \n \n \n \n \n \nvegetabilizaci\u00f3n en un 4,6%.\n \n \nEn\ncuanto\na\nla\nconcentraci\u00f3n\nde\nlos\ningredientes\nactivos,\nel\n22,7%\n \n \n \n \n \n \n \n \n \n \n \nde\nlos\nmedicamentos\nantropos\u00f3ficos\nevaluables\n(n\n=\n389/1711)\nse\n \n \n \n \n \n \n \n \n \nfabricaron\nen\nforma\nponderal,\nincluidas\nlas\ntinturas\nmadres,\nel\n37,2%\nen\n \n \n \n \n \n \n \n \n \n \n \npotencias\ndecimales\nde\nD1a\nD3,\nel\n29,7%\nen\nD4\na\nD6\ny\nel\n10,3%\nen\nlas\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \npotencias\n\u2265\nD7.\nLas\nformas\nde\nadministraci\u00f3n\nde\nlos\nmedicamentos\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\nprescritos\nse\nadministran\npor\nv\u00eda\noral\n(44.9%,\nn\n=\n774\n/\n \n \n \n \n \n \n \n \n \n \n \n \n1.722\nmedicamentos\nantropos\u00f3ficos),\npor\nv\u00eda\nparenteral\n(38.4%),\npor\n \n \n \n \n \n \n \n \nv\u00eda\ncut\u00e1nea\n(11.7%),\npor\nv\u00eda\noft\u00e1lmica\n(2.3%),\nv\u00eda\nrectal\n(1.7%)\ny\notras\n \n \n \n \n \n \n \n \n \n \n \n \n(0.9%) .\n \n \n \n3.3.3 Reacciones adversas a medicamentos\n \nEn\nel\nper\u00edodo\nde\ndocumentaci\u00f3n,\nlos\nm\u00e9dicos\nde\nEvaMed\n \n \n \n \n \n \n \n \n \ndocumentaron\nun\ntotal\nde\n111\ncasos\nde\nreacciones\nadversas\nderivados\n \n \n \n \n \n \n \n \n \n \nde\nlos\nmedicamentos\nantropos\u00f3ficos.\nDe\n\u00e9stos,\nla\nrelaci\u00f3n\ncausal\ncon\n \n \n \n \n \n \n \n \n \n \nlos\nmedicamentos\nantropos\u00f3ficos\nen\ncuesti\u00f3n\nfue\nevaluada\npor\nlos\n \n \n \n \n \n \n \n \n \ninvestigadores\nde\nFIH\n(Instituto\nde\ninvestigaci\u00f3n\nde\nHavelh\u00f6he)\nc\u00f3mo\n \n \n \n \n \n \n \n \n \ncierta\n(n\n=\n33),\nprobable\n(n\n=\n37),\nposible\n(n\n=\n30),\nimprobable\n(n\n=\n9)\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nno\nclasificada\n(n\n=\n2)\nLos\n100\ncasos\ncon\nrelaci\u00f3n\ncausal\nevaluados\n \n \n \n \n \n \n \n \n \n \n \n \ncomo\nciertos,\nprobables\no\nposibles\nse\nclasificaron\ncomo\nreacciones\n \n \n \n \n \n \n \n \n \nadversas\na\nmedicamentos\nconfirmadas\npara\nmedicamentos\n \n \n \n \n \n \nantropos\u00f3ficos\ne\nincluidos\nen\nel\nan\u00e1lisis\nde\nreacciones\nadversas\na\n \n \n \n \n \n \n \n \n \n \nmedicamentos.\n \n \nLas\n100\nreacciones\nadversas\na\nmedicamentos\nconfirmadas\nfueron\n \n \n \n \n \n \n \n \ncausadas\npor\nun\ntotal\nde\n109\nmedicamentos\nantropos\u00f3ficos,\nsiendo\n83\n \n \n \n \n \n \n \n \n \n medicamentos\nantropos\u00f3ficos\ndiferentes.\nLa\ncausa\nde\nla\nreacciones\n \n \n \n \n \n \n \n \nadversas\na\nmedicamentos\nfue\nun\nsolo\nmedicamento\nantropos\u00f3fico\nen\nel\n \n \n \n \n \n \n \n \n \n \n92.0%\nde\nlos\ncasos\n(n\n=\n92/100)\ne\nintervinieron\ndos\no\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos antropos\u00f3ficos en el 8.0% de los casos.\n \n \n \nLa\nfrecuencia\nde\nreacciones\nadversas\natribuibles\na\nun\n \n \n \n \n \n \n \n \nmedicamento\nantropos\u00f3fico\nfue\nde\nsiete\nreacciones\nadversas\nen\nel\n \n \n \n \n \n \n \n \n \ncaso\nde\nun\nmedicamento\nantropos\u00f3fico\nconcreto,\ncinco\nreacciones\n \n \n \n \n \n \n \n \nadversas\nen\nel\ncaso\nde\n3\nmedicamentos\nantropos\u00f3ficos,\nde\ndos\n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nmedicamentos\nen\nel\ncaso\nde\n5\nmedicamentos\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\ny\nuna\n\u00fanica\nreacci\u00f3n\nadversa\na\nmedicamento\natribuibles\n \n \n \n \n \n \n \n \n \na\n77\nmedicamentos\nantropos\u00f3ficos\ndiferentes.\nCon\nel\nfin\nde\nidentificar\n \n \n \n \n \n \n \n \n \n \nposibles\ngrupos\nde\nreacciones\nadversas\na\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \n \nse\nagruparon\nen\nfunci\u00f3n\nde\nsus\ncomponentes\nsimilares\nform\u00e1ndose\nas\u00ed\n \n \n \n \n \n \n \n \n \n \nnueve\ngrupos\nde\nmedicamentos\nantropos\u00f3ficos\ndiferentes.\nDe\nestos,\nun\n \n \n \n \n \n \n \n \n \ngrupo\nde\nmedicamentos\nantropos\u00f3ficos\n(productos\nprovenientes\ndel\n \n \n \n \n \n \n \nmu\u00e9rdago\n=\nmedicamentos\nantropos\u00f3ficos\ncon\nel\nViscum\nalbum\ncomo\n \n \n \n \n \n \n \n \n \ningrediente\nprincipal)\ncaus\u00f3\n11\nreacciones\nadversas\na\nmedicamentos\ny\n \n \n \n \n \n \n \n \n \nlos\nocho\ngrupos\nde\nmedicamentos\nantropos\u00f3ficos\nrestantes\ncausaron\n \n \n \n \n \n \n \n \nsolo dos reacciones adversas cada uno.\n \n \nLas\n100\nreacciones\nadversas\na\nlos\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \n \nafectaron\na\n95\npacientes:\n90\ncon\nuna\nsola\nreacci\u00f3n\nadversa\ny\ncinco\ncon\n \n \n \n \n \n \n \n \n \n \n \n \n \ndos\nreacciones\nadversas\na\nmedicamentos.\nDe\nlos\n95\npacientes,\n54\neran\n \n \n \n \n \n \n \n \n \n \n \nadultos\ncon\nedad\n\u2265\n18\na\u00f1os\ny\n51\neran\nni\u00f1os\nde\n0\na\n17\na\u00f1os.\nel\npaciente\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nque\npadeci\u00f3\nuna\nreacci\u00f3n\nadversa\ncontaba\ncon\nuna\nedad\nmedia\nde\n36,0\n \n \n \n \n \n \n \n \n \n \n \n \na\u00f1os\n(IQR\n2.0-51,0\na\u00f1os,\nmedia\n31,9,\nSD\n27.7).\nUn\ntotal\nde\n85.2%\n(n\n=\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n46/54)\nde\nlas\npersonas\nadultas\ny\n42,5%\n(n\n=\n17/40)\nde\nlos\nni\u00f1os\ncon\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nreacciones adversas a medicamentos antropos\u00f3ficos fueron mujeres.\n \n \nLa\nintensidad\nde\nlas\nreacciones\nadversas\na\nlos\nmedicamentos\n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\nfue\ndel\nGrado\nI\n(leve)\nen\n50,0%\n(n\n=\n50/100)\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \n \ncasos,\nde\nGrado\nII\n(moderado)\nen\n43,0%de\nlos\ncasos,\nde\nGrado\nIII\n \n \n \n \n \n \n \n \n \n \n \n \n(severo)\nen\n7,0%\ny\nGrado\nIV\n(con\namenaza\npara\nla\nvida\n)\nen\n0%.\nEl\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \nn\u00famero\nde\ns\u00edntomas\ndocumentados\npara\ncada\nreacciones\nadversas\na\n \n \n \n \n \n \n \n \n medicamentos\nfue\nde\nuno\nsolo\nen\nel\n74,0%\nde\nlos\ncasos\n(n\n=\n74/100)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nreacciones\nadversas.\nCon\ndos\ns\u00edntomas\nen\nel\n18,0%,\ncon\ntres\n \n \n \n \n \n \n \n \n \n \n \ns\u00edntomas\nen\nel\n4,0%,\ncon\ncuatro\ns\u00edntomas\nen\nel\n3,0%\ny\ncinco\ns\u00edntomas\n \n \n \n \n \n \n \n \n \n \n \n \n \nen\nel\n1,0%,\ncon\nuna\nmedia\nde\n1,4\ns\u00edntomas\npor\nreacci\u00f3n\nadversa\na\n \n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\n(SD\n0,79,\nmedia\n1.0,\nIQR\n1.0-2.0).\nEn\ntotal,\nse\n \n \n \n \n \n \n \n \n \n \ndocumentaron\n139\ns\u00edntomas\nde\nreacciones\nadversas\na\nmedicamentos,\n \n \n \n \n \n \n \n \ncon\nintensidad\nde\ns\u00edntomas\nclasificada\ncomo\nleve\nen\nun\n18,7%\n(n\n=\n \n \n \n \n \n \n \n \n \n \n \n \n25/134)\nde\nlos\ns\u00edntomas\nevaluables,\nmoderada\nen\nun\n59,7%\ny\nfuerte\n(en\n \n \n \n \n \n \n \n \n \n \n \n \nalem\u00e1n:\n\"stark\")\nen\n21,6%.\nLos\ns\u00edntomas\nde\nreacciones\nadversas\na\n \n \n \n \n \n \n \n \n \n \nmedicamentos\nm\u00e1s\ncomunes,\nde\nacuerdo\ncon\nla\nclasificaci\u00f3n\nMedDRA\n \n \n \n \n \n \n \n \n \nde\nSystem\nOrgan\nClasses,\nfueron\nlos\ntrastornos\nde\nla\npiel\ny\ndel\ntejido\n \n \n \n \n \n \n \n \n \n \n \n \n \nsubcut\u00e1neo\n(21,6%\nde\nlos\ns\u00edntomas,\nn\n=\n30/139),\ntrastornos\n \n \n \n \n \n \n \n \n \npsiqui\u00e1tricos\n(19.4%),\ntrastornos\ngastrointestinales\n(17.3%),\ntrastornos\n \n \n \n \n \n \ngeneralizados\ncondicionados\nal\nlugar\nde\nadministraci\u00f3n\n(9,4%)\ny\n \n \n \n \n \n \n \n \ntrastornos respiratorios, tor\u00e1cicos y mediast\u00ednicos (6,5%).\n \n \n \nLas\nreacciones\nadversas\nocurrieron\nsolo\nuna\nvez\nen\n17,0%\n(n\n=\n \n \n \n \n \n \n \n \n \n \n \n17/100)\nde\nreacciones\nadversas,\nocurrieron\nvarias\nveces\nen\n40,0%\ny\n \n \n \n \n \n \n \n \n \n \nfueron\ncontinuas\nen\n43,0%.\nLa\nduraci\u00f3n\nde\nla\nreacciones\nadversas\na\n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nfue\n<24\nh\nen\n4,3%\n(n\n=\n4/94)\nde\nreacciones\nadversas\na\n \n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nevaluables,\n1-2\nd\u00edas\nen\n29,8%,\n3-6\nd\u00edas\nen\n36,2%,\n7-13\n \n \n \n \n \n \n \n \n \n \n \nd\u00edas\nen\n10,6%,\n14-30\nd\u00edas\nen\n10,6%,\ny\n31-103\nd\u00edas\nen\n8,5%,\ncon\nuna\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nduraci\u00f3n\nmedia\nde\n4\nd\u00edas\n(IQR\n2,0-7,5\nd\u00edas,\npromedio\nde\n9,8\nd\u00edas,\nSD\n \n \n \n \n \n \n \n \n \n \n \n \n \n17,0).\nEl\nmanejo\nde\nlas\nreacciones\nadversas\nfue\nla\nretirada\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\ncausantes\nen\nun\n80,4%\n(n\n=\n78/97)\nde\nlas\nreacciones\n \n \n \n \n \n \n \n \n \n \n \nadversas\nevaluables,\nuna\nreducci\u00f3n\nde\nla\ndosis\nen\n11,3%\ny\nning\u00fan\n \n \n \n \n \n \n \n \n \n \n \ntratamiento\nen\nel\n8,2%.\nLa\nreacci\u00f3n\nadversa\nal\nmedicamento\nse\n \n \n \n \n \n \n \n \n \n \n'recuper\u00f3'\nen\nel\n95,0%\n(n\n=\n95/100)\nde\nlos\ncasos\ny\nno\nse\nrecuper\u00f3\nen\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n5,0%.\n \nDe\nlas\n100\nreacciones\nadversas\na\nlos\nmedicamentos\n \n \n \n \n \n \n \n \nantropos\u00f3ficos,\nlos\ninvestigadores\ns\u00f3lo\nconsideraron\nuna\ncomo\nSADR\n \n \n \n \n \n \n \n \n(Reacci\u00f3n\nadversa\na\nmedicamentos\nsevera).\nSin\nembargo,\nhay\nque\n \n \n \n \n \n \n \n \n \nconsiderar\nque\nla\ndocumentaci\u00f3n\nrecogida\npara\nesta\nreacci\u00f3n\nresult\u00f3\n \n \n \n \n \n \n \n \n \nambigua\ny\ncon\nerrores.\nLa\nreacci\u00f3n\nadversa\na\neste\nmedicamento\nse\n \n \n \n \n \n \n \n \n \n \n clasific\u00f3\ncomo\ngrave\ndebido\na\nque\nse\ndocument\u00f3\ncomo\n\"potencialmente\n \n \n \n \n \n \n \n \n \n \nmortal\nen\nla\naparici\u00f3n\nde\nlos\ns\u00edntomas\",\npero\nla\nintensidad\ngeneral\nde\nla\n \n \n \n \n \n \n \n \n \n \n \n \n \nreacciones\nno\nse\ndocument\u00f3\ncomo\nGrado\nIV\n(potencialmente\nmortal)\n \n \n \n \n \n \n \n \n \nsino\ncomo\nGrado\nIII\n(grave).\nNo\nobstante,\nla\nclasificaci\u00f3n\ncomo\nuna\n \n \n \n \n \n \n \n \n \n \n \nreacci\u00f3n\nadversa\na\nmedicamentos\nsevera\nfue\nconfirmada\nen\nel\nan\u00e1lisis.\n \n \n \n \n \n \n \n \n \n \nLa\nreacci\u00f3n\nadversa\na\nmedicamentos\nsevera\nse\nprodujo\nen\nuna\nmujer\n \n \n \n \n \n \n \n \n \n \n \nde\n45\na\u00f1os\ncon\nc\u00e1ncer\nde\nmama\nductal\ninvasivo\npreexistente\n(CIE-10\n \n \n \n \n \n \n \n \n \n \n \nC50.9)\ny\nneumot\u00f3rax\n(J93)\ny\nfue\ncausada\npor\nun\nmedicamentos\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\nde\nmu\u00e9rdago\n(\nViscum\nalbum\nsubsp.\nAbietis,\n10\nmg\n \n \n \n \n \n \n \n \n \n \nampollas\npara\ninyecci\u00f3n\nsubcut\u00e1nea).\nLos\ns\u00edntomas\nde\nla\nreacci\u00f3n\n \n \n \n \n \n \n \n \n \nadversa\na\nmedicamentos\nsevera\ncon\nla\ngravedad\nde\nlos\ns\u00edntomas\n \n \n \n \n \n \n \n \n \n \nrespectivos\nfueron\ndisnea\n(moderada),\np\u00e1nico\n(fuerte),\nparestesia\nde\nlas\n \n \n \n \n \n \n \n \n \nmanos\n(moderada)\ny\nansiedad\n(fuerte).\nLa\nrelaci\u00f3n\ncausal\nentre\nel\n \n \n \n \n \n \n \n \n \n \nmu\u00e9rdago\ny\nla\nreacci\u00f3n\nadversa\nse\nclasific\u00f3\ncomo\nprobable.\nAl\nmismo\n \n \n \n \n \n \n \n \n \n \n \ntiempo\nque\nel\nmu\u00e9rdago,\nmedicamento\nantropos\u00f3fico,\nla\npaciente\n \n \n \n \n \n \n \n \ntambi\u00e9n\nestaba\nusando\nun\naceite\nde\nArgania\nspinosa,\nque\nse\nconsider\u00f3\n \n \n \n \n \n \n \n \n \n \n \nno\nrelacionado\ncon\nla\nreacci\u00f3n\nadversa\na\nmedicamentos\nsevera\n.\nLa\n \n \n \n \n \n \n \n \n \n \n \nreacci\u00f3n\nadversa\na\nmedicamentos\nsevera\nocurri\u00f3\nuna\nvez,\nla\nduraci\u00f3n\n \n \n \n \n \n \n \n \n \n \nfue\nmenos\nde\n24\nhoras,\nel\ntratamiento\nfue\nla\nretirada\ndel\nmedicamento\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \nel resultado fue \"recuperada\".\n \n \nLa\nfrecuencia\nde\nreacciones\nadversas\na\nlos\nmedicamentos\n \n \n \n \n \n \n \n \nantropos\u00f3ficos\nen\nrelaci\u00f3n\ncon\nlas\nprescripciones\nde\neste\ntipo\nde\n \n \n \n \n \n \n \n \n \n \nmedicamentos\nse\ncalcul\u00f3\npor\nseparado\npara\nlas\nreacciones\nadversas\na\n \n \n \n \n \n \n \n \n \n \nmedicamentos\nde\ntodas\nlas\nintensidades\n(muestra\nrestringida\na\n \n \n \n \n \n \n \n \npacientes\nde\nm\u00e9dicos\nprescriptores,\nya\nque\nsolo\nestos\nestaban\n \n \n \n \n \n \n \n \n \nobligados\na\ndocumentar\nreacciones\nadversas\nde\ncualquier\nintensidad)\ny\n \n \n \n \n \n \n \n \n \npara\nreacciones\nadversas\na\nmedicamentos\ncon\nintensidad\ngrados\nIII-IV\n \n \n \n \n \n \n \n \n \n(todos los pacientes) (Tabla 4):\n \n \nTabla\n4\nFrecuencia\nde\nReacciones\nadversas\na\nmedicamentos\nen\n \n \n \n \n \n \n \n \n \nrelaci\u00f3n al n\u00famero de prescripciones\n \n \nTodos\nlos\ngrupos\n \n \n \nde\nedad\n(0-101\n \n \n \na\u00f1os)\n \nTodos\nlos\n \n \ngrupos\nde\nedad\n \n \n \n(0-101 a\u00f1o\n \nNi\u00f1os\nde\n0\na\n17\n \n \n \n \n \na\u00f1os\n \nNi\u00f1os\nde\n0\na\n17\n \n \n \n \n \na\u00f1os\n \n \nTodos\nlos\n \n \nTodos\nlos\n \n \nTodos\nlos\n \n \nTodos\nlos\n \n medicamentos\n \nantropos\u00f3ficos\n \nmedicamentos\n \nNo\n \nantropos\u00f3ficos\n \nmedicamentos\n \nantropos\u00f3ficos\n \nmedicamentos\n \nNo\n \nantropos\u00f3ficos\n \nPacientes\ncon\n \n \nuna\n \nprescripci\u00f3n\n \nm\u00e9dica\n \n \n \n \n \nCon\nuna\nRA\n \n \n \ngrado I-IV\n \n67\n \n612\n \n37\n \n574\n \nPrescripciones\n \n94.734\n \n148.413\n \n59.265\n \n120.638\n \n%RA/prescr\n \n0,071\n \n0,412\n \n0.062\n \n0,453\n \nPacientes\ncon\n \n \nuna RA\n \n65\n \n569\n \n36\n \n532\n \nPacientes\ncon\n \n \nuna prescripci\u00f3n\n \n12.596\n \n11.652\n \n9.162\n \n8.550\n \nPacientes\ncon\n \n \nRA/\nPacientes\n \n \ncon\n \nprescripciones\n \n(%)\n \n0,502\n \n4,88\n \n0,393\n \n6,22\n \nPacientes\nde\n \n \ntodos\nlos\n \n \nm\u00e9dicos\n \n \n \n \n \nRA\nsolo\nGrado\nIII\n \n \n \n \ny IV\n \n7\n \n82\n \n2\n \n59\n \nPrescripciones\n \n311.731\n \n405.814\n \n193.851\n \n243.560\n \nRA/Prescripcione\ns (%)\n \n0,002\n \n0,020\n \n0,001\n \n0,024\n \nPacientes con RA\n \n7\n \n82\n \n2\n \n59\n \nPacientes\ncon\n \n \nprescripciones\n \n44.662\n \n39.473\n \n28.355\n \n25.587\n \nPacientes\ncon\n \n \nRA/pac\ncon\n \n \nprescripciones\n \n0,016\n \n0,208\n \n0,007\n \n0,231\n \nRA (Reacci\u00f3n adversa)\n \n \nTabla 5\n \nFrecuencia\nde\nReacciones\nadversas\na\nmedicamentos\nantropos\u00f3ficos,\n \n \n \n \n \n \n \nan\u00e1lisis de subgrupos\n \n Pacientes\ncon\nuna\n \n \n \nprescripci\u00f3n\nde\n \n \ncualquier edad\n \nRA\nde\n \n \ncualquier\n \ntipo\n \nPrescripciones\n \nRA/\n \nPrescripciones\n \nen %\n \nPacientes\n \ncon RA\n \nPacientes\ncon\n \n \nuna\n \nprescripci\u00f3n\n \nPacientes\ncon\n \n \nRA\n/\nPacientes\n \n \n \ncon\n \nprescripciones\n \n(%)\n \nTodos\nlos\n \n \npacientes\nde\n \n \nm\u00e9dicos\n \nprescriptores\n \n67\n \n94.734\n \n0,071\n \n65\n \n12.596\n \n0,502\n \nMedicamentos\n \nantropos\u00f3ficos\no\n \n \ngrupos\n \n \n \n \n \n \n \nAmpollas\nde\n \n \nViscum\n \n3\n \n4687\n \n0,064\n \n3\n \n551\n \n0,544\n \nFragaria/Vitis\n \ncomprimidos\n \n7\n \n3322\n \n0,211\n \n7\n \n1.771\n \n0,395\n \nApis\nBelladonna\n \n \ndiluci\u00f3n\n \n5\n \n2572\n \n0,194\n \n4\n \n2.116\n \n0,189\n \nBelladonna/Chamo\nnmilla supositorios\n \n5\n \n9717\n \n0,051\n \n5\n \n5100\n \n0,098\n \nHepar\n \nsulfuris/Membrana\n \nsinuum\n \nparanassalium\n \nbovis ampollas\n \n5\n \n1722\n \n0,290\n \n4\n \n1069\n \n0,374\n \nForma\n \nfarmac\u00e9utica\n \n \n \n \n \n \n \nInyectables\n \n27\n \n16.378\n \n0,165\n \n24\n \n3633\n \n0,661\n \nOral\n \n67\n \n53,444\n \n0,125\n \n58\n \n11.660\n \n0,497\n \nAplicaci\u00f3n\nlocal\n \n \n(d\u00e9rmica,\n \noft\u00e1lmica,\nrectal\nu\n \n \n \notras\n \n15\n \n24.875\n \n0,060\n \n15\n \n8679\n \n0,173\n \nConcentraciones\n \n \n \n \n \n \n \nNo diluida\n \nD1-D3\n \n84\n \n76.164\n \n0,110\n \n78\n \n12.635\n \n0,617\n \nDiuciones\n \nsuperiores a D$\n \n24\n \n17.249\n \n0,139\n \n23\n \n6346\n \n0,357\n \n \n\u25cf\nLas\nreacciones\nadversas\nde\ncualquier\nintensidad\nocurrieron\nen\n \n \n \n \n \n \n \n \n0,071%\nde\nlas\nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos\ny\n \n \n \n \n \n \n \n \nen\n0,502%\nde\nlas\npacientes\nque\nrecibieron\nmedicamentos\n \n \n \n \n \n \n \n \nantropos\u00f3ficos.\n \n \u25cf\nLas\nreacciones\nadversas\ncon\nintensidad\ngrados\nIII-IV\nocurrieron\nen\n \n \n \n \n \n \n \n \n \nel\n0,002%\nde\nlas\nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \n \ny\nen\nel\n0,016%\nde\nlas\npacientes\nque\nrecibieron\nmedicamentos\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos.\n \n \nSe\nrealizaron\nan\u00e1lisis\nde\nsubgrupos\nde\nla\nfrecuencia\nde\nreacciones\n \n \n \n \n \n \n \n \n \n \nadversas\na\nmedicamentos\nantropos\u00f3ficos\nen\nrelaci\u00f3n\ncon\nlas\n \n \n \n \n \n \n \n \nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos\nentre\npacientes\nde\n \n \n \n \n \n \n \nm\u00e9dicos\nprescriptores,\nque\ncomprendieron\nedad\n(ni\u00f1os,\nun\ngrupo),\n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nespec\u00edficos\no\ngrupos\nde\nmedicamentos\n \n \n \n \n \n \n \nantropos\u00f3ficos\n(cinco\ngrupos),\nformas\nde\ndosificaci\u00f3n\n(tres\ngrupos)\ny\n \n \n \n \n \n \n \n \n \nconcentraciones\n(dos\ngrupos),\nobteniendo\nun\ntotal\nde\n11\ngrupos.\nCon\n \n \n \n \n \n \n \n \n \n \nuna\nfrecuencia\nglobal\nde\nreacciones\nadversas\na\nmedicamentos\nde\n \n \n \n \n \n \n \n \n \n0,071%\nde\nprescripciones.\nEsta\nfrecuencia\nvari\u00f3\ndel\n0,051%\n \n \n \n \n \n \n \n \n(Belladonna\n/\nChamomilla\nrecutita,\nRadix\ncomp.,\nSupositorios)\nal\n0,290%\n \n \n \n \n \n \n \n \n \n(Hepar\nsulfuris\n/\nMembrana\nsinuum\nparanasalium\nbovis,\nAmpollas)\n \n \n \n \n \n \n \n \n(Tabla 5\n\u200b\n).\n \n \n \nTabla\n5\nFrecuencia\nde\nreacciones\nadversas\na\nmedicamentos\n \n \n \n \n \n \n \n \nantropos\u00f3ficos, an\u00e1lisis de subgrupos\n \n \nTodos los\n \ngrupos de\n \npacientes y\n \nde m\u00e9dicos\n \nprescriptores\n \nReacciones\n \nadversas de\n \ntodos los\n \ntipos\n \nN\u00famero de\n \nPrescripcione\ns\n \n%Reacciones\n \nadversas\n \nfrente a\n \nn\u00famero de\n \nprescripcione\ns\n \nPacientes\n \ncon\n \nReacciones\n \nadversas\n \nPacientes\n \ncon\n \nprescripci\u00f3n\n \n% de\n \nPacientes\n \ncon\n \nReacciones\n \nadversas\n \nfrente a\n \nPacientes\n \ncon\n \nprescripci\u00f3n\n \nTodos los\n \npacientes de\n \nm\u00e9dicos\n \nprescriptores\n \n67\n \n94.734\n \n0,071\n \n65\n \n12.956\n \n0,502\n \nGrupos\n \nespec\u00edficos de\n \nmedicamentos\n \nantropos\u00f3ficos\n \n \n \n \n \n \n \nAmpollas de\n \nViscum\n \n(Mu\u00e9rdago)\n \n3\n \n4687\n \n0,064\n \n3\n \n551\n \n0,544\n \nFragaria/Vitis\n \ncompr\n \n7\n \n3322\n \n0,211\n \n7\n \n1771\n \n0,395\n Apis/Belladon\nna dil\n \n5\n \n2572\n \n0,194\n \n4\n \n2116\n \n0,189\n \nBelladonna/\n \nChamomilla\n \n \nSupositorios\n \n5\n \n9717\n \n0,051\n \n5\n \n5100\n \n0,098\n \nHepar sulf\n \nMembr sinuum\n \nparanaslium\n \nbovis\n \namp\n \n5\n \n1722\n \n0,290\n \n4\n \n1069\n \n0,374\n \nFormas\n \nfarmac\u00e9uticas\n \n \n \n \n \n \n \nInyectables\n \nparenterales\n \n27\n \n16.738\n \n0,165\n \n24\n \n3633\n \n0,661\n \nOral\n \n67\n \n53.444\n \n0,125\n \n58\n \n11.660\n \n0,497\n \nLocal\n \n(dermatol\u00f3gico\n, oft\u00e1lmico,\n \nrectal etc)\n \n15\n \n24.875\n \n0,060\n \n15\n \n8679\n \n0,173\n \nPor\n \nconcentraci\u00f3n\n \n \n \n \n \n \n \nNo diluido\n \n(D1D3)\n \n84\n \n76.164\n \n0,110\n \n78\n \n12.635\n \n0,617\n \nMayor igual a\n \nD4\n \n24\n \n17.249\n \n0,139\n \n23\n \n6436\n \n0,357\n \n \n \n3.4 Medicamentos no antropos\u00f3ficos\n \n3.4.1 Prescripciones y productos\n \n \nDurante\nel\nper\u00edodo\nque\nse\ndocument\u00f3\neste\nestudio,\nlos\n44.662\n \n \n \n \n \n \n \n \n \n \npacientes\nrecibieron\nun\ntotal\nde\n405.814\nprescripciones\nde\n \n \n \n \n \n \n \n \nmedicamentos no antropos\u00f3ficos.\n \n \nUn\ntotal\nde\n11,6%\n(n\n=\n5,189\n/\n44,662)\nde\nlos\npacientes\nno\nten\u00edan\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nninguna\nprescripci\u00f3n\nde\nmedicamentos\nno\nantropos\u00f3ficos.\nUn\n41,5%\n \n \n \n \n \n \n \n \nten\u00edan\n1-4\nprescripciones\nde\nmedicamentos\nno\nantropos\u00f3ficos,\nun\n \n \n \n \n \n \n \n \n20,3%\nten\u00edan\n5-9\nprescripciones\nde\nmedicamentos\nno\nantropos\u00f3ficos,\n \n \n \n \n \n \n \n \nun\n14,8%\nten\u00edan\nde\n10\na\n19\nrecetas\nde\nmedicamentos\nno\nantropos\u00f3ficos\n \n \n \n \n \n \n \n \n \n \n \n \ny\nun\n11.8%\nten\u00edan\nigual\no\nm\u00e1s\nde\n20\nprescripciones\nde\nmedicamentos\n \n \n \n \n \n \n \n \n \n \n \n \nno\nantropos\u00f3ficos.\nPor\ntanto\nla\nmedia\nde\nprescripciones\nde\n \n \n \n \n \n \n \n \n \nmedicamentos\nno\nantropos\u00f3ficos\nse\nelev\u00f3\na\n4.0\npara\ncada\npaciente\n \n \n \n \n \n \n \n \n \n (IQR\n1.0-10.0,\nmedia\n9.1,\nSD\n16.3,\nrango\n0-447\nprescripciones\nde\n \n \n \n \n \n \n \n \n \n \nmedicamentos no antropos\u00f3ficos.\n \n \nLos\ngrupos\nde\nmedicaci\u00f3n\nm\u00e1s\ncomunes,\nde\nacuerdo\ncon\nel\n \n \n \n \n \n \n \n \n \n \nprimer\nnivel\ndel\nsistema\nATC,\nfueron\nel\nsistema\nrespiratorio\n(26,6%,\nn\n=\n \n \n \n \n \n \n \n \n \n \n \n \n107.997\n/\n405.814\nde\nprescripciones\nde\nmedicamentos\nno\n \n \n \n \n \n \n \n \nantropos\u00f3ficos),\nel\ntracto\ndigestivo\ny\nel\nmetabolismo\n(14,5%),\nvarios\n \n \n \n \n \n \n \n \n \n(12,5%),\nsistema\nnervioso\n(9,8%),\nsistema\ncardiovascular\n(8,2%),\n \n \n \n \n \n \n \nmedicamentos\ndermatol\u00f3gicos\n(6,4%)\ny\nantibi\u00f3ticos\nde\nuso\nsist\u00e9mico\n \n \n \n \n \n \n \n \n(6,2%).\nLos\ngrupos\nde\nsegundo\nnivel\nm\u00e1s\ncomunes\nfueron\nR05\n \n \n \n \n \n \n \n \n \n \nf\u00e1rmacos\npara\nla\ntos\ny\nel\nresfriado\n(13,7%,\nn\n=\n55.475\n/\n405,814\n \n \n \n \n \n \n \n \n \n \n \n \n \nprescripciones),\nV60\nmedicamentos\nhomeop\u00e1ticos\n(9,5%),\nR01\n \n \n \n \n \n \nPreparados\nnasales\n(6,8%),\nJ01\nAntibacterianos\npara\nuso\nsist\u00e9mico\n \n \n \n \n \n \n \n \n(5,2%)\n,\nAnalg\u00e9sicos\nN02\n(4,8%),\nR03\nF\u00e1rmacos\npara\nenfermedades\n \n \n \n \n \n \n \n \n \nobstructivas\nde\nlas\nv\u00edas\nrespiratorias\n(4,2%)\ny\nM01\nantiinflamatorios\ny\n \n \n \n \n \n \n \n \n \n \nantirreum\u00e1ticos (3,2%).\n \n \n3.4.2 Reacciones adversas a medicamentos no antropos\u00f3ficos\n \n \nSe\ndocumentaron\nun\ntotal\nde\n695\ncasos\nde\nreacciones\nadversas\na\n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nno\nantropos\u00f3ficos,\nde\nlos\ncuales\n682\nfueron\nconfirmados\n \n \n \n \n \n \n \n \n \npor\nlos\ncient\u00edficos\ninvestigadores\nde\nla\nFIH\n(Instituto\nde\ninvestigaci\u00f3n\nde\n \n \n \n \n \n \n \n \n \n \n \nHavelh\u00f6he).\nLas\n682\nreacciones\nadversas\nafectaron\na\n637\npacientes\ny\n \n \n \n \n \n \n \n \n \n \nfueron causadas por 775  medicamentos no antropos\u00f3ficos diferentes.\n \n \n \nDe\nlas\n682\nreacciones\nadversas,\n29\n(4,3%)\nfueron\nreacciones\n \n \n \n \n \n \n \n \n \nadversas a medicamentos severas, afectando a 29 pacientes diferentes.\n \nLas\ncausas\nm\u00e1s\ncomunes\nde\nreacciones\nadversas\na\nmedicamentos\nno\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\nseg\u00fan\nel\nsegundo\nnivel\ndel\nsistema\nATC,\nfueron\nlas\n \n \n \n \n \n \n \n \n \n \nvacunas\nJ07\n(46,0%,\nn\n=\n353/768),\nJ01\nantibi\u00f3ticos\nde\nuso\nsist\u00e9mico\n \n \n \n \n \n \n \n \n \n \n \n(241%) y R05 preparados para la tos y el resfriado (7,4%).\n \n \n3.5\nComparativa\nentre\nmedicamentos\nantropos\u00f3ficos\ny\nno\n \n \n \n \n \n \n \nantropos\u00f3ficos\n \n 3.5.1 Indicaciones\n \n \nComparando\nlas\nindicaciones\nm\u00e1s\nfrecuentes\nen\nadultos\ny\nen\n \n \n \n \n \n \n \n \n \nni\u00f1os\nrespectivamente\nde\nun\nmedicamento\nantropos\u00f3fico\nfrente\na\nun\n \n \n \n \n \n \n \n \n \nmedicamento\nno\nantropos\u00f3fico\nla\nfrecuencia\nrelativa\nde\nlos\ncap\u00edtulos\nde\n \n \n \n \n \n \n \n \n \n \ndiagn\u00f3stico\nICD-10\nfue\nsimilar:\nlas\n\u00fanicas\ndiferencias\nsuperiores\nal\n3%\n \n \n \n \n \n \n \n \n \n \nen\nporcentajes\nabsolutos\nfueron\npara\nlas\nEnfermedades\ndel\nsistema\n \n \n \n \n \n \n \n \n \ncirculatorio\n(I00-I99)\n(10,3%\nde\nlas\nprescripciones\nde\nmedicamentos\n \n \n \n \n \n \n \n \nantropos\u00f3ficos\nfrente\na\n15,8%\nde\nlas\nprescripciones\nde\nmedicamentos\n \n \n \n \n \n \n \n \n \nno\nantropos\u00f3ficos),\ny\nEndocrinas,\nnutricionales\ny\nenfermedades\n \n \n \n \n \n \n \nmetab\u00f3licas\n(\nE00-E90)\ndonde\nlos\nporcentajes\nse\nsit\u00faan\nen\nun\n7,8%\n \n \n \n \n \n \n \n \n \n \n \nfrente\na\n11,5%\nen\nadultos\ny\nA00-B99\nTambi\u00e9n\nexisten\ndiferencias\nen\n \n \n \n \n \n \n \n \n \n \n \nciertas\nenfermedades\ninfecciosas\ny\nparasitarias\ninfantiles\n(9,9\nvs\n \n \n \n \n \n \n \n \n13.1%).\n \n \n3.5.2 Caracter\u00edsticas de las reacciones adversas a medicamentos\n \n \nLlevando\na\ncabo\nuna\ncomparaci\u00f3n\nde\nlas\n\u200b\nfrecuencias\nrelativas\n(no\n \n \n \n \n \n \n \n \n \n \nen\nt\u00e9rminos\nabsolutos)\nde\nlas\ncaracter\u00edsticas\nde\nlas\nreacciones\nadversas\n \n \n \n \n \n \n \n \n \n \na\nmedicamentos\na\nlos\nmedicamentos\nantropos\u00f3ficos\nfrente\na\nlos\n \n \n \n \n \n \n \n \n \nmedicamentos\nno\nantropos\u00f3ficos,\nlas\nreacciones\nde\nlos\nprimeros\nresult\u00f3\n \n \n \n \n \n \n \n \n \ntener\nuna\ngravedad\nsignificativamente\nmenor\nque\nfrente\na\nlos\nsegundos.\n \n \n \n \n \n \n \n \n \n \nAs\u00ed\nla\nintensidad\nde\nGrado\nI\nfue\nla\ncaracter\u00edstica\nprincipal\nen\nel\n50,0%\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nlos\ncasos\nde\nreacciones\nadversas\na\nmedicamentos\nantropos\u00f3ficos,\n \n \n \n \n \n \n \n \nmientras\nque\nen\nel\ncaso\nde\nlos\nmedicamentos\nno\nantropos\u00f3ficos\nel\n \n \n \n \n \n \n \n \n \n \n \nescal\u00f3n\nm\u00e1s\nbajo\nde\ngravedad\nde\nreacci\u00f3n\nadversa\nfue\ndel\n20,4%.\nLa\n \n \n \n \n \n \n \n \n \n \n \n \nprobabilidad\nde\nreacciones\nadversas\nse\ncifr\u00f3\nen\np\n<0.0001),\ny\nla\n \n \n \n \n \n \n \n \n \n \n \nposibilidad\nde\nque\nestos\nefectos\nse\nmantuvieran\nde\nmanera\ncontinuada\n \n \n \n \n \n \n \n \n \n \nen\nel\ntiempo\nse\nsit\u00fao\nen\nun\n43,0%\nen\nel\ncaso\nde\nmedicamentos\n \n \n \n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\nfrente\na\nun\n79,4%\nen\nel\ncaso\nde\nmedicamentos\nno\n \n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos.\nCon\nla\nretirada\ndel\nmedicamento\nlas\nreacciones\n \n \n \n \n \n \n \n \nadversas\ndesaparecieron\nen\nel\n80,4%\nde\nlos\ncasos\nde\nlos\n \n \n \n \n \n \n \n \n \n \nmedicamentos\nno\nantropos\u00f3ficos\nfrente\na\n56,5%\nde\nlos\nmedicamentos\n \n \n \n \n \n \n \n \n \nno\nantropos\u00f3ficos.\n(p\n<0.0001).\nCon\nrespecto\na\nla\ngravedad,\nla\nduraci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \ny\nel\nresultado\nde\nlas\nreacciones\nadversas\na\nmedicamentos,\nlas\n \n \n \n \n \n \n \n \n \n frecuencias\nrelativas\nno\nmostraron\ndiferencias\nsignificativas\nentre\nlos\n \n \n \n \n \n \n \n \ndos grupos.\n \n \n3.5.3\nFrecuencias\nde\nlas\nreacciones\nadversas\na\nmedicamentos,\nen\n \n \n \n \n \n \n \n \n \nrelaci\u00f3n con la prescripci\u00f3n\n \n \nEntre\nlos\npacientes\nde\nm\u00e9dicos\nque\nprescribieron\nmedicamentos,\n \n \n \n \n \n \n \n \nla\nfrecuencia\nde\nreacciones\nadversas\na\nmedicamentos\nde\ncualquier\n \n \n \n \n \n \n \n \n \n\u00edndice\nde\ngravedad,\nen\nrelaci\u00f3n\ncon\nla\ntasa\nde\nprescripci\u00f3n,\nfue\n \n \n \n \n \n \n \n \n \n \n \nsignificativamente\nmenor\npara\nlos\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n(0,071%,\nn\n=\n67\nADR\n/\n94.734\nrecetas)\nque\npara\nlos\nmedicamentos\nno\n \n \n \n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\n(0,412%,\nn\n=\n612\nADR\n/\n148.413\nrecetas)\n[odds\nratio\n \n \n \n \n \n \n \n \n \n \n \n(OR)\npara\nreacciones\nadversas\na\nmedicamentos\nantropos\u00f3ficos\nfrente\na\n \n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nmedicamentos\nno\nantropos\u00f3ficos\n0,17,\nIC\n95%\n \n \n \n \n \n \n \n \n \n0,13-0,22, p <0.0001] (Tabla 4).\n \n \n \nLa\nfrecuencia\nde\nreacciones\nadversas\nde\nmedicamentos\n \n \n \n \n \n \n \nantropos\u00f3ficos\nfrente\na\nmedicamentos\nno\nantropos\u00f3ficos\n \n \n \n \n \n \nrespectivamente,\nse\nanaliz\u00f3\nen\nlos\ntres\nmayores\nsubgrupos\nde\n \n \n \n \n \n \n \n \n \ndiagn\u00f3stico\ntanto\nen\nadultos\ncomo\nen\nni\u00f1os.\nEn\nlos\nseis\nsubgrupos,\nlas\n \n \n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\nfrente\na\nlos\nmedicamentos\nno\nantropos\u00f3ficos\n \n \n \n \n \n \n \n \nfueron\nm\u00e1s\nfrecuentes\nque\nlas\nreacciones\nadversas\nfrente\na\nlos\n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos.\nLas\ndiferencias\nresultaron\nsignificativas\n \n \n \n \n \n \npara\ndos\nsubgrupos\nde\nni\u00f1os:\naquellos\nque\npadecieron\nenfermedades\n \n \n \n \n \n \n \n \n \ninfecciosas\ncap\u00edtulos\n(ICD\nA00-B99),\ndonde\nla\nOR\npara\nlas\nreacciones\n \n \n \n \n \n \n \n \n \n \nadversas\na\nmedicamentos\nantropos\u00f3ficos\nse\nsit\u00fao\nen\nun\nIC\n95%\n0,02%\n \n \n \n \n \n \n \n \n \n \n \nfrente\na\nun\n0,33%\nde\nreacciones\nadversas\na\nmedicamentos\nno\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\np<0,0001)\ny\nen\nel\ncaso\nde\nlas\nenfermedades\n \n \n \n \n \n \n \n \n \nrespiratorias\nJ00-J99\n,\nOR\n0,34,\nIC\ndel\n95%:\ndonde\nestos\nporcentajes\nse\n \n \n \n \n \n \n \n \n \n \n \n \nsituaron en  0,21-0,53, respectivamente p <0,0001) (Tabla 6).\n \n \nEntre\ntodos\nlos\npacientes,\nla\nfrecuencia\ncorrespondiente\nde\n \n \n \n \n \n \n \n \nreacciones\nadversas\nde\nlos\ngrados\nIII-IV\nfue\ndel\n0,002%\n(n\n=\n7\nADR\n/\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n311.731\nrecetas)\ny\ndel\n0,020%\n(82\nreacciones\nadversas\n/\n405,814\n \n \n \n \n \n \n \n \n \n \nrecetas)\npara\nlos\nmedicamentos\nantropos\u00f3ficos\ny\nlos\nmedicamentos\nno\n \n \n \n \n \n \n \n \n antropos\u00f3ficos,\nrespectivamente\n(OR\n0,11,\n95%\nCI\n0,05-0,24,\np\n \n \n \n \n \n \n \n \n<0,0001) (v\u00e9ase tambi\u00e9n la Tabla 6 para los subgrupos de diagn\u00f3stico).\n \n \n \nLa\nfrecuencia\nde\nreacciones\nadversas\nseveras\nfue\nde\n0,0003%\n(1\n \n \n \n \n \n \n \n \n \n \nreacci\u00f3n\nadversa\nsevera\n/\n311,731\nrecetas)\npara\nmedicamentos\n \n \n \n \n \n \n \n \nantropos\u00f3ficos\ny\n0,0071%\n(29\nreacciones\nadversas\nseveras\n/\n405,814\n \n \n \n \n \n \n \n \n \nrecetas)\npara\nmedicamentos\nno\nantropos\u00f3ficos\n(O\n0.045,\nIC\n95%\n \n \n \n \n \n \n \n \n \n0.001-0.271, p <0.0001).\n \n \nTabla 6\n \n \n \n \nFrecuencia\nde\nreacciones\nadversas\na\nlos\nmedicamentos\nen\nrelaci\u00f3n\ncon\n \n \n \n \n \n \n \n \n \n \nlas\nprescripciones\nen\nlos\ntres\nmayores\nsubgrupos\nde\ndiagn\u00f3stico\nen\n \n \n \n \n \n \n \n \n \n \nadultos y ni\u00f1os, respectivamente.\n \n \nMA\n \nMedicamentos antropos\u00f3ficos\n \nMNA\n \nMedicamentos no antropos\u00f3ficos\n \n \nAdultos mayores de 18 a\u00f1os\n \n \n \nEnfermedades\n \ncardiocirculatorias\n \n(100-199)\n \nEnferm\n \nmusculoesquel\u00e9ticas\n \n(M00-M99)\n \nEnf\n \nRespiratorias\n \n(ICD 10-J00-J99)\n \n \nMA\n \nMNA\n \nMA\n \nMNA\n \nMA\n \nMNA\n \nPacientes\ncon\n \n \nprescripci\u00f3n\n \n \n \n \n \n \n \nRA Grados I-IV\n \n8\n \n18\n \n11\n \n10\n \n9\n \n13\n \nPrescripciones\n \n3614\n \n4665\n \n4145\n \n2995\n \n3922\n \n2784\n \nRA/prescripciones\n \n(%)\n \n0,221\n \n0,386\n \n0,265\n \n0,334\n \n0,229\n \n0,467\n \nPacientes con RA\n \n7\n \n17\n \n11\n \n10\n \n8\n \n12\n \nPacientes\ncon\n \n \nPrescripciones\n \n878\n \n678\n \n1013\n \n716\n \n1670\n \n1159\n \nPacientes\ncon\nRA/\n \n \n \n0,8\n \n2,51\n \n1,09\n \n1,40\n \n0,48\n \n1,04\n Pacientes\ncon\n \n \nPrescripciones (%)\n \n \nPacientes\nde\n \n \ntodos\nlos\n \n \nm\u00e9dicos\n \n \n \n \n \n \n \nRA\nSolo\ngrado\nIII\ny\n \n \n \n \n \nIV\n \n2\n \n7\n \n1\n \n7\n \n2\n \n7\n \nPrescripciones\n \n11.904\n \n25.408\n \n13.404\n \n17.250\n \n13.314\n \n14.681\n \nPacientes\ncon\nRA/\n \n \n \nPacientes\ncon\n \n \nPrescripciones (%)\n \n0,017\n \n0,028\n \n0,007\n \n0,041\n \n0,015\n \n0,048\n \nPacientes con RA\n \n2\n \n7\n \n1\n \n7\n \n2\n \n7\n \nPacientes\ncon\n \n \nPrescripciones\n \n3613\n \n3490\n \n4004\n \n3662\n \n5795\n \n4626\n \nPacientes\ncon\nRA/\n \n \n \nPacientes\ncon\n \n \nPrescripciones (%)\n \n0,06\n \n0,20\n \n0,02\n \n0,19\n \n0,03\n \n0,15\n \n \n \nMA\n \nMedicamentos antropos\u00f3ficos\n \nMNA\n \nMedicamentos no antropos\u00f3ficos\n \n \nRA\n \nReacciones adversas\n \n \nNi\u00f1os de 0 a 17  a\u00f1os\n \n \n \nEnf\n \nRespiratorias\n \n(ICD 10-J00-J99\n \nEnfermedades\n \ninfecciosas\n \n(A00-B99)\n \nS\u00edntomas\ny\nsignos\n \n \n \nhallados\nno\nclasificados\n \n \n \nen otro lugar (R00-R99)\n \n \nMA\n \nMNA\n \nMA\n \nMNA\n \nMA\n \nMNA\n \nPacientes\ncon\n \n \nprescripci\u00f3n\n \n \n \n \n \n \n \nRA Grados I-IV\n \n24\n \n154\n \n3\n \n82\n \n5\n \n22\n \nPrescripciones\n \n18.261\n \n40.217\n \n6690\n \n19.926\n \n6162\n \n10.759\n \nRA/prescripciones\n \n(%)\n \n0,131\n \n0,383\n \n0,045\n \n0,412\n \n0,081\n \n0,204\n \nPacientes con RA\n \n23\n \n145\n \n3\n \n80\n \n5\n \n22\n Pacientes\ncon\n \n \nPrescripciones\n \n6429\n \n6641\n \n3732\n \n5711\n \n3463\n \n4384\n \nPacientes\ncon\n \n \nRA/\nPacientes\n \n \ncon\n \nPrescripciones\n \n(%)\n \n0,36\n \n2,18\n \n0,08\n \n1,40\n \n0,14\n \n0,50\n \nPacientes\nde\n \n \ntodos\nlos\n \n \nm\u00e9dicos\n \n \n \n \n \n \n \nRA\nSolo\ngrado\nIII\n \n \n \n \ny IV\n \n2\n \n14\n \n0\n \n6\n \n0\n \n2\n \nPrescripciones\n \n61.127\n \n74.714\n \n18.689\n \n31.078\n \n18.485\n \n25.343\n \nPacientes\ncon\n \n \nRA/\nPacientes\n \n \ncon\n \nPrescripciones\n \n(%)\n \n0,003\n \n0,019\n \n0,000\n \n0,019\n \n0,000\n \n0,008\n \nPacientes con RA\n \n2\n \n14\n \n0\n \n6\n \n0\n \n2\n \nPacientes\ncon\n \n \nPrescripciones\n \n19.414\n \n17.187\n \n10.082\n \n11.928\n \n9906\n \n10.334\n \nPacientes\ncon\n \n \nRA/\nPacientes\n \n \ncon\n \nPrescripciones\n \n(%)\n \n0,01\n \n0,08\n \n0,000\n \n0,05\n \n0,000\n \n0,02\n \n \n \n \n \n \n \n \n \nMA Medicamento antropos\u00f3fico\n \nMNA Medicamento antropos\u00f3fico\n \nRA Reacciones adversas\n \n \n \n \n \n \n \n \n \n 4.\nDiscusi\u00f3n\n \n \n \n4.1 Principales resultados\n \n \nEste\nes\nel\nmayor\nan\u00e1lisis\nde\nseguridad\nde\nmedicamentos\n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\nen\nuna\nposible\ncohorte\nde\npacientes\nhasta\nel\nmomento:\n \n \n \n \n \n \n \n \n \n \n44.662\npacientes\nde\nla\nred\nde\nfarmacovigilancia\nEvaMed\ncon\nun\ntotal\nde\n \n \n \n \n \n \n \n \n \n \n \n \n311.731\nprescripciones\nde\nmedicamentos\nantropos\u00f3ficos.\nLos\n \n \n \n \n \n \npacientes\nfueron\nseguidos\ndurante\nuna\nmedia\nde\n27\nmeses.\nLas\n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nlos\nmedicamentos\nantropos\u00f3ficos\nfueron\npoco\n \n \n \n \n \n \n \n \nfrecuentes\n(0,071%\nde\nlas\nprescripciones\nde\nmedicamentos\n \n \n \n \n \n \n \nantropos\u00f3ficos\n),\nlas\nreacciones\nadversas\nde\nalta\nintensidad\ny\nlas\n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\nseveras\nfueron\nmuy\nraras\n(0,002%\ny\n0,0003%,\n \n \n \n \n \n \n \n \n \nrespectivamente).\nEntre\nlos\n11\nsubgrupos\nanalizados,\nla\nfrecuencia\nm\u00e1s\n \n \n \n \n \n \n \n \n \nalta\nde\nreacciones\nadversas\nse\nhallaba\nen\nel\nrango\n\"poco\ncom\u00fan\"\n \n \n \n \n \n \n \n \n \n \n \n(0,290%\nde\nlas\nprescripciones\npara\nun\nmedicamentos\nantropos\u00f3fico\n \n \n \n \n \n \n \n \nespec\u00edfico).\nEn\ncomparaci\u00f3n\ncon\nlos\nreacciones\nadversas\na\nlos\n \n \n \n \n \n \n \n \n \nmedicamentos\nno\nantropos\u00f3ficos,\nlas\nreacciones\nadversas\na\nlos\n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nson\nmenos\nfrecuentes\n(OR\npara\nlas\n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nlos\nmedicamentos\nantropos\u00f3ficos\ny\nlos\n \n \n \n \n \n \n \n \nmedicamentos\nno\nantropos\u00f3ficos\n,\nrespectivamente,\nque\nvan\ndesde\n \n \n \n \n \n \n \n \n0,045\npara\nlos\nreacciones\nadversas\nsevera\nhasta\n0,17\npara\ncualquier\n \n \n \n \n \n \n \n \n \n \nreacci\u00f3n adversa).\n \n \n \n4.2 Fortalezas y limitaciones del estudio\n \n \nUna\nfortaleza\nimportante\ndel\nestudio\nEvaMed\ny\nde\nsu\nan\u00e1lisis\n \n \n \n \n \n \n \n \n \n \nradica\nen\nla\nextracci\u00f3n\nautom\u00e1tica\nde\ndatos\nde\nlos\nregistros\nm\u00e9dicos\n \n \n \n \n \n \n \n \n \n \n \nelectr\u00f3nicos\npor\nparte\nde\nlos\nm\u00e9dicos\nparticipantes.\nEste\nprocedimiento\n \n \n \n \n \n \n \n \n \npermiti\u00f3\nla\ninclusi\u00f3n\nde\ntodas\nlas\nprescripciones\nmedicamentos\na\ntodos\n \n \n \n \n \n \n \n \n \n \nlos\npacientes\nsin\nninguna\nselecci\u00f3n,\ny\nayud\u00f3\na\nlograr\nuna\nmuestra\nmuy\n \n \n \n \n \n \n \n \n \n \n \n \ngrande\nde\nni\u00f1os\ny\nadultos\ncon\nprescripciones,\naumentando\nel\npoder\nde\n \n \n \n \n \n \n \n \n \n \n \ndetectar\nreacciones\nadversas\npoco\nfrecuentes,\nas\u00ed\ncomo\nclasificar\nestas\n \n \n \n \n \n \n \n \n \nen\nsubgrupos\nde\ninter\u00e9s.\nOtras\nventajas\nes\nque\nincluye\nuna\nbuena\n \n \n \n \n \n \n \n \n \n \n representaci\u00f3n\nde\nla\natenci\u00f3n\nambulatoria\nen\n12\nde\nlos\n16\nestados\n \n \n \n \n \n \n \n \n \n \n \nfederales\nalemanes\ny\nun\nlargo\nper\u00edodo\nde\ndocumentaci\u00f3n;\nel\nestudio\nde\n \n \n \n \n \n \n \n \n \n \n \ntres\ncuartas\npartes\nde\ntodos\nlos\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \n \ncomercializados\nen\nAlemania\ndurante\nel\nper\u00edodo\nde\nestudio;\ny\nuna\n \n \n \n \n \n \n \n \n \n \nevaluaci\u00f3n\nexhaustiva\ny\nrigurosa\nde\nlos\nreacciones\nadversas\npara\ntodos\n \n \n \n \n \n \n \n \n \n \nlos medicamentos.\n \n \nEl\nestudio\nno\nfue\ndise\u00f1ado\npara\nevaluar\nla\neficacia\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \nmedicamentos,\npor\nlo\ntanto,\nno\nse\ndocumentaron\nresultados\ncl\u00ednicos.\nLa\n \n \n \n \n \n \n \n \n \n \ndocumentaci\u00f3n\nde\nseguridad\nestaba\nrestringida\na\nsospechas\nde\n \n \n \n \n \n \n \n \nreacciones\nadversas\na\ncualquier\nmedicamento.\nNo\nfue\nfactible\nuna\n \n \n \n \n \n \n \n \n \ndocumentaci\u00f3n\ncontinuada\ny\nmantenida\ny\nla\nevaluaci\u00f3n\nde\ntodos\nlos\n \n \n \n \n \n \n \n \n \n \neventos\nadversos\nposteriores\na\nla\nprescripci\u00f3n\nde\nmedicamentos\nen\n \n \n \n \n \n \n \n \n \nesta\ngran\nmuestra\nde\npacientes.\nPor\nlo\ntanto,\nno\nse\npueden\nexcluir\n \n \n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\ninusuales\no\ninesperados\nde\nmedicamentos\n \n \n \n \n \n \n \nantropos\u00f3ficos\nu\notros,\nno\nreconocidos\ncomo\ntales\n(esta\npregunta\nse\nha\n \n \n \n \n \n \n \n \n \n \n \nevaluado\nen\notros\nestudios\nde\nterapia\ncon\nmedicina\nantropos\u00f3fica,\npor\n \n \n \n \n \n \n \n \n \n \nejemplo\n[22,\n41]).\nAdem\u00e1s,\nla\ndocumentaci\u00f3n\ndel\nestudio\nno\nincluy\u00f3\n \n \n \n \n \n \n \n \n \n \nninguna\nvisita\nde\nseguimiento\nprogramada;\nen\nconsecuencia,\nla\n \n \n \n \n \n \n \n \ndetecci\u00f3n\nde\nreacciones\nadversas\ndepend\u00eda\nde\nque\nlos\npacientes\n \n \n \n \n \n \n \n \n \nregresaran\npara\nconsultas\nposteriores\no\nque\nlo\nnotificaran\nde\notro\nmodo\n \n \n \n \n \n \n \n \n \n \n \na\nlos\nm\u00e9dicos.\nPor\nlo\ntanto,\nen\neste\nestudio\nno\nse\npuede\nexcluir\nel\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nsubregistro\nde\nsospechas\nde\nreacciones\nadversas\npor\nparte\nde\nlos\n \n \n \n \n \n \n \n \n \n \npacientes a sus m\u00e9dicos, similar a la pr\u00e1ctica m\u00e9dica en el mundo real.\n \n \nTeniendo\nen\ncuenta\nel\nlargo\nper\u00edodo\nde\ndocumentaci\u00f3n\nde\n27\n \n \n \n \n \n \n \n \n \n \nmeses\nde\npromedio\npor\ncada\nm\u00e9dico\ny\nla\ninclusi\u00f3n\nde\ntodos\nlos\n \n \n \n \n \n \n \n \n \n \n \n \npacientes\natendidos\npor\nlos\nm\u00e9dicos\nen\nel\nproyecto\nde\nestudio,\nel\n \n \n \n \n \n \n \n \n \n \n \nsubregistro\nde\nreacciones\nadversas\npor\nparte\nde\nlos\nm\u00e9dicos\ntambi\u00e9n\n \n \n \n \n \n \n \n \n \n \npuede\nresultar\nun\nposible\nsesgo.\nLas\nmedidas\nde\nprecauci\u00f3n\npara\nevitar\n \n \n \n \n \n \n \n \n \n \n \nla\nfalta\nde\nnotificaci\u00f3n\nm\u00e9dica\nse\ntomaron\na\nnivel\nde\norganizaci\u00f3n\ndel\n \n \n \n \n \n \n \n \n \n \n \n \nestudio,\nas\u00ed\ncomo\ndel\nan\u00e1lisis:\ncada\nm\u00e9dico\nse\ncapacit\u00f3\nindividualmente\n \n \n \n \n \n \n \n \n \n \nen\nla\npresentaci\u00f3n\nde\ninformes\nde\nreacciones\nadversas\n[39].\nAdem\u00e1s,\nla\n \n \n \n \n \n \n \n \n \n \n \nobligaci\u00f3n\nde\nlos\nm\u00e9dicos\nde\ninformar\nde\nlas\nreacciones\nadversas\nse\n \n \n \n \n \n \n \n \n \n \n \ncalific\u00f3:\ntodos\nlos\nm\u00e9dicos\ninformaron\ndel\ntipo\nde\nreacciones\nadversas\n \n \n \n \n \n \n \n \n \n que\nse\nnotan\nf\u00e1cilmente\ny\nde\nlas\ncuales\nse\npuede\ntener\nm\u00e1s\n \n \n \n \n \n \n \n \n \n \n \n \nconsciencia,\nes\ndecir,\nreacciones\nadversas\ngraves\ny\nreacciones\n \n \n \n \n \n \n \n \nadversas\ngraves\nde\nalta\nintensidad.\nLa\ndocumentaci\u00f3n\nadicional\nde\nlas\n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nmedicamentos\nno\ngraves\ny\nde\nintensidad\nleve\na\n \n \n \n \n \n \n \n \n \n \n \nmoderada\nse\nlimit\u00f3\na\nun\ngrupo\nm\u00e1s\npeque\u00f1o\nde\nm\u00e9dicos\n\"prescriptores\"\n \n \n \n \n \n \n \n \n \n \n \nque\nhab\u00edan\naceptado\nexpl\u00edcitamente\nhacerlo.\nCon\nel\nfin\nde\ntener\nuna\n \n \n \n \n \n \n \n \n \n \n \nestimaci\u00f3n\nimparcial\nde\nla\nfrecuencia\nde\nestas\nreacciones\nadversas\nen\n \n \n \n \n \n \n \n \n \n \nrelaci\u00f3n\ncon\nlas\ntasas\nde\nprescripci\u00f3n,\nla\nmuestra\npara\neste\nan\u00e1lisis\nse\n \n \n \n \n \n \n \n \n \n \n \n \nlimit\u00f3\na\nlos\npacientes\nde\nlos\nm\u00e9dicos\nque\nprescribieron\neste\ntipo\nde\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos.\n \n \nA\nlos\nm\u00e9dicos\nEvaMed\nse\nles\npag\u00f3\n15\neuros\npor\ninforme\nreacci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \nadversa\na\nmedicamento\npresentado\ncomo\ncompensaci\u00f3n\npor\nel\ntiempo\n \n \n \n \n \n \n \n \n \ndedicado\na\ninvestigar\nla\nsospecha\nde\n\u00e9sta,\nentrevistar\nal\npaciente\ny\n \n \n \n \n \n \n \n \n \n \n \npresentar\nel\ninforme\n[40].\nEstos\nm\u00e9dicos\ntrabajaban\ndentro\ndel\nSistema\n \n \n \n \n \n \n \n \n \n \nAlem\u00e1n\nde\nSalud,\ndonde\nse\nles\npaga\npor\ncada\nservicio\nproporcionado\nal\n \n \n \n \n \n \n \n \n \n \n \n \npaciente,\nmientras\nque\nlos\nm\u00e9dicos\npagan\ntodos\nlos\ngastos\nde\noficina,\n \n \n \n \n \n \n \n \n \n \n \nequipo,\nsalarios\na\nlos\nasistentes,\netc.\nSe\ncalcul\u00f3\nque\nla\nsuma\nde\n15\n \n \n \n \n \n \n \n \n \n \n \n \n \neuros\nera\nlo\nsuficientemente\nalta\npara\nque\nlos\nm\u00e9dicos\nEvaMed\nno\n \n \n \n \n \n \n \n \n \n \n \nsufran\nuna\np\u00e9rdida\nfinanciera\ndebido\nal\ntiempo\ny\nesfuerzo\nque\nlos\n \n \n \n \n \n \n \n \n \n \n \ninformes\nde\nreacciones\nadversas\nles\npudieran\nllevar,\npero\nlo\n \n \n \n \n \n \n \n \n \nsuficientemente\nbajos\ncomo\npara\nque\nesta\nactividad\nno\nsea\n \n \n \n \n \n \n \n \n \nfinancieramente\natractiva.\nPor\nlo\ntanto,\npor\nesta\nraz\u00f3n\nno\nse\nesperar\u00eda\n \n \n \n \n \n \n \n \n \n \n \nun\nexceso\nde\nsesgos\ndebido\na\nganancias\necon\u00f3micas\nni\nun\nsesgo\nde\n \n \n \n \n \n \n \n \n \n \n \n \nsubestimaci\u00f3n\ndebido\na\nla\nevitaci\u00f3n\nde\nla\ntensi\u00f3n\necon\u00f3mica.\nEn\n \n \n \n \n \n \n \n \n \n \ncomparaci\u00f3n\ncon\nlos\ncostos\ntotales\ndel\nestudio,\nlos\ncostos\npara\n \n \n \n \n \n \n \n \n \n \nreembolsar\na\nlos\nm\u00e9dicos\npor\nla\nRAM\nfueron\ninsignificantes;\ndicha\ntarifa\n \n \n \n \n \n \n \n \n \n \n \npodr\u00eda considerarse tambi\u00e9n para otros proyectos de farmacovigilancia.\n \n \nAlgunos\nelementos\nde\ninter\u00e9s\npara\nla\nevaluaci\u00f3n\nde\nseguridad\nno\n \n \n \n \n \n \n \n \n \n \nfueron\ndocumentados,\ncomo\nel\nn\u00famero\nde\nd\u00edas\nde\nempleo\no\nlas\n \n \n \n \n \n \n \n \n \n \n \naplicaciones\npara\ncada\nmedicamentos\nprescrito,\ny\nel\ncumplimiento\ndel\n \n \n \n \n \n \n \n \n \npaciente\no,\nen\nsu\ncaso,\ndel\ncuidador\ncon\nlas\nprescripciones.\nAdem\u00e1s,\nla\n \n \n \n \n \n \n \n \n \n \n \n \ndocumentaci\u00f3n\nde\nlos\ndatos\ndemogr\u00e1ficos\ny\nla\nmorbilidad\ninicial\nse\n \n \n \n \n \n \n \n \n \n \nlimitaba\na\nla\nedad,\nel\ng\u00e9nero\ny\nlos\ndiagn\u00f3sticos,\nlo\nque\nofrec\u00eda\n \n \n \n \n \n \n \n \n \n \n \n posibilidades\nlimitadas\npara\nanalizar\nlos\nfactores\nasociados\ncon\nla\n \n \n \n \n \n \n \n \n \naparici\u00f3n\nde\nreacciones\nadversas,\nadem\u00e1s\nde\nlas\nvariables\nrelacionadas\n \n \n \n \n \n \n \n \n \ncon el medicamento.\n \n \n4.3 Comparaci\u00f3n con otros estudios. Interpretaci\u00f3n\n \n \nLos\nhallazgos\nde\neste\nan\u00e1lisis\nde\nla\nseguridad\nde\nmedicamentos\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos\nse\npueden\ncomparar\ncon\notros\ndos\nan\u00e1lisis\nde\nseguridad\n \n \n \n \n \n \n \n \n \n \nde\nmedicamentos\nantropos\u00f3ficos\nde\ncohortes\nprospectivas\n[21,\n22],\npara\n \n \n \n \n \n \n \n \n \nlos\ncuales\nse\ndispone\nde\ndatos\na\nnivel\nde\npaciente.\nLos\ntres\nestudios\n \n \n \n \n \n \n \n \n \n \n \n \n \nfueron\nde\npacientes\nambulatorios,\nprincipalmente\nde\natenci\u00f3n\nprimaria,\n \n \n \n \n \n \n \n \nde\nconsultas\nm\u00e9dicas\nen\nlos\npa\u00edses\noccidentales\ny\ntodos\nincluyeron\nla\n \n \n \n \n \n \n \n \n \n \n \ndocumentaci\u00f3n\nintegral\nde\nreacciones\nadversas\ncon\nla\nevaluaci\u00f3n\nde\n \n \n \n \n \n \n \n \n \ncausalidad\npor\nparte\ndel\npersonal\nde\ninvestigaci\u00f3n\nindependiente.\nPara\n \n \n \n \n \n \n \n \n \nlas\ndos\ncomparaciones,\nlas\nmuestras\nde\nEvaMed\ny\nlos\nestudios\nde\n \n \n \n \n \n \n \n \n \n \n \ncomparaci\u00f3n\nse\nrestringieron\npara\ntener\ngrupos\nde\nedad\ny\ndiagn\u00f3stico\n \n \n \n \n \n \n \n \n \n \nid\u00e9nticos:\n \n \n\u25cf\nEl\n\u200b\nInternational\nIntegrative\nPrimary\nCare\nOutcomes\nStudy\n \n \n \n \n \n \n \n(IIPCOS)\nse\nenfoc\u00f3\nen\npacientes\ncon\ninfecciones\nrespiratorias\ny\n \n \n \n \n \n \n \n \n \ndel\no\u00eddo\nagudas;\npor\nlo\ntanto,\nla\ncomparaci\u00f3n\nse\nlimit\u00f3\na\npacientes\n \n \n \n \n \n \n \n \n \n \n \n \nEvaMed\ncon\nlos\nmismos\ndiagn\u00f3sticos.\nLas\nreacciones\nadversas\na\n \n \n \n \n \n \n \n \n \nlos\nmedicamentos\nantropos\u00f3ficos\nfueron\nigualmente\ninfrecuentes\n \n \n \n \n \n \nen\nIIPCOS\ny\nEvaMed\n(0,28%\nfrente\na\n0.34%\nde\nlos\nusuarios\nde\n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos).\nLlama\nla\natenci\u00f3n\nque\nel\nn\u00famero\n \n \n \n \n \n \n \n \nabsoluto\nde\nreacciones\nadversas\na\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \nen\nIIPCOS\nfue\nbajo\n(n\n=\n2);\npor\nlo\ntanto,\nel\nan\u00e1lisis\nEvaMed\n \n \n \n \n \n \n \n \n \n \n \n \n \nconfirma los resultados de IIPCOS para este grupo de pacientes\n \n \n\u25cf\nEl\nEstudio\n\u200b\nAnthroposophic\nmedic\nstudy\n(AMOS)\ntuvo\nuna\nmuestra\n \n \n \n \n \n \n \n \n \nde\npacientes\ncon\nuna\nedad\nmucho\nm\u00e1s\navanzada\nque\nEvaMed\ny\n \n \n \n \n \n \n \n \n \n \n \nel\n80%\nde\ntodas\nlas\nreacciones\nadversas\nconfirmadas\na\nlos\n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nen\nAMOS\nse\nprodujo\nen\nadultos;\n \n \n \n \n \n \n \n \npor\nlo\ntanto,\nla\ncomparaci\u00f3n\nse\nlimit\u00f3\na\npacientes\nadultos.\nEn\n \n \n \n \n \n \n \n \n \n \n \nAMOS,\nlos\npacientes\ny\nlos\nm\u00e9dicos\ncompletaron\nen\nrepetidas\n \n \n \n \n \n \n \n \n ocasiones\nlos\ncuestionarios\nde\nseguimiento\n(EvaMed\nno\nten\u00eda\n \n \n \n \n \n \n \n \ndocumentaci\u00f3n\nde\nseguimiento\nprogramada)\ny\nlas\nsospechas\nde\n \n \n \n \n \n \n \n \nreacci\u00f3n\nadversa\na\nlos\nmedicamentos\nfueron\ndocumentadas\n \n \n \n \n \n \n \nindependientemente\npor\npacientes\ny\nm\u00e9dicos\n(EvaMed:\nsolo\n \n \n \n \n \n \n \nm\u00e9dicos),\ncon\nun\ntercio\nde\nlas\nreacciones\nadversas\nconfirmadas\n \n \n \n \n \n \n \n \n \npor\nm\u00e9dicos\na\nlos\nmedicamentos\nantropos\u00f3ficos\nen\nel\nan\u00e1lisis\n \n \n \n \n \n \n \n \n \nAMOS\nque\nest\u00e1n\ndocumentados\nsolo\npor\npacientes\n[22].\nLas\n \n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nlos\nmedicamentos\nantropos\u00f3ficos\nfueron\n \n \n \n \n \n \n \naproximadamente\n4,5\nveces\nm\u00e1s\nfrecuentes\nen\nAMOS\nque\nen\n \n \n \n \n \n \n \n \n \nEvaMed\n(3,08%\nfrente\na\n0,69%\nde\nlos\nusuarios\nde\nmedicamentos\n \n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos);\nesta\ndiferencia\npodr\u00eda\nexplicarse\npor\nlas\n \n \n \n \n \n \n \ndiferencias\nmencionadas\nanteriormente\nen\nla\ndocumentaci\u00f3n\ndel\n \n \n \n \n \n \n \nestudio por parte del paciente.\n \n \nLas\nreacciones\nadversas\nseveras\na\nlos\nmedicamentos\n \n \n \n \n \n \n \nantropos\u00f3ficos\nfueron\nmuy\nraras\nen\nEvaMed\n(0,0022%\nde\n44.662\n \n \n \n \n \n \n \n \n \nusuarios) y no ocurrieron en los otros dos estudios.\n \n \nAdem\u00e1s,\nla\nfrecuencia\nde\nreacciones\nadversas\na\nlos\n \n \n \n \n \n \n \n \nmedicamentos\nno\nantropos\u00f3ficos\nen\neste\nestudio\nse\npuede\ncomparar\n \n \n \n \n \n \n \n \n \ncon\notros\nestudios.\nSe\ncentr\u00f3\nen\nni\u00f1os\nde\n0\na\n17\na\u00f1os,\nque\n \n \n \n \n \n \n \n \n \n \n \n \n \nconstituyeron\ncasi\ndos\ntercios\n(63,6%)\nde\nlos\npacientes\ndel\nestudio\n \n \n \n \n \n \n \n \n \n \nanal\u00edtico,\ny\nse\ncombinaron\npara\nel\ndise\u00f1o\ndel\nestudio\n(estudios\n \n \n \n \n \n \n \n \n \n \nobservacionales),\nel\nentorno\n(pacientes\nambulatorios)\ny\nel\ndenominador\n \n \n \n \n \n \n \n \n(n\u00famero\nde\npacientes\nexpuestos\na\nf\u00e1rmacos),\nidentific\u00e1ndose\nas\u00ed\ncuatro\n \n \n \n \n \n \n \n \n \nestudios\nde\nuna\nreciente\nrevisi\u00f3n\nsistem\u00e1tica\nmuy\ncompleta\nde\nlas\n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\nen\nni\u00f1os\n[37].\nLa\nfrecuencia\nde\nreacciones\n \n \n \n \n \n \n \n \n \nadversas\na\nmedicamentos\nno\nantropos\u00f3ficos\nentre\nlos\npacientes\n \n \n \n \n \n \n \n \npedi\u00e1tricos\nexternos\nexpuestos\nal\nf\u00e1rmaco\nfue\nde\n6,22%\nen\nEvaMed\n \n \n \n \n \n \n \n \n \n \n(Tabla\n4)\ny\n5.92%\nen\nlos\ncuatro\nestudios\n[17,\n28,\n35,\n36]\n(media\n \n \n \n \n \n \n \n \n \n \n \n \n \nponderada:\nn\n=\n404/6824\npacientes,\ncf.\nFig.\n3\nen\n[37]).\nA\u00fan\nteniendo\nen\n \n \n \n \n \n \n \n \n \n \n \n \n \ncuenta\nlas\nlimitaciones\nde\ntales\ncomparaciones\nfrente\na\nfactores\nde\n \n \n \n \n \n \n \n \n \n \nconfusi\u00f3n\npor\notras\nvariables\n(por\nejemplo,\nindicaciones\ny\ntipo\nde\n \n \n \n \n \n \n \n \n \n \nmedicamentos),\nla\nincidencia\nde\nreacciones\nadversas\na\nmedicamentos\n \n \n \n \n \n \n \n no\nantropos\u00f3ficos\nen\nEvaMed\nparece\nestar\nen\nel\nmismo\norden\nde\n \n \n \n \n \n \n \n \n \n \n \nmagnitud que en el de los otros estudios observacionales.\n \n \nEl\nenfoque\nprincipal\nde\neste\nan\u00e1lisis\nfue\nla\nseguridad\nde\nlos\n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos,\nque\nes\nun\ntema\nque\ndistingue\na\neste\neste\n \n \n \n \n \n \n \n \n \n \n \nestudio\npara\npoder\nllegar\na\nuna\nperspectiva\nregulatoria.\nSin\nembargo,\n \n \n \n \n \n \n \n \n \n \ncomo\nla\nmedicina\nantropos\u00f3fica\nes\nun\nsistema\nintegral\nde\nmedicina,\nlos\n \n \n \n \n \n \n \n \n \n \n \nm\u00e9dicos\nde\nesta\nrama\nprescriben\nno\ns\u00f3lo\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \n \n \nen\nsu\natenci\u00f3n\nal\npaciente,\nsino\ntambi\u00e9n\notro\ntipo\nde\nf\u00e1rmacos.\nEn\n \n \n \n \n \n \n \n \n \n \n \n \nconsecuencia,\nun\nenfoque\nde\nsalud\np\u00fablica\nm\u00e1s\namplio\nsobre\nla\n \n \n \n \n \n \n \n \n \n \nseguridad\nde\ntodos\nlos\nmedicamentos\nprescritos\ntambi\u00e9n\nes\nrelevante.\n \n \n \n \n \n \n \n \n \nEn\neste\nan\u00e1lisis,\nlas\nreacciones\nadversas\na\ncualquier\nmedicamento\n \n \n \n \n \n \n \n \n \nfueron\npoco\nfrecuentes\n(0,28%\nde\nlas\nprescripciones,\nn\n=\n679\n/\n \n \n \n \n \n \n \n \n \n \n \n243,147).\nCabe\ndestacar\nque,\ndentro\nde\neste\nenfoque\namplio,\nlas\n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nlos\nmedicamentos\nantropos\u00f3ficos\nfueron\nmenos\n \n \n \n \n \n \n \n \nfrecuentes\nque\nlas\nreacciones\nadversas\na\nlos\nmedicamentos\nno\n \n \n \n \n \n \n \n \n \nantropos\u00f3ficos,\ncon\nOR\npara\nlas\nreacciones\nadversas\na\nlos\n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\ny\nlos\nmedicamentos\nno\nantropos\u00f3ficos,\n \n \n \n \n \n \n \nrespectivamente,\nde\n0,17.\nEsta\ndiferencia\nfue\na\u00fan\nmayor\npara\nlos\n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\nde\nalta\nintensidad\n(OR\n0,11)\ny\naquellas\nque\npon\u00edan\n \n \n \n \n \n \n \n \n \n \n \nen\nriesgo\nla\nvida\no\nintegridad\ndel\npaciente\n(O\n0,045).\nNotablemente,\nlos\n \n \n \n \n \n \n \n \n \n \n \n \ndos\ntipos\nde\nmedicamentos\nten\u00edan\nindicaciones\nrelativamente\nsimilares.\n \n \n \n \n \n \n \n \nPor\nlo\ntanto,\nen\nla\natenci\u00f3n\nambulatoria\nde\nrutina,\nlos\nriesgos\nde\nuso\nde\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nmedicamentos\nantropos\u00f3ficos\nparecen\nser\nbajos,\nno\ns\u00f3lo\nen\nt\u00e9rminos\n \n \n \n \n \n \n \n \n \nabsolutos,\nsino\ntambi\u00e9n\nen\ncomparaci\u00f3n\ncon\nlos\nriesgos\nde\notros\ntipos\n \n \n \n \n \n \n \n \n \n \n \nde medicamentos utilizados por los pacientes.\n \n \n5.\nConclusi\u00f3n\n \nEste\nan\u00e1lisis\nde\nm\u00e1s\nde\n40.000\npacientes\nambulatorios\nen\nun\n \n \n \n \n \n \n \n \n \n \nestudio\nprospectivo\nde\ncohortes\nconfirma\nlos\nhallazgos\nprevios\nde\notros\n \n \n \n \n \n \n \n \n \n \nestudios\ncon\nmenos\nde\n1000\npacientes\n[21,\n22]:\nque\nsupone\nque\nlas\n \n \n \n \n \n \n \n \n \n \n \n \nreacciones\nadversas\na\nlos\nmedicamentos\nantropos\u00f3ficos\nfueron\nraras\n \n \n \n \n \n \n \n \n(0,071%\nde\nlas\nprescripciones),\nlas\nreacciones\nadversas\nde\nalta\n \n \n \n \n \n \n \n \n \nintensidad\ny\nlas\nque\nponen\nen\nriesgo\nla\nvida\nfueron\nmuy\nraras\n(0.002\ny\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n0.0003%, respectivamente).\n  \nAgradecimientos y reconocimientos\n \nEl\nestudio\nEvaMed\nfue\nfinanciado\npor\nSoftware\nAG-Stiftung.\nEste\n \n \n \n \n \n \n \n \n \nan\u00e1lisis\ny\npublicaci\u00f3n\nfue\nencargado\npor\nla\nCooperativa\nCient\u00edfica\n \n \n \n \n \n \n \n \n \nEuropea\nde\nMedicamentos\nAntropos\u00f3ficos\n(http://www.escamp.org)\ncon\n \n \n \n \n \n \nel\napoyo\nfinanciero\nde\nfundaciones\n(Christophorus-Stiftung,\n \n \n \n \n \n \nDamus-Donata-Stiftung,\nEkhagastiftelsen,\nMahle-Stiftung,\nSoftware\nAG\n \n \n \n \n \n-Stiftung)\ny\nlos\nfabricantes\nde\nmedicamentos\nantropos\u00f3ficos\n(Wala,\n \n \n \n \n \n \n \n \nWeleda).\nSe\ndebe\nrecalcar\nque\nlos\npatrocinadores\nno\ntuvieron\ninfluencia\n \n \n \n \n \n \n \n \n \n \nen\nla\nplanificaci\u00f3n\no\nrealizaci\u00f3n\ndel\nestudio\nEvaMed;\nas\u00ed\ncomo\ntampoco\n \n \n \n \n \n \n \n \n \n \n \nen\nla\nrecopilaci\u00f3n,\npreparaci\u00f3n,\nan\u00e1lisis\no\ninterpretaci\u00f3n\nde\ndatos\npara\n \n \n \n \n \n \n \n \n \n \neste\ndocumento;\nni\nsobre\nla\npreparaci\u00f3n,\nrevisi\u00f3n\no\naprobaci\u00f3n\ndel\n \n \n \n \n \n \n \n \n \n \nmanuscrito.\n \n \nContribuciones de los autores\n \nHarald\nJohann\nHamre,\nAnja\nGlockmann\ny\nKirsten\nHeckenbach\n \n \n \n \n \n \n \n \nescribieron\ndise\u00f1aron\neste\nan\u00e1lisis.\nAnja\nGlockmann\ny\nKirsten\n \n \n \n \n \n \n \n \nHeckenbach\nprepararon\ny\nestudiaron\nlos\ndatos.\nAnja\nGlockmann\nanaliz\u00f3\n \n \n \n \n \n \n \n \n \nlos\ndatos.\nHarald\nJohann\nHamre\ndise\u00f1\u00f3\ny\ndirigi\u00f3\nel\nestudio\nEvaMed.\n \n \n \n \n \n \n \n \n \n \n \nHarald\nJohann\nHamre\nfue\nel\nautor\nprincipal,\nteniendo\nacceso\na\ntoda\nla\n \n \n \n \n \n \n \n \n \n \n \n \ninformaci\u00f3n\ny\npermaneciendo\nen\ntodo\nmomento\ncomo\ngarante\nde\nella.\n \n \n \n \n \n \n \n \n \n \nTodos los autores aprobaron el manuscrito final.\n \n \n \nCumplimiento de los est\u00e1ndares \u00e9ticos\n \nComo\nse\nasegur\u00f3\nla\ncalidad,\nel\ncumplimiento\nde\nlas\n \n \n \n \n \n \n \n \n \ndirectrices y su aprobaci\u00f3n\n \n \nEl\nestudio\nEvaMed\nse\nbas\u00f3\nen\ndatos\nproporcionados\npor\nm\u00e9dicos\n \n \n \n \n \n \n \n \n \n \ny\nse\nadhiri\u00f3\na\nlas\nrecomendaciones\nde\nbuenas\npr\u00e1cticas\nen\nel\nan\u00e1lisis\n \n \n \n \n \n \n \n \n \n \n \n \nde\ndatos\nsecundarios\ndel\nGrupo\nde\ntrabajo\nalem\u00e1n\nsobre\nla\nrecopilaci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \ny\nel\nuso\nde\ndatos\nsecundarios\n[38].\nEl\nestudio\nfue\naprobado\npor\nel\noficial\n \n \n \n \n \n \n \n \n \n \n \n \n \n \nde\nseguridad\nde\ndatos\nresponsable.\nComo\ntodos\nlos\ndatos\nse\n \n \n \n \n \n \n \n \n \n \nrecopilaron\nan\u00f3nimamente\nsin\nninguna\ndocumentaci\u00f3n\npor\nparte\nde\nlos\n \n \n \n \n \n \n \n \n \npacientes,\ny\ndado\nque\nel\nestudio\nno\nimplicaba\nninguna\nintervenci\u00f3n\no\n \n \n \n \n \n \n \n \n \n \n investigaci\u00f3n\nexperimental,\nno\nse\nrequiri\u00f3\naprobaci\u00f3n\n\u00e9tica\n[16].\nEste\n \n \n \n \n \n \n \n \n \ninforme\nsigui\u00f3\nlas\npautas\nde\nSTROBE\npara\nestudios\nobservacionales\n \n \n \n \n \n \n \n \n \n[42].\n \n \nConflictos de intereses\n \nEn\nlos\n\u00faltimos\n3\na\u00f1os,\nHJH\nrecibi\u00f3\nsubvenciones\npara\nla\n \n \n \n \n \n \n \n \n \n \ninvestigaci\u00f3n\npor\nparte\nde\nfabricantes\nde\nmedicamentos\nantropos\u00f3ficos\n \n \n \n \n \n \n \n \n(Wala,\nWeleda).\nDesde\n2012\n(despu\u00e9s\nde\nque\nse\ncomplet\u00f3\nel\nestudio\n \n \n \n \n \n \n \n \n \n \n \nEvaMed),\nHarald\nMatthes\nha\nsido\nmiembro\nde\nla\nJunta\nDirectiva\nde\n \n \n \n \n \n \n \n \n \n \n \nWeleda,\nfabricante\nde\nmedicamentos\nantropos\u00f3ficos.\nAnja\nGlockmann\ny\n \n \n \n \n \n \n \n \nKirsten\nHeckenbach\ndeclaran\nque\nno\ntienen\nintereses\nque\nentren\nen\n \n \n \n \n \n \n \n \n \n \nconflicto.\n \n \nAcceso a este art\u00edculo\n \nEl\npresente\nart\u00edculo\nest\u00e1\ndistribuido\nbajo\nlas\ncondiciones\nCreative\n \n \n \n \n \n \n \n \n \nCommons Attribution-Non Commercial 4.0. Licencia intenacional\n \nhttps://creativecommons.org/licenses/by-nc/4.0\n \nque\npermite\ncualquier\ntipo\nde\nuso\nno\ncomercial,\nas\u00ed\ncomo\nsu\ndistribuci\u00f3n\n \n \n \n \n \n \n \n \n \n \n \n \ny\nreproducci\u00f3n\nen\ncualquier\nmedio,\nsiempre\nque\nse\ncite\nde\nmanera\n \n \n \n \n \n \n \n \n \n \n \nadecuada\na\nlos\nautores,\nque\nse\nponga\nun\nlink\na\nla\nlicencia\nCreative\n \n \n \n \n \n \n \n \n \n \n \n \n \nCommons y se indiquen si se han realizado cambios en \u00e9l.\n \n \n \n \n \n \n \n \n \n \n \n Bibliograf\u00eda\n \n \n1.\nAgbabiaka\nTB,\nSavovic\nJ,\nErnst\nE.\nMethods\nfor\ncausality\nassessment\nof\n \n \n \n \n \n \n \n \n \n \n \nadverse\ndrug\nreactions:\na\nsystematic\nreview.\nDrug\nSaf.\n \n \n \n \n \n \n \n \n2008;31:21\u201337.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n1.\n2.\n \n2.\nAnonymous\n(2014)\nArzneimittelgesetz\nin\nder\nFassung\nder\n \n \n \n \n \n \n \nBekanntmachung\nvom\n12.\nDezember\n2005\n(BGBl.\nI\nS.\n3394),\ndas\nzuletzt\n \n \n \n \n \n \n \n \n \n \n \ndurch\nArtikel\n2a\ndes\nGesetzes\nvom\n27.\nM\u00e4rz\n2014\n(BGBl.\nI\nS.\n261)\n \n \n \n \n \n \n \n \n \n \n \n \n \nge\u00e4ndert\nworden\nist.\nBundesministerium\nder\nJustiz\nund\nf\u00fcr\n \n \n \n \n \n \n \n \nVerbraucherschutz, Bonn.\n\u200b\nGoogle Scholar\n \n3.\n3.\n \n4.\nAnonymous\n(2016)\nEMA\npharmacovigilance\nsystem\nmanual.\nVersion\n \n \n \n \n \n \n \n1.2. In: European Medicines Agency, p. 26.\n\u200b\nGoogle Scholar\n \n5.\n4.\n \n6.\nAnonymous.\nFacts\nand\nfigures\non\nAnthroposophic\nMedicine\nworldwide.\n \n \n \n \n \n \n \n \nBrussels:\nIVAA-International\nFederation\nof\nAnthroposophic\nMedical\n \n \n \n \n \n \nAssociations; 2012.\n\u200b\nGoogle Scholar\n \n7.\n5.\n \n8.\nAnonymous\n(2007)\nFrequency\nof\nadverse\ndrug\nreactions\n(CIOMS).\nIn:\n \n \n \n \n \n \n \n \n \nDefinitions. World Health Organization, Geneva, p. 10.\n\u200b\nGoogle Scholar\n \n9.\n6.\n \n10.\nAnonymous\n(1997)\nICH\nharmonised\ntripartite\nguideline.\nGuideline\nfor\n \n \n \n \n \n \n \n \ngood\nclinical\npractice.\nIn:\nInternational\nconference\non\nharmonisation\nof\n \n \n \n \n \n \n \n \n \ntechnical\nrequirements\nfor\nregistration\nof\npharmaceuticals\nfor\nhuman\n \n \n \n \n \n \n \n \nuse (ICH), Geneve.\n\u200b\nGoogle Scholar\n \n11.\n7.\n \n12.\nAnonymous.\nSafety\nissues\nin\nthe\npreparation\nof\nhomeopathic\nmedicines.\n \n \n \n \n \n \n \n \n \nGeneva: World Health Organization; 2009.\n\u200b\nGoogle Scholar\n \n13.\n8.\n \n14.\nAnonymous.\nSafety\nmonitoring\nof\nmedicinal\nproducts:\nguidelines\nfor\n \n \n \n \n \n \n \n \nsetting\nup\nand\nrunning\na\npharmacovigilance\ncentre.\nUppsala:\nUppsala\n \n \n \n \n \n \n \n \n \nMonitoring Centre; 2000.\n\u200b\nGoogle Scholar\n \n15.\n9.\n \n16.\nAnonymous.\nThe\nsafety\nof\nmedicines\nin\npublic\nhealth\nprogrammes:\n \n \n \n \n \n \n \n \n \npharmacovigilance\nan\nessential\ntool.\nGeneva:\nWorld\nHealth\n \n \n \n \n \n \n \nOrganization; 2006.\n\u200b\nGoogle Scholar\n 17.\n10.\n \n18.\nAnonymous.\nThe\nstory\nof\nUMC\nand\nthe\nWHO\nProgramme.\nUppsala:\n \n \n \n \n \n \n \n \n \n \nUppsala\nMonitoring\nCentre-WHO\nCollaborating\nCentre\nfor\n \n \n \n \n \n \nInternational Drug Monitoring; 2017.\n\u200b\nGoogle Scholar\n \n19.\n11.\n \n20.\nAnonymous.\nWHO\nguidelines\non\nsafety\nmonitoring\nof\nherbal\n \n \n \n \n \n \n \n \nmedicines\nin\npharmacovigilance\nsystems.\nGeneva:\nWorld\nHealth\n \n \n \n \n \n \n \nOrganization; 2004.\n\u200b\nGoogle Scholar\n \n21.\n12.\n \n22.\nBaars\nEW,\nHamre\nHJ.\nWhole\nmedical\nsystems\nversus\nthe\nsystem\nof\n \n \n \n \n \n \n \n \n \n \n \nconventional\nbiomedicine:\na\ncritical\nreview\nof\nsimilarities,\ndifferences\n \n \n \n \n \n \n \n \nand\nfactors\nthat\npromote\nthe\nintegration\nprocess.\nEvid\nBased\n \n \n \n \n \n \n \n \n \nComplement\nAltern\nMed\neCAM.\n2017.\ndoi:\n \n \n \n \n \n \n10.1155/2017/4904930\n\u200b\n.\n\u200b\nGoogle Scholar\n \n23.\n13.\n \n24.\nBaghel\nM.\nThe\nnational\npharmacovigilance\nprogram\nfor\nayurveda,\n \n \n \n \n \n \n \n \nsiddha\nand\nunani\ndrugs:\ncurrent\nstatus.\nInt\nJ\nAyurveda\nRes.\n \n \n \n \n \n \n \n \n \n \n2010;1:197\u20138.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nPubMedCentral\n\u200b\nGoogle Scholar\n \n25.\n14.\n \n26.\nBornh\u00f6ft\nG,\nMatthiessen\nPF.\nHomeopathy\nin\nhealthcare:\n \n \n \n \n \n \n \neffectiveness,\nappropriateness,\nsafety,\ncosts.\nBerlin:\nSpringer;\n \n \n \n \n \n \n2011.\n\u200b\nCrossRef\n\u200b\nGoogle Scholar\n \n27.\n15.\n \n28.\nBuchholzer\nML,\nWerner\nC,\nKnoess\nW.\nCurrent\nconcepts\non\n \n \n \n \n \n \n \n \n \nintegrative\nsafety\nassessment\nof\nactive\nsubstances\nof\nbotanical,\nmineral\n \n \n \n \n \n \n \n \n \nor\nchemical\norigin\nin\nhomeopathic\nmedicinal\nproducts\nwithin\nthe\n \n \n \n \n \n \n \n \n \nEuropean\nregulatory\nframework.\nRegul\nToxicol\nPharmacol.\n \n \n \n \n \n \n2013;68:193\u2013200.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n29.\n16.\n \n30.\nChenot\nJF,\nHeidenreich\nR.\nThe\nrole\nof\nethics\ncommittees\nin\nprimary\n \n \n \n \n \n \n \n \n \n \n \ncare\nresearch\nprojects.\nZ\nAllg\nMed.\n2004;80:279\u201381.\n\u200b\nCrossRef\n\u200b\nGoogle\n \n \n \n \n \n \n \nScholar\n \n31.\n17.\n \n32.\nCirko-Begovic\nA,\nVrhovac\nB,\nBakran\nI.\nIntensive\nmonitoring\nof\nadverse\n \n \n \n \n \n \n \n \n \n \ndrug\nreactions\nin\ninfants\nand\npreschool\nchildren.\nEur\nJ\nClin\nPharmacol.\n \n \n \n \n \n \n \n \n \n \n \n1989;36:63\u20135.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n33.\n18.\n 34.\nDavies\nEC,\nRowe\nPH,\nJames\nS,\net\nal.\nAn\ninvestigation\nof\n \n \n \n \n \n \n \n \n \n \n \ndisagreement\nin\ncausality\nassessment\nof\nadverse\ndrug\nreactions.\nPharm\n \n \n \n \n \n \n \n \n \nMed. 2011;25:17\u201324.\n\u200b\nCrossRef\n\u200b\nGoogle Scholar\n \n35.\n19.\n \n36.\nFeise\nRJ.\nDo\nmultiple\noutcome\nmeasures\nrequire\np-value\n \n \n \n \n \n \n \n \nadjustment?\nBMC\nMed\nRes\nMethodol.\n \n \n \n \n \n2002;2:8.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nPubMedCentral\n\u200b\nGoogle Scholar\n \n37.\n20.\n \n38.\nFonneb\u00f8\nV,\nGrimsgaard\nS,\nWalach\nH,\net\nal.\nResearching\n \n \n \n \n \n \n \n \n \ncomplementary\nand\nalternative\ntreatments\u2014the\ngatekeepers\nare\nnot\nat\n \n \n \n \n \n \n \n \nhome.\nBMC\nMed\nRes\nMethodol.\n \n \n \n \n \n2007;7:7.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nPubMedCentral\n\u200b\nGoogle Scholar\n \n39.\n21.\n \n40.\nHamre\nHJ,\nGlockmann\nA,\nFischer\nM,\net\nal.\nUse\nand\nsafety\nof\n \n \n \n \n \n \n \n \n \n \n \n \nanthroposophic\nmedications\nfor\nacute\nrespiratory\nand\near\ninfections:\na\n \n \n \n \n \n \n \n \n \nprospective\ncohort\nstudy.\nDrug\nTarget\nInsights.\n \n \n \n \n \n \n2007;2:209\u201319.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nPubMedCentral\n\u200b\nGoogle Scholar\n \n41.\n22.\n \n42.\nHamre\nHJ,\nWitt\nCM,\nGlockmann\nA,\net\nal.\nUse\nand\nsafety\nof\n \n \n \n \n \n \n \n \n \n \n \n \nanthroposophic\nmedications\nin\nchronic\ndisease:\na\n2-year\nprospective\n \n \n \n \n \n \n \n \nanalysis. Drug Saf. 2006;29:1173\u201389.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n43.\n23.\n \n44.\nJeschke\nE,\nOstermann\nT,\nLuke\nC,\net\nal.\nRemedies\ncontaining\n \n \n \n \n \n \n \n \n \n \nAsteraceae\nextracts:\na\nprospective\nobservational\nstudy\nof\nprescribing\n \n \n \n \n \n \n \n \npatterns\nand\nadverse\ndrug\nreactions\nin\nGerman\nprimary\ncare.\nDrug\nSaf.\n \n \n \n \n \n \n \n \n \n \n \n2009;32:691\u2013706.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n45.\n24.\n \n46.\nJeschke\nE,\nOstermann\nT,\nTabali\nM,\net\nal.\nDiagnostic\nprofiles\nand\n \n \n \n \n \n \n \n \n \n \n \nprescribing\npatterns\nin\neveryday\nanthroposophic\nmedical\npractice\u2014a\n \n \n \n \n \n \n \nprospective\nmulti-centre\nstudy.\nForsch\nKomplementmed.\n \n \n \n \n \n2009;16:325\u201333.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n47.\n25.\n \n48.\nJeschke\nE,\nOstermann\nT,\nTabali\nM,\net\nal.\nAnthroposophic\nmedicine\n \n \n \n \n \n \n \n \n \n \nin\npediatric\nprimary\ncare\u2014a\nprospective,\nmulticentre\nobservational\n \n \n \n \n \n \n \nstudy\non\nprescribing\npatterns.\nAltern\nTher\nHealth\nMed.\n \n \n \n \n \n \n \n \n2011;17:18\u201328.\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n49.\n26.\n 50.\nJones\nG,\nMaier\nJ,\nPedersen\nP,\net\nal.,\neditors.\nAnthroposophic\n \n \n \n \n \n \n \n \n \n \nPharmaceutical\nCodex\nAPC.\n4th\ned.\nDornach:\nInternational\nAssociation\n \n \n \n \n \n \n \n \nof Anthroposophic Pharmacists; 2017.\n\u200b\nGoogle Scholar\n \n51.\n27.\n \n52.\nJong\nMC,\nJong\nMU,\nBaars\nEW.\nAdverse\ndrug\nreactions\nto\n \n \n \n \n \n \n \n \n \n \nanthroposophic\nand\nhomeopathic\nsolutions\nfor\ninjection:\na\nsystematic\n \n \n \n \n \n \n \n \nevaluation\nof\nGerman\npharmacovigilance\ndatabases.\n \n \n \n \n \nPharmacoepidemiol\nDrug\nSaf.\n \n \n \n2012;21:1295\u2013301.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n53.\n28.\n \n54.\nKaushal\nR,\nGoldmann\nDA,\nKeohane\nCA,\net\nal.\nAdverse\ndrug\nevents\nin\n \n \n \n \n \n \n \n \n \n \n \n \npediatric\noutpatients.\nAmbul\nPediatr\nOff\nJ\nAmbul\nPediatr\nAssoc.\n \n \n \n \n \n \n \n \n \n2007;7:383\u20139.\n\u200b\nGoogle Scholar\n \n55.\n29.\n \n56.\nKienle\nGS,\nAlbonico\nHU,\nFischer\nL,\net\nal.\nComplementary\ntherapy\n \n \n \n \n \n \n \n \n \n \nsystems\nand\ntheir\nintegrative\nevaluation.\nExplore\n(NY).\n \n \n \n \n \n \n \n2011;7:175\u201387.\n\u200b\nCrossRef\n\u200b\nGoogle Scholar\n \n57.\n30.\n \n58.\nKienle\nGS,\nGlockmann\nA,\nGrugel\nR,\net\nal.\nKlinische\nForschung\nzur\n \n \n \n \n \n \n \n \n \n \n \nAnthroposophischen\nMedizin\u2014Update\neines\nHealth\nTechnology\n \n \n \n \n \nAssessment-Berichts\nund\nStatus\nQuo\n[Clinical\nresearch\non\n \n \n \n \n \n \n \nanthroposophic\nmedicine:\nupdate\nof\na\nhealth\ntechnology\nassessment\n \n \n \n \n \n \n \n \nreport\nand\nstatus\nquo].\nForsch\nKomplementmed.\n \n \n \n \n \n \n2011;18:269\u201382.\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n59.\n31.\n \n60.\nMittal\nN,\nGupta\nMC.\nComparison\nof\nagreement\nand\nrational\nuses\nof\n \n \n \n \n \n \n \n \n \n \n \nthe\nWHO\nand\nNaranjo\nadverse\nevent\ncausality\nassessment\ntools.\nJ\n \n \n \n \n \n \n \n \n \n \nPharmacol\nPharmacother.\n \n \n2015;6:91\u20133.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nPubMedCentral\n\u200b\nGoogle Scholar\n \n61.\n32.\n \n62.\nMol\nC,\nRoemer\nF,\nScheer\nR,\net\nal.\nArzneimittel\n[\u00fcberarbeitete\n \n \n \n \n \n \n \n \n \n \nMonographien\nder\nKommission\nC].\nIn:\nGl\u00f6ckler\nM,\neditor.\n \n \n \n \n \n \n \n \nAnthroposophische\nArzneitherapie\nf\u00fcr\n\u00c4rzte\nund\nApotheker.\nStuttgart:\n \n \n \n \n \n \n \nWissenschaftliche Verlagsgesellschaft; 2008.\n\u200b\nGoogle Scholar\n \n63.\n33.\n \n64.\nMouton\nJP,\nMehta\nU,\nRossiter\nDP,\net\nal.\nInterrater\nagreement\nof\ntwo\n \n \n \n \n \n \n \n \n \n \n \n \nadverse\ndrug\nreaction\ncausality\nassessment\nmethods:\na\nrandomised\n \n \n \n \n \n \n \n \ncomparison\nof\nthe\nLiverpool\nAdverse\nDrug\nReaction\nCausality\n \n \n \n \n \n \n \n Assessment\nTool\nand\nthe\nWorld\nHealth\nOrganization-Uppsala\n \n \n \n \n \n \n \nMonitoring\nCentre\nsystem.\nPLoS\nOne.\n \n \n \n \n \n2017;12:e0172830.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nPubMedCentral\n\u200b\nGoogle Scholar\n \n65.\n34.\n \n66.\nNaranjo\nCA,\nBusto\nU,\nSellers\nEM,\net\nal.\nA\nmethod\nfor\nestimating\nthe\n \n \n \n \n \n \n \n \n \n \n \n \n \nprobability\nof\nadverse\ndrug\nreactions.\nClin\nPharmacol\nTher.\n \n \n \n \n \n \n \n \n1981;30:239\u201345.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n67.\n35.\n \n68.\nRebelo\nGomes\nE,\nFonseca\nJ,\nAraujo\nL,\net\nal.\nDrug\nallergy\nclaims\nin\n \n \n \n \n \n \n \n \n \n \n \n \n \nchildren:\nfrom\nself-reporting\nto\nconfirmed\ndiagnosis.\nClin\nExp\nAllergy\nJ\n \n \n \n \n \n \n \n \n \n \nBr Soc Allergy Clin Immunol. 2008;38:191\u20138.\n\u200b\nGoogle Scholar\n \n69.\n36.\n \n70.\nSanz\nE,\nBoada\nJ.\nAdverse\ndrug\nreactions\nin\npaediatric\noutpatients.\n \n \n \n \n \n \n \n \n \n \nInt J Clin Pharmacol Res. 1987;7:169\u201372.\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n71.\n37.\n \n72.\nSmyth\nRM,\nGargon\nE,\nKirkham\nJ,\net\nal.\nAdverse\ndrug\nreactions\nin\n \n \n \n \n \n \n \n \n \n \n \n \nchildren\u2014a\nsystematic\nreview.\nPLoS\nOne.\n \n \n \n \n \n2012;7:e24061.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nPubMedCentral\n\u200b\nGoogle Scholar\n \n73.\n38.\n \n74.\nSwart\nE,\nGothe\nH,\nGeyer\nS,\net\nal.\nGood\npractice\nof\nsecondary\ndata\n \n \n \n \n \n \n \n \n \n \n \n \n \nanalysis\n(GPS):\nguidelines\nand\nrecommendations.\nGesundheitswesen.\n \n \n \n \n \n \n2015;77:120\u20136.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n75.\n39.\n \n76.\nTabali\nM,\nJeschke\nE,\nBockelbrink\nA,\net\nal.\nEducational\nintervention\nto\n \n \n \n \n \n \n \n \n \n \n \nimprove\nphysician\nreporting\nof\nadverse\ndrug\nreactions\n(ADRs)\nin\na\n \n \n \n \n \n \n \n \n \n \nprimary\ncare\nsetting\nin\ncomplementary\nand\nalternative\nmedicine.\nBMC\n \n \n \n \n \n \n \n \n \nPublic\nHealth.\n2009;9:274.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nPubMedCentral\n\u200b\nGoogle\n \n \n \nScholar\n \n77.\n40.\n \n78.\nTabali\nM,\nOstermann\nT,\nJeschke\nE,\net\nal.\nAdverse\ndrug\nreactions\nfor\n \n \n \n \n \n \n \n \n \n \n \n \nCAM\nand\nconventional\ndrugs\ndetected\nin\na\nnetwork\nof\nphysicians\n \n \n \n \n \n \n \n \n \n \ncertified\nto\nprescribe\nCAM\ndrugs.\nJ\nManag\nCare\nPharm.\n \n \n \n \n \n \n \n \n \n2012;18:427\u201338.\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \n79.\n41.\n \n80.\nTr\u00f6ger\nW,\nGalun\nD,\nReif\nM,\net\nal.\n\u200b\nViscum\nalbum\n[L.]\nextract\ntherapy\n \n \n \n \n \n \n \n \n \n \n \n \n \nin\npatients\nwith\nlocally\nadvanced\nor\nmetastatic\npancreatic\ncancer:\na\n \n \n \n \n \n \n \n \n \n \nrandomised\nclinical\ntrial\non\noverall\nsurvival.\nEur\nJ\nCancer.\n \n \n \n \n \n \n \n \n \n2013;49:3788\u201397.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n 81.\n42.\n \n82.\nVon\nElm\nE,\nAltman\nDG,\nEgger\nM,\net\nal.\nThe\nstrengthening\nthe\n \n \n \n \n \n \n \n \n \n \n \n \nreporting\nof\nobservational\nstudies\nin\nepidemiology\n(STROBE)\n \n \n \n \n \n \n \nstatement:\nguidelines\nfor\nreporting\nobservational\nstudies.\nAnn\nIntern\n \n \n \n \n \n \n \n \nMed. 2007;147:573\u20137.\n\u200b\nCrossRef\n\u200b\nGoogle Scholar\n \n83.\n43.\n \n84.\nZhang\nL,\nYan\nJ,\nLiu\nX,\net\nal.\nPharmacovigilance\npractice\nand\nrisk\n \n \n \n \n \n \n \n \n \n \n \n \ncontrol\nof\ntraditional\nChinese\nmedicine\ndrugs\nin\nChina:\ncurrent\nstatus\n \n \n \n \n \n \n \n \n \n \nand\nfuture\nperspective.\nJ\nEthnopharmacol.\n \n \n \n \n \n2012;140:519\u201325.\n\u200b\nCrossRef\n\u200b\nPubMed\n\u200b\nGoogle Scholar\n \nCopyright information\n \n\u00a9 The Author(s) 2017\n \nOpen\nAccessThis\narticle\nis\ndistributed\nunder\nthe\nterms\nof\nthe\nCreative\n \n \n \n \n \n \n \n \n \n \n \nCommons\nAttribution-NonCommercial\n4.0\nInternational\nLicense\n \n \n \n \n \n(http://creativecommons.org/licenses/by-nc/4.0/),\nwhich\npermits\nany\n \n \n \n \nnoncommercial\nuse,\ndistribution,\nand\nreproduction\nin\nany\nmedium,\nprovided\n \n \n \n \n \n \n \n \n \nyou\ngive\nappropriate\ncredit\nto\nthe\noriginal\nauthor(s)\nand\nthe\nsource,\nprovide\na\n \n \n \n \n \n \n \n \n \n \n \n \n \nlink to the Creative Commons license, and indicate if changes were made.\n \n \n \n \n \n \n \n \n \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}